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ABSTRACT 
 Previous study conducted by Abdul-Rahman et al. (2007) has highlighted the 
enhanced expression of a 35 kDa glycoprotein, termed lectin-detected protein 1 (LDP1), in 
sera of patients with endometrial adenocarcinoma (EACa).  In this study, LDP1 was 
isolated from sera of patients with EACa using immobilised champedak-galactose-binding 
(CGB) lectin affinity chromatography.  Subjecting LDP1 to mass spectrometry analysis, 
LDP1 was identified as the 35 kDa cleavage fragment of inter-α-trypsin-inhibitor heavy 
chain 4 (ITIH4f).   
Subsequent to its identification, expression of ITIH4f in sera of patients with breast 
carcinoma (BrCa; n=10), epithelial ovarian carcinoma (EOCa; n=10), germ cell ovarian 
carcinoma (GOCa; n=10), nasopharyngeal carcinoma (NPCa; n=13) and osteosarcoma 
(OsSa; n=10) was investigated using 2-DE and HRP-CGB lectin approach.  When 
compared to control sera, expression of ITIH4f was enhanced in sera of patients with BrCa, 
EOCa and GOCa, but not in patients with NPCa and OsSa.  The data of this study, when 
taken together with reports of previous researchers, appeared to link the over-expression of 
ITIH4f with cancers associated with estrogen dysregulation.  As such, the expression of 
ITIH4f is also likely to be enhanced in other diseases associated with increased levels of 
estrogen.  Hence, its expression in women with normal pregnancy (NP; n=20), 
hydatidiform mole (HM; n=20) and menopausal women under the hormone replacement 
therapy (HRT; n=10) were studied.  When compared to controls (n=20), it was 
demonstrated that the expression of ITIH4f was over-expressed in women with NP and 
HM, but was not altered in women with HRT.  Hence, the expression of ITIH4f was not 
exclusive to cancers but was also enhanced in normal and benign conditions that are 
associated with estrogen dysregulation.   
v 
 
An attempt to establish the serum protein profiles of women with NP and HM was 
subsequently performed via 2-DE.  Protein detection was either performed by silver 
staining or CGB lectin.  Image analyses performed on profiles of pregnant women 
demonstrated that the expression of ITIH4f, α1-antichymotrypsin (ACT) and leucine-rich-
glycoprotein (LRG) was significantly enhanced in the women with NP.  However, ITIH4f 
was the sole serum glycoprotein which appeared to be altered in sera of women with HM. 
Comparative analysis performed on the silver-stained protein profiles demonstrated 
enhanced expression of ACT, LRG, clusterin (CLU) and zinc-α2- glycoprotein (ZAG) in 
sera of women with NP.  In contrast, women with HM were characterized by the up-
regulated expression of CLU and LRG.  However, the LRG of women with HM appeared 
to be differentially glycosylated from that of women with NP and CLU in women with HM 
seemed to be more cationic, relative to than that of NP women.  All proteins which showed 
differential expression were identified by mass spectrometry analysis.  The aberrant 
expression of the identified proteins was subsequently validated using immunoblotting 
technique.   
Finally, an attempt to simultaneously detect the differential expression of the 
respective proteins was performed using multiplex immunoassay.  A multiplex 
immunoassay was developed to evaluate the expression of eight proteins but the 
development was only successful for three proteins- anti-thrombin III (ATR), CLU and 
ceruloplasmin (CLP).  Nonetheless, the assay was capable of confirming the up-regulated 
expression of CLU and the unaltered expression of ATR and CLP. 
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ABSTRAK 
Kajian terdahulu yang dijalankan oleh Abdul Rahman et al. pada tahun 2007 telah 
menonjolkan peningkatan pengekspresan suatu glikoprotein 35 kDa, yang dinamai protein 
yang dikesan lektin (LDP1), di dalam serum pesakit yang baru didiagnosis dengan 
adenokarsinoma endometrium (EACa). Protein LDP1 menunjukkan interaksi yang kuat 
dengan lektin pengikat galaktosa cempedak (CGB) berikat enzim walaupun sebelum ini ia 
tidak dikesan pada profil protein pesakit EACa yang diwarnai perak. Dalam hal ini, adalah 
agak menarik untuk mengenal pasti kelompok tompokan LDP1. Memandangkan LDP1 
sebelum ini dikesan pada membran nitroselulosa, satu pendekatan alternatif telah diguna 
pakai untuk mengasingkannya.  Dalam kajian ini, LDP1 telah diasingkan daripada 
campuran beberapa serum pesakit EACa menggunakan kromatografi afiniti jerapan lektin 
CGB.  Dengan memisahkan glikoprotein terjerap-lektin menggunakan2-DE dan analisa 
spektometri jisim, LDP1 dikenalpasti sebagai serpihan 35 kDa rantai berat 4inter-α-
perencat tripsin (ITIH4f). 
Selepas pengenalpastiannya, pengekspresan serpihan 35 kDa ITIH4f di dalam 
serum pesakit karsinoma payudara (BrCa; n=10), karsinoma epitelium ovari (EOCa; n=10), 
karsinoma sel germa ovari (GOCa; n=10), karsinoma nasofaring (NPC; n=13) dan 
osteosarkoma (OsSa; n=10) telah disiasat menggunakan pendekatan 2-DE dan lektin CGB 
berikat enzim.  Apabila dibandingkan dengan sera kawalan (n=20), pengekspresan serpihan 
35 kDa ITIH4f didapati meningkat dengan ketara dalam serum pesakit BrCa, EOCa dan 
GOCa, tetapi tidak pada pesakit NPC dan OsSa.  Data dari kajian ini, apabila diambil 
bersama dengan laporan penyelidik-penyelidik sebelumnya kelihatan menghubungkan 
peningkatan pengekspresan ITIH4f secara khusus dengan kanser yang berkait dengan 
disregulasi estrogen.  Dalam kes yang sedemikian, walau bagaimanapun, pengekspresan 
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serpihan ini juga berkemungkinan tinggi berlaku dalam penyakit-penyakit lain yang 
berkaitan dengan peningkatan paras estrogen.  Oleh itu, pengekspresan serpihan ITIH4f di 
dalam wanita hamil yang normal (NP; n=20), pengidap hydatidiform mol (HM; n=20) dan 
wanita menopaus yang menjalani terapi penggantian hormon (HRT; n=10) telah dikaji.  
Apabila dibandingkan dengan serum kawalan, pengekspresan serpihan ITIH4f didapati 
adalah tinggi di dalam kumpulan wanita NP dan HM, tetapi tidak berubah di dalam 
kumpulan wanita yang menjalani HRT.  Oleh itu, data kajian ini mengambarkan bahawa 
pengekspresan serpihan 35 kDa ITIH4f adalah tidak eksklusif kepada kanser tetapi ia juga 
tinggi dalam keadaan normal dan benigna yang berkait dengan disregulasi estrogen.  
Dalam bahagian kedua kajian ini, satu cubaan untuk mewujudkan profil serum 
protein wanita NP dan HM telah dilakukan melalui pendekatan 2-DE.  Pengesanan protein 
dilaksanakan dengan menggunakan lektin CGB berikat enzim atau pun pewarnaan perak.  
Apabila serum protein yang dipisahkan menggunakan 2-DE dari dua kumpulan wanita 
hamil tersebut didedahkan kepada lektin CGB berikat enzim, profil yang terdiri daripada 
hanya protein O-terglikosilat telah diperolehi.  Analisa imej yang dilakukan ke atas profil 
kedua-dua kumpulan wanita hamil menunjukkan perubahan berbeza pengekspresan O-
glikoprotein, relatif kepada subjek kawalan.  Keputusan yang diperoleh menunjukkan 
bahawa pengekspresan serpihan 35 kDa ITIH4f, α1-antikimotripsin (ACT) dan glikoprotein 
kaya leusina (LRG) telah dipertingkatkan dengan ketara dalam kumpulan wanita NP.  
Walau bagaimanapun, serpihan 35 kDa ITIH4f merupakan glikoprotein serum tunggal yang 
kelihatan berubahdengan ketara dalam serum wanita HM. 
Sampel serum wanita NP dan HM kemudiannya dipisahkan menggunakan 2-DE, 
diikuti oleh analisa imej profil protein yang diwarnakan perak.  Analisa perbandingan yang 
dilakukan ke atas profil protein serum menunjukkan peningkatan pengekspresan ACT, 
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LRG, klusterin (CLU) dan zink-α2-glikoprotein (ZAG) di dalam serum wanita NP.  
Sebaliknya, wanita HM telah dicirikan dengan peningkatan pengekspresan CLU dan LRG.  
Walau bagaimanapun, LRG wanita HM menunjukkan pengglikosilan berbeza berbanding 
wanita NP.  Di samping itu, kelompok tompok protein CLU di dalam serum wanita HM 
kelihatan lebih kationik, relatif kepada wanita NP.  Kesemua lima protein yang 
menunjukkan pengekspresan berbeza dalam kajian ini telah berjaya dikenalpasti dengan 
analisa spektrometri jisim.  Perbezaan pengekspresan protein yang dikenal pasti di dalam 
serum wanita NP serta HM seterusnya divalidasikan menggunakan teknik imunoblot.  
Dalam bahagian akhir kajian, satu cubaan untuk mengesan perbezaan 
pengekspresan panel protein secara serentak, bagi kumpulan wanita NP dan HM, telah 
dilakukan dengan menggunakan ujian imun multipleks.  Satu ujian imun multipleks telah 
dibangunkan dengan tujuan untuk menilai pengekspresan lapan proteinberbeza tetapi hanya 
berjaya untuk menentukan tiga protein iaitu, anti-trombin III (ATR), CLU dan 
seruloplasmin (CLP).  Namun itu, ujian tersebut mampu mengesahkan peningkatan 
pengekspresan CLU dan ketidakubahan pengekspresan ATR dan CLP di dalam kumpulan 
wanita yang dikaji. 
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1.1 Benign Neoplasm 
The term neoplasm describes any new and abnormal growth which involved 
progressive and uncontrolled cell multiplication.  It usually forms a distinct mass of tissue 
called a tumor, which may be either benign or malignant.  The growth tissue generally 
shows partial or complete lack of structural organization and functional coordination with 
the normal tissues and serves no physiological function.  `Benign‟ implies a mild and non-
progressive condition.  The term benign neoplasm thus describes any tumor or abnormal 
growth which is non-malignant, treatable and lacks the ability to metastasize to other areas 
of the body.  Benign neoplasms are very diverse.  They are typically composed of cells 
which bear strong resemblance to normal cells in the organs from where they originated.  
Most of the benign conditions are named based on their organ of origin followed by the 
suffix “-oma” which refers to tumor in Latin.  Common examples include lipomas and 
adenomas which refer to benign tumors of lipocytes and gland forming cells, respectively.    
Even though benign tumors lack the invasive properties of cancer, they may still 
cause health problems.  The negative effects are usually dependent on their anatomical 
location and tissue type.  Among the pathological effects of some benign tumors are 
obstruction or compression of vital organs, cosmetic changes and over-production of 
certain hormones when involving tumors of the endocrine tissues.  Surgery is usually the 
most effective approach for treatment of benign tumors. 
 
1.1.1 Hydatidiform mole 
Hydatidiform mole (HM) is the most common type of gestational trophoblastic 
disease (Alifrangis and Seckl, 2010; Batorfi et al., 2003).  Gestational trophoblastic disease 
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(GTD) describes a spectrum of abnormal trophoblastic proliferation which originated from 
the placental trophoblastic epithelium of the uterus (Altieri et al., 2003).  It is characterized 
by the production of irregular forms of human chorionic gonadotropin (HCG), which is a 
glycoprotein hormone produced by trophoblasts of the placenta.  Examples of the abnormal 
forms of HCG include ßHCG, nicked HCG as well as dessialylated and hyperglycosylated 
forms of HCG (Altieri et al., 2003; Cole et al., 2001; Imamura et al., 1987).  At present, 
under the WHO classification, GTD includes hydatidiform mole, invasive mole, 
choriocarcinoma and the rare placental site trophoblastic tumor (Alifrangis and Seckl, 
2010; Seki et al., 2004; Li et al., 2002).  The benign end of GTD is HM, whilst the 
malignant end is choriocarcinoma.  HM can be further classified into complete and partial 
moles on the basis of its morphological, cytogenetic and clinical features (Jauniaux et al., 
1999).  Complete HM is characterized by hydrophobic degeneration of all villi and absence 
of embryo, cord and amniotic membranes.  In contrast, partial HM is characterized by focal 
trophoblastic proliferation with a mixture of normal and edematous villi.  An embryo, cord 
and amniotic fluid are usually present (Slim and Mehio, 2007). 
The incidence of HM varies in different countries, being more common in South-East 
Asia (Ngan, 2003).  Its prevalence also varies between ethnic groups (Slim and Mehio, 
2007) and in Malaysia, the highest frequency being amongst the Chinese women (Loh et 
al., 2004).  The higher rate of incidence in a particular ethnic group has been suggested to 
be attributed to genetic and various environmental factors such as food preferences (Slim 
and Mehio, 2007).   HM results from an abnormal conception event and is characterized by 
the absence of a fetus with an inappropriate implacentation (Wihman et al., 1998).  The 
classical clinical presentation used to be vaginal bleeding in the middle trimester of 
pregnancy.  This may be accompanied by the passage of grape-like structures consisting of 
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edematous clusters of vesicles, 0.5 to 2.0 cm in size with varying amounts of hemorrhage 
and necrosis (Lage et al., 2003).   More aggressive symptoms may include excessive 
uterine size, anemia, preeclampsia, hyperthyrodisim or hyperemesis.  Nowadays, HM 
rarely presents with the classical symptoms due to the widespread use of obstetric 
ultrasound.  Routine use of ultrasonography allowed for early diagnosis at 8.5 to 9.5 weeks 
of gestation, following incidence of vaginal bleeding.  However, early diagnosis of this 
tumor is not always easy as in the initial stages it resembles normal pregnancy except for 
the higher level of HCG.  Extremely marked elevation of maternal serum β-HCG for the 
fetus gestational age is suggestive but not diagnostic of HM.  However, individual variation 
and other factors can cause problems in the clinical practice of β-HCG (Cole et al., 2006; 
Khanlian et al., 2003).  Hence, diagnosis of HM relies greatly on ultrasonogram and in 
cases of uncertainty, histological diagnosis will be performed (Ngan, 2003).  The standard 
treatment for HM involved suction evacuation of the uterus and removal of the mole by 
curettage.    
 
1.2 Cancer 
1.2.1 Cancer as a disease 
 Cancer is opposite of benign conditions.  It is a disease that begins in the cells and it 
encompass a broad range of different types, all of which involved unregulated cell growth. 
To date there are over 100 different known cancers that afflict human.  Cancer is generally 
characterized by an uncontrolled cellular growth and development of malignant cells.  
These cellular activities lead to excessive proliferation and spreading of cells which will 
later form a tumor.  The tumor can damage neighboring tissues or organs as it can invade 
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through the lymphatic system or the bloodstream (Hill and Tannock, 1998).  The character 
of the cancerous cell fits its Latin meaning i.e, crab, due to its ability to „crawl‟ and causing 
pain to any part of the body. 
The diagnosis of cancer can be performed in a number of approaches involving the 
detection of certain signs and symptoms, physical examination, screening tests or via 
medical imaging.  Once a possible cancer is detected further diagnosis will involve 
histological examination of tissue samples.  Following diagnosis, management of patients 
usually involves treatment with chemotherapy, radiation therapy or surgery for removal of 
tumor cells.  The chances of surviving the disease vary greatly by the type and location of 
the cancer and the extent of disease at the start of treatment. 
 
1.2.2 Etiology of cancer 
The question of the etiology of cancer has been the focus of medical scientists for 
many years.  However, little is definitely known on the essential causes of a cancer due to 
the complex nature of this disease.  At present, there are a number of predisposing factors 
that bear relation to the development of cancer.  It has been suggested that 90-95% of 
cancer cases arise from environmental or non-genetic factors, whilst only 5-10% are due to 
genetic factors (Anand et al., 2008).  Genetic defects have been implicated with various 
types of hereditary cancers (Knudson, 1985) with the most common being the breast and 
ovarian cancers.  Alterations in the BRCA1and BRCA2 genes are most closely associated 
with increased susceptibility to the two types of cancers (Scully, 2000). Likewise, 
mutations of the MLH1, MSH2 and MSH6 genes have been linked to increased risk of 
hereditary non-polyposis colorectal cancer (Wagner et al., 2003). 
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Environmental elements account for a substantial portion of the predisposing factors 
and are believed to contribute to the variation in the incidence of cancer (Brody and Rudel, 
2003).  Some of the environmental factors that have been associated with cancer include 
tobacco (Sasco et al., 2004; Hecht, 2003; Biesalski et al., 1998; Hackshaw et al., 1997), 
diet (Divisi et al., 2006; Abdulla and Gruber, 2000; Fraser, 1999), infection (Franco and 
Harper, 2005; Clifford et al., 2003; Kuper et al., 2000), radiation (Brody et al., 2007; 
Leszczynski et al., 2002) and environmental pollutants (Clapp et al., 2008; Cohen et al., 
2000).  In addition, hormonal factors have also been suggested as another causative agent 
for cancer (Brody and Rudel, 2003; Ames et al., 1995; Colditz et al., 1995), especially in 
cancers of the breast (Russo and Russo, 2006; Kaaks et al., 2005; Key et al., 2003), 
endometrium (Emons et al., 2000; Henderson et al., 1988) and prostate (Shaneyfelt et al., 
2000; Gann et al., 1996) which involved the sex-hormones, as well as cancer of the thyroid 
which may be promoted by the growth hormones (Haymart et al., 2009; Soh et al., 1996).  
Factors such as obesity, alcohol consumption and lack of physical activity, all of which 
may affect hormone levels, are also believed to underlie the increased risk of certain 
cancers (Brody and Rudel, 2003).  However, it is nearly impossible to prove the true cause 
of cancer in any individual, as most cancers resulted from interplay between genetic and 
environmental factors (Heston, 1965). 
 
1.2.3 Female sex hormone-related cancers 
 Hormones are natural substances made by the glands and are carried in the blood 
circulation.  There are many different types of hormones with each controlling or acting as 
messenger for particular cells or organs.  Sex-hormones are produced mainly by the 
gonads, i.e. the ovaries and testis with small amounts produced by the adrenal glands and 
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other tissues such as the liver.  There are three main classes of sex hormones, with 
androgens being considered as the male sex hormones while estrogens and progestogens 
are called the female sex hormones.   
Estrogens, which are the dominant type of female sex hormone, are present at 
significantly higher levels in women of reproductive age.  They are associated with 
ovulation and menstruation.  In addition, they are also involved in promoting the 
development of the female secondary sexual characteristics, such as the breast, vagina and 
uterus.  Disturbance in the female sex-hormone may result in a variety of disorders, with 
attention is usually focused on cancer.  In light of their functions, the female sex hormone-
related cancers generally encompass cancers of the breast, endometrium, cervix and ovary.  
 
1.2.3.1  Cancer of the breast 
Breast cancer is the most common cancer in women (Parkin et al., 2001).  Incidence 
is highest in North America, Northern Europe and Australia and lowest in Asia and Africa.  
Nevertheless, according to the National Cancer Registry Report for 2007 (2011), breast 
cancer is the leading cancer affecting women in Malaysia.  In 2007 alone, there were 3,242 
female breast cancer cases diagnosed, which accounted for 18.1% of all cancer cases 
reported, and 32.1% of female cancers.  Out of this, only 58% of cases were detected at 
stages I and II.  The confounding factor could be in that at an early stage, the breast cancer 
usually does not cause any pain.  In fact, when it first develops, there may be no symptoms 
at all.  Only as the cancer grows, it causes changes such as a lump or thickening in/near the 
breast or in the underarm area or a change in the size or shape of the breast.  
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At present, mammogram is the best tool available for diagnosing breast cancer 
(Veronesi et al., 1995).  Nevertheless, they have some limitations as a mammogram may 
miss some cancers (false negative) or may find abnormalities that turn out not to be cancer 
(false positive).  Ultrasonography for visualization of breast tissues has also been developed 
and so far it has been used in symptomatic patients to distinguish benign lesions from 
malignant ones.  The limitation of this method lies in its inability to detect tumors of less 
than 5 mm diameter and also microcalcifications, which are important indicators of early 
malignant lesions (Veronesi et al., 1995).  Screening by detection of circulating tumor 
markers for breast cancer is less well established.  The widely used markers in breast cancer 
are the cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) (Duffy, 2006; 
Safi et al., 1991). 
 
1.2.3.2  Cancer of the cervix 
 Cancer of the cervix is the third most common cancer among Malaysian women and 
the fifth most common cancer in the entire general population in this country (National 
Cancer Registry Report, 2011).  Cervical cancer is divided into two major subtypes 
constituting squamous cell cervical carcinoma (SCCa) and adenocervical carcinoma 
(ACCa).  Other less common types include the adenosquamous, clear cell and small cell 
carcinomas.  In general, this form of cancer arises from cells at the junction between the 
primary columnar epithelium of the endocervix and the squamous epithelium of the 
ectocervix.  SCCa, which is the most common form of cervical cancer, involved the 
squamous epithelial cells that line the cervix (Parkin et al., 2001), while ACCa is associated 
with changes in the glandular epithelial cells.  Similar to the other types of cancers, the 
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early stage of cervical cancers may be completely asymptomatic.  In more advanced stages, 
vaginal bleeding or a vaginal mass may indicate the presence of malignancy.    
Cervical cytology screening is the common method for early detection of 
premalignant cervical lesion and it has been shown to be an effective screening approach 
(Kurman et al., 1994).  However, confirmation of the diagnosis of cervical cancer requires 
a biopsy of the cervix for histological diagnosis.  This is often performed during 
colposcopy, which is an internal vaginal examination to look for abnormalities in the 
cervix.  The use of tumor markers further refines the diagnosis as well as the management 
and prognosis of cervical cancers.  For SCCa, the squamous cell carcinoma (SCC) antigen 
is the marker of choice (De Bruijn et al., 1998; Brioschi et al., 1991), while cancer antigen 
125 (CA 125) has been suggested to have possible utility in the diagnosis and monitoring of 
ACCA (Gadducci et al., 2009; Borras et al., 1995). 
 
1.2.3.3  Cancers of the ovaries 
 Ovarian cancer is the fourth most common cancer in Malaysian females.  It is a 
cancerous growth that occurs in one or both ovaries.  Early ovarian cancer may not cause 
any symptoms.  When symptoms do appear, ovarian cancer is often in a more advanced 
stage.  Among the symptoms are pain or swelling in the abdomen, pain in the pelvis or 
gastrointestinal problems such as bloating and constipation.  However, early diagnosis is 
difficult as the symptoms are non-specific.  
At present, there are several types of ovarian cancers which are separated based on 
their distinct and pathological features i.e., epithelial, germ cell and sex cord stromal 
carcinomas (Trope et al., 1997).  Most ovarian cancers are classified as epithelial ovarian 
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carcinoma (EOCa), which comprises approximately 80% of ovarian cancer cases (Morgan 
et al., 2011).  In EOCa cases, development of cancerous cells begins in the lining of the 
ovary and the majority of EOCa cases are diagnosed in premenopausal women (median age 
range of 63 years).  Germ cell ovarian cancer (GOCa), on the other hand, is associated with 
the egg producing cells within the body of the ovary.  Unlike the EOCa, germ cell tumor 
occurs in young women of child-bearing age i.e., under 30 years of age and is highly 
curable (Ozols et al., 2001).  Another type of ovarian cancer is the sex cord stromal cancer 
which is very rare.  This cancer arises in the cells that releases steroid hormones and can 
occur in women of any age. 
Diagnosis of ovarian cancer starts with a physical examination to check for any 
visible abnormalities of the uterus.  Bimanual pelvic examination has been the most 
commonly used method for the detection of ovarian cancers.  However, this technique is 
too insensitive and cannot reliably detect early disease (Neijt et al., 1995).  The most 
effective screening method at present is a combination of serum CA 125 levels and 
transvaginal sonography.  However, measurement of CA 125 alone is not reliable enough 
as it is not always present in ovarian cancer, and it may be present in benign ovarian 
conditions (Petricoin et al., 2002).  Confirmation of diagnosis is thus performed by taking 
biopsies of the affected tissue and also by doing laparoscopy, colonoscopy and abdominal 
fluid aspiration. 
 
1.2.3.4  Cancers of the endometrium 
 Endometrial cancer refers to several types of malignancies that arise from the 
endometrium or lining of the uterus.  It is also referred to as womb cancer, cancer of the 
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corpus uteri and uterine cancer (Bull and Woolas, 2011).  Tumors of the endometrium can 
be divided into two main subtypes i.e., endometrial adenocarcinoma (EACa) and uterine 
sarcomas.  EACa is the major subtype and usually occurs in post-menopausal women.  This 
cancer originates from the single layer of epithelial cells within the uterine lining (Amant et 
al., 2005).  Other less common types of endometrial cancers are the papillary serous, clear 
cell, mucinous and squamous cell adenocarcinomas.   
 Cancer of the endometrium is easily recognizable due to its usual presentation of 
postmenopausal abnormal vaginal bleeding (Hubbard and Holcombe, 1990).  However, in 
younger women, this symptom may lead to a delay in diagnosis of cancer as this symptom 
may be due to many other causes.  Initial diagnosis of endometrial cancer is usually 
performed by doing a vaginal examination followed by an ultrasound scan of the uterus.   
For confirmation of endometrial cancer, biopsy is commonly performed for histological 
examination of the endometrial and endocervical tissue samples.  To date, there has been no 
existing reliable biomarker for screening of endometrial malignancy (Banno et al., 2012).  
The only available biomarker that could aid in the diagnosis of endometrial cancer is CA 
125.  However, as mentioned earlier, the up-regulated level of this tumor marker is also 
seen in patients with ovarian cancer. 
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1.2.4 Non-sex hormone related cancers  
1.2.4.1  Osteosarcoma 
Osteosarcoma is the most common primary malignant bone cancer.  Primary bone 
cancer refers to cancer that forms in cells of the bone.  In contrast, secondary bone cancer 
refers to cancer which originates from a different place but metastasizes to the bones.  For 
this type of sarcoma, the age-specific incidence curve peaks in the adolescent period of 
between 10 and 20 years old, and again in old age (Henderson et al., 1982).  It was 
suggested that the incidence peak during adolescent is associated with the pattern of 
skeletal growth in which within these ages, there is rapid growth of the bone.  Skeletal 
growth is highly influenced by a combination of factors including the stimulation by 
hormones, especially the pituitary growth hormones and the thyroid hormones (Henderson 
et al., 1982).  This cancer often occurs in the long bones of the arms and legs, in particular 
at areas of rapid growth around the knees and shoulders.  This type of cancer is often very 
aggressive with risk of spread to the lungs.  The five-year survival rate is about 65%. 
Patients with osteosarcoma may present with persistent pain, swelling or tenderness 
of a bone.  They may have unexplained fracture of one or more bones, sometimes without 
noticeable trauma.  The presenting radiologic finding on X-ray is often destruction of bone. 
Currently, diagnosis relies heavily on imaging techniques with the lack of available clinical 
tumor markers.  Development in the field of imaging has contributed to effective diagnosis 
and management of osteosarcoma.  These included computed tomography (CT) and 
magnetic resonance (MR) evaluation of the bone and soft tissue for the detection of 
metastatic disease as well as to facilitate surgical planning (Tan et al., 2006).  A biopsy 
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sample of the tumor will be obtained either through a small needle (needle biopsy) or 
through a small incision (incisional biopsy) for histological investigation.   
 
 
1.2.4.2  Nasopharyngeal carcinoma 
The term nasopharyngeal carcinoma (NPCa) encompasses any carcinoma arising in 
the nasopharynx.   The nasopharynx is a tubular space, situated at the base of the skull and 
it represents a transitional area between the nasal cavities and the oropharynx.  This cancer 
is common in men particularly of Chinese ancestry (Huang, 1991).  In Malaysia, NPCa is 
the fourth most common cancer among Malaysian and the third most common cancer 
among males (National Cancer Registry, 2011).  NPCa is linked to three factors, which 
may play an inter-mingling role in its pathogenesis.  Epstein-Barr virus infection, 
occupational exposure to wood dust and consumption of certain preservatives or salted 
foods, more specifically the „Cantonese dried fish‟, has been suggested to be amongst the 
risk factors of NPC (Huang, 1991).  To date, the etiology of NPCa has not been associated 
with any hormonal factors.  
Symptoms that are common to NPCa include a lump or sore that does not heal, 
trouble speaking, breathing or swallowing, frequent headaches, pain or ringing in the ears. 
NPC is diagnosed by endoscopy using a nasopharyngoscope inserted through the nose, X-
ray, CT scan, magnetic resonance imaging (MRI) and biopsy.  To date, biopsy is the 
reliable test for confirmation of NPCa (Woo and Waldran, 1991).  However, in some 
atypical cases, especially when the disease is submucosal, additional investigations are 
required.  One of them is the detection of IgA antibodies to EB-virus specific antigens, 
which appeared to be helpful in the diagnosis of NPCa (Woo and Waldran, 1991).  In 
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addition, the potential use of serum markers such as the circulating intercellular adhesion 
molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin, CYFRA 
21-1 and C-erb B2 has also been reported (Lee et al., 2001; Yazici et al., 2001; Liu et al., 
1999; Kuo et al., 1996). 
 
1.3 Cancer and tumor markers: limitations 
A tumor marker is a soluble substance produced by the tumor or in some cases, by 
the body in response to the diseased condition (Malati, 2007).   They can also be defined as 
biological molecules found in blood, other body fluid or tissue, which signifies normal or 
abnormal process or condition or disease.  Tumor markers may be present as intracellular 
substances in tissues or may be released into the circulation and appear in the serum of 
patients with cancer.  Thus, based on their measurements in the blood or other body 
secretions, these markers can be used as an indicator of presence of cancer (Malati, 2007). 
These tumor markers may aid in the diagnosis, assessment of prognosis, selection of 
treatment, monitoring of progress during and after treatment, and/or be used as screening 
tests.  
The need for specific and sensitive tumor markers for screening of cancer is critical 
as a timely diagnosis of cancer represents one of the most important ways of reducing 
cancer mortality.  The success of treatment for cancer relies on the ability to detect it at its 
earliest stage (Wulfkuhle et al., 2003; Hutter and Sinha, 2001) whereby the tumor is still 
small enough to be completely removed surgically.  Hence, finding sensitive and effective 
tumor markers is critical in the battle against cancer and has an important public health 
impact (Ardekani et al., 2002).  At present, the diagnosis of cancer still relies greatly upon 
   
 15 
histological and cytological investigations.  Thus, patients had to be subjected to the 
invasive diagnostic procedure, which is not feasible for screening purposes.  The ideal 
diagnostic choice would then be to use serum tumor markers due to its easy and 
inexpensive accessibility.   
However, there are not many available tumor markers that are specific for the 
detection of cancer.  Tumor markers such as CA 19-9, CA 125, CEA, SCC, HCG and PSA 
are currently used clinically as diagnostic clues.  Although such tumor markers may have 
been in widespread use for many years, there still remain unresolved issues with regards to 
their optimal clinical use.  This is due to the fact that these markers of cancers are also 
found to be expressed in other benign conditions as demonstrated in Table 1.1.  In addition, 
many tumor markers, particularly CA125, CA 15-3, CA19-9 and CEA, are also raised in 
several other cancers.  Owing to the „low‟ diagnostic sensitivity and specificity, the 
biomarkers could not be applied in the screening of an asymptomatic population for the 
purpose of early detection.  An ideal biomarker would require a specificity of greater than 
99% to avoid the consequence of a high rate of false-positive results.   
While some of these proteins have been examined individually as potential 
biomarkers and found to have „low‟ sensitivity or specificity as individual tests, growing 
evidence indicates that these limitations may be overcome using panels of candidate tumor 
markers that together could better represent the patient‟s status.  There is high probability 
of increasing the diagnostic power of the current tumor markers if supplemented by other 
tumor markers or aberrantly expressed proteins such as the acute-phase reactant proteins 
(Pang et al., 2010), instead of relying on single tumor marker as currently practiced.  The 
concept of using more than one marker in a multiplexed format is not new.  It has been 
used for many years for thyroid and Down‟s syndrome testing but has been limited in the  
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Table 1.1: Clinically available biomarkers for cancer 
 
Tumor marker Cancer 
Other conditions in which marker may be raised 
Cancer Other 
α fetoprotein   (AFP) Germ cell/testicular tumour; 
Hepatocellular carcinoma  
Colorectal; gastric; lung; hepatobiliary; 
hepatocellular; pulmonary          
Liver degeneration 
Cancer antigen 125 
(CA125)          
Ovarian cancer            Breast; cervical; endometrial; hepatocellular; 
lung; non-Hodgkin’s lymphoma; pancreas; 
peritoneal; uterus  
Leiomyoma; acute hepatitis; acute/chronic 
pancreatitis; arthritis; osteoarthritis; 
rheumatoid arthritis; chronic liver disease 
Cancer antigen 19-9 (CA19-
9)         
Pancreatic cancer         Colorectal; gastric; hepatocellular; 
oesophageal; ovarian   
Acute/chronic pancreatitis; cholestasis; 
chronic liver disease; jaundice 
Carcinoembryonic antigen 
(CEA)  
Colorectal cancer         Breast; gastric; lung; mesothelioma; 
oesophageal; pancreatic          
Chronic renal failure; Jaundice;  Chronic liver 
diseases- Cirrhosis 
Squamous cell carcinoma 
(SCC)             
Cervical cancer                 Head and neck; lung; esophagus; anal canal       Extensive liver disease 
Prostate specific antigen 
(PSA)   
Prostate cancer            None known Acute urinary retention; benign prostatic 
hyperplasia 
  Data derived from Malati, 2007 
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use for the diagnosis of cancer (Whiteley, 2006).  Recent studies conducted by several 
groups of researchers have shown that by using multiple tumor markers, they managed to 
develop a more accurate detection method for the early diagnosis of cancers of the breast 
(Li et al., 2002) and prostate (Laxman et al., 2008).  Clearly, there is a need for more and 
better tumor markers with higher sensitivity and specificity to replace or complement the 
existing ones.  This is where the emergence of proteomics technology could greatly 
facilitate the discovery of new markers for the development of highly accurate diagnostic 
approach for early diagnosis of cancer. 
  
1.4 Pregnancy as a hormone-related condition 
 Pregnancy is the fertilization and development of one or more offspring, known as 
an embryo or fetus, in a woman‟s uterus.  However, in a pregnancy, there can be multiple 
gestations as in twins or triplets and unfortunately, pregnancy could also be of abnormal 
form such as with ectopic and molar (hydatidiform mole) pregnancies.  Pregnancy begins 
with implantation of the blastocyst, which is a developed form of the fertilized egg (zygote) 
to the uterine wall.  This is the beginning of the embryonic stage which lasts for eight 
weeks.  During this period, the embryonic cells differentiate to develop various basic body 
systems.  By the end of this stage, early features of the eyes, mouth, ears and fingers could 
be seen.  Once the embryonic stage is completed, the embryo enters the final stage where it 
becomes known as a fetus.  The fetus then develops and grows in weight and length until 
the last week of pregnancy (Norwitz et al., 2001).  A pregnancy usually occurs within 38 to 
40 weeks after conception and is arbitrarily divided into three trimesters.  The first twelve 
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weeks is considered as the first trimester, while the second and third trimesters cover the 
period of week 13 to 28 and week 29-40, respectively.  
During the pregnancy period, a pregnant woman experiences several physiological 
changes.  The various alterations are required to support fetal growth and development 
(Mansourian, 2010).  The growth and development of the fetus requires several hormones, 
progesterone and estrogen in particular, to fulfill the cellular and molecular demand related 
to the pregnancy period (Bacq et al., 1996).  These hormones are required to regulate 
endometrial differentiation and function, pregnancy recognition signaling, uterine 
receptivity for implantation and conceptus-uterine interactions (Spencer and Bazer 2004; 
Norwitz et al., 2001).  During pregnancy, the serum estrogen and progesterone levels 
increase progressively and reach a maximum during the third trimester.  Estrogen is 
produced by the ovaries, and later by the placenta, with the levels increasing steadily until 
birth.  It plays important roles in the key physiological events essential to the development 
and maintenance of the fetus as well as protection of the mother.  Estrogen is also 
implicated to the production of progesterone.  Progesterone is one of the members of the 
progestogen group of hormones.  It is produced first by the ovaries and followed by the 
placenta but at a much later time compared to the production of estrogen.  Progesterone 
starts to be produced at the beginning of the second trimester and plays important role in 
maintenance of the pregnancy condition.  It is involved in maintaining the uterine lining, 
function of the placenta and stimulates the growth of breast tissue. 
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1.5 PROTEOMICS 
Currently, the search for new tumor markers is gaining momentum through the use of 
proteomics technologies (Wulfkuhle et al., 2003; Verma et al., 2001).  Recent proteomics 
studies in cancer have identified proteins that were differentially regulated in cancer 
samples and have led to the discovery of several candidate biomarkers.  This is further 
accelerated by the immense diagnostic potential of using serum or plasma.  From a medical 
viewpoint, serum is the most informative proteome.  Almost all cells in the body 
communicate with plasma directly or through extracellular or cerebrospinal fluids and may 
release at least part of their contents into plasma upon damage or death.  Hence, any 
diseased state will produce some specific patterns of protein change in the body‟s working 
fluid (Anderson et al., 2004).   
 
 
1.5.1 Definition of proteomics 
 The term proteome is an analogy to the term genome and was first introduced in 
1994 by Marc Wilkins (Wilkins et al., 1995).  Later, in 1995, Wasinger defined proteome 
as `the total protein complement encoded by a genome or by a particular cell or specific 
tissue type‟ (Wasinger et al., 1995).  Proteins are the vital parts of a living organism as they 
are the main components of cellular physiological metabolic pathways.  Hence, in order to 
study the cell metabolism or to identify possible disease-specific biomarkers or even 
possible drug targets, analyses on the proteome of the cell needs to be carried out.   
Proteomics, on the other hand is defined as the systematic analysis of the protein 
expression of a proteome or more likely, a subproteome (Wilkins et al., 1995).  It is also 
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defined as a large-scale characterization of the entire protein complement of a cell line, 
tissue or organism (Anderson and Anderson, 1996).  However, Graves and Halstead later 
formulated a more extensive definition where proteomics could be seen as a large scale 
screening process that aims to profile the overall distribution of proteins in cells, 
characterize and identify proteins of interest and finally to elucidate their relationships and 
functional roles (Graves and Haystead, 2002).  As such, proteomics at its simplest level is 
the study of protein expression in a proteome.  It is a platform which attempts to understand 
the relative levels of protein within a mixture, characterize the proteins, compare variations 
in the expression levels between normal and disease states, study their interactions with 
other proteins and identify their functional roles. 
 
1.5.2 Proteomics studies 
Genomics and proteomics, in principle, hold promise for systematic routes for 
tumor marker discovery and as such have rapidly become popular.  After genomics, 
proteomics is seen as the next step towards understanding complexities of biological 
systems.  The development and progression of proteomics in the past decade have been 
substantially facilitated by the availability of developments in mass spectrometry (MS) and 
genomic information.  Invention of mass spectrometry coupled with knowledge on the 
DNA sequence of human and other genomes has opened doors for proteomics by providing 
a sequence-based framework for protein identification and characterization.  
However, proteomics is much more complicated than genomics mostly because 
while an organism's genome is more or less constant, the proteome is dynamic in nature.  
Gene expression analysis allows determination of transcript levels for many thousands of 
   
 21 
genes, but this does not necessarily equate to the production of functional protein (Mischak 
et al., 2007).  Production of protein differs from cell to cell and is highly influenced by the 
cell‟s current physiological state.  As such, even though the complete human genome and 
many other important genomes have been successfully deciphered, direct correlation 
between genomic information and protein function is complicated.  
There are numerous reports highlighting the disparity between mRNA transcript and 
protein expression levels (Varambally et al., 2005; Gygi et al., 1999).  A possible reason 
for this phenomenon could be that even though mRNA were produced in abundance, they 
may be degraded rapidly or translated inefficiently, resulting in a small amount of protein.  
To add to these complexities, most mRNA transcripts are subjected to a wide variety of 
chemical modification subsequent to their translation.  The post-translational modifications, 
such as phosphorylation, ubiquitination, methylation, acetylation, nitrosylation, oxidation 
and glycosylation, have the ability to change the functional activity of a protein.  Some 
proteins even undergo all of these modifications, often in time-dependent combinations, 
aptly illustrating the potential complexity when studying protein structure and function 
(Jensen, 2006).  In addition, a single gene may code for more than one protein due to 
alternative splicing of the mRNA (Graveley, 2001).  Hence, genomic analysis alone is 
unable to provide adequate information on post-translational events that may often change 
in diseased conditions (Mischak et al., 2007).  This problem may be directly addressed by 
proteomics, which can potentially capture dynamic changes in protein expression.  In 
addition, as the proteome is far more extensive than the genome, it offers a richer source of 
potential tumor markers (Mischak et al., 2007).  However, the advantages of proteomics 
also present enormous challenges, as the levels of complexity and dynamic range in body 
fluids are difficult to analyze and measure. 
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1.5.2.1  Areas of proteomics research 
Currently, application of proteomics is rapidly growing with the scope of 
applications extending from microbiology to plant research, drug discovery, and clinical 
diagnostics.  In the clinical field, proteomics can be divided in practice into three major 
areas: expression proteomics, functional proteomics and proteome related bioinformatics 
(Westermeier and Naven, 2002).  Expression proteomics also known as structural 
proteomics is an important component of proteomics which deals with quantitative analysis 
and identification of large number of proteins encoded by genomes in a given cell type 
(Anderson and Seilhamer, 1997).  The main focus of this approach is to search for aberrant 
differences in the expression of proteins between normal and diseased conditions and 
between different diseased states. 
Functional proteomics, on the other hand, is targeted on obtaining information on 
protein function (Lee and Lee, 2004) and to look at complexing of proteins at the molecular 
level (Naylor and Kumar, 2003).  The main goal of this type of study is to look into protein 
signaling, protein interactions and disease mechanism. In this area of research, it is 
important that the method of choice will maintain the activity and integrity of the particular 
protein or protein-protein complexes.   
In the proteome related bioinformatics approach, bioinformatics is utilized to derive 
knowledge from computer analysis of biological data.  Research in this area uses a large 
range of techniques including primary sequence alignment, protein 3D structure alignment, 
phylogenetic tree construction, prediction and classification of protein structure, prediction 
of RNA structure, prediction of protein function and expression data clustering.  
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1.5.2.2  Techniques of proteomics 
Classically, research on protein science relied mostly on antibodies to a particular 
protein.  With the introduction of proteomics, which requires separation and analysis of 
complex mixture containing as many as several thousand proteins, a number of 
technological platforms have been developed.  The most commonly used laboratory 
techniques in proteomics are two-dimensional electrophoresis (2-DE) and mass 
spectrometry. Both techniques can be used in combination with more traditional 
techniques, including affinity column chromatography and western blotting.  For a more 
quantitative determination of protein amount, technique such as enzyme-linked 
immunosorbent assay (ELISA) was and is still the gold-standard technique used. 
 Two-dimensional electrophoresis (2-DE) is a powerful gel-based separation 
technique already introduced in the early 1970s.  The initial protein research projects using 
this method were carried out in 1975 by O‟Farrell (1975), Klose (1975) and Scheele (1975) 
to map proteins from Escherichia coli, mouse and guinea pig, respectively.  Since then, a 
number of modifications have been made to make gels more reproducible and more 
amenable to the higher-throughput use necessary for proteomics applications.  The strength 
of this technique lies in its ability to separate and display thousands of proteins 
simultaneously in a single gel. 
However, starting in the late 1990s, several companies began developing protein 
chips as an alternative to the gel-based 2-DE technique.  These chips allow researchers to 
collect minute quantities of proteins that bind to specific molecules on their surface. 
Another advantage offered by this new technique is that the protein chips are often linked 
to the direct analysis of the protein or peptide such as the ProteinChip arrays in tandem with 
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Surface Enhance Laser Desorption/Ionization-Mass Spectrometry (SELDI-MS).  Another 
emerging non-gel based proteomics approach that is currently applied by researchers is the 
Multi-dimensional Protein Identification Technology (MudPIT).  This approach utilizes 
one- and two-dimensional liquid chromatography for the separation of peptides followed by 
on-line mass spectrometry analysis (2D LC-MS/MS). 
The primary attributes in identifying protein include the protein's mass and its N-
and C-terminal sequence tags.  The first major technology to emerge for the identification 
of proteins was the sequencing of proteins using Edman N-terminal sequencing or Edman 
degradation (Edman, 1949).  However, in today‟s modern proteomics workflow, mass 
spectrometry (MS) has assumed a key role for the analysis and identification of proteins. 
This is attributed by its sensitivity, accuracy, speed and capabilities to perform high 
throughput analysis (Biemann, 1988).  Availability of database in turn allows protein 
information harvested from either Edman sequencing or MS to be used for protein 
identification.  
The most comprehensive information about specific proteins is found in databases 
that store protein sequences.  One of the first and probably the best known such database is 
SWISS-PROT, which was created in 1986.  Other sequence-based protein databases 
include the Yeast Proteome Database and Human PSD.  There are also a number of widely 
used pattern and profile databases that are used to reveal relationships among proteins 
based on the presence of particular groups of amino acids in the proteins' sequences.  Some 
of the best known pattern and profile databases are: PROSITE, Pfam, PRINTS, and 
BLOCKS. 
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The value of protein quantitation for proteomics research is very substantial.  The 
application of monoclonal antibodies had sparked discovery through close coupling of 
protein with simple quantitative monoclonal antibody-based assays such as the enzyme-
linked immunosorbent assay (ELISA).  However, the conventional immunoassay technique 
allows for the detection of single antigens or antibodies at a time. With the progression of 
proteomics, a multiplexed microsphere bead-based assay that utilizes the xMAP technology 
(Luminex Corporation, Austin, TX, USA) was invented with the aim of developing a more 
rapid, less time consuming and less sample demanding approach as compared to ELISA.  
This approach also permits analyses in a high-throughput manner from a single run. 
 Meanwhile, in determining proteins which are post-translationally modified, one 
way is by developing an antibody which is specific to a certain modification.  This antibody 
can then be used to determine the set of proteins that have undergone the modification of 
interest.  However, a more common way to determine post-translational modification is to 
subject the mixture of proteins to 2-DE which allows visualization of small differences in a 
protein.  While for sugar modifications, such as glycosylation of proteins, certain lectins 
have been discovered which bind sugars.  These lectin-binding properties offer alternative 
methods to investigate glycoprotein changes.  
Most proteins function in collaboration with other proteins, and one goal of 
proteomics is to identify which proteins interact.  This is especially useful in determining 
potential partners in cell signaling cascades.  Several methods are available to probe these 
protein-protein interactions.  The traditional technique applied in establishing protein-
protein interaction was the yeast two-hybrid analysis.  More recent techniques such as 
immunoaffinity chromatography, protein microarrays followed by mass spectrometry, dual 
polarization interferometry and experimental methods such as phage display and 
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computational methods have been used by researchers for this type of study.  However, 
over the last decade, the use of surface plasmon resonance (SPR) technology with biosensor 
chip for interaction analysis has made it possible to look into the kinetics of protein-protein, 
protein-peptide and DNA-protein systems.  
 
 
1.5.3 Application of proteomics in clinical research 
One of the most promising developments to come from the study of human proteins 
has been the identification of potential tumor markers to monitor disease progression as 
well as discovery of new therapeutic targets and new drugs.  Understanding the proteome, 
the protein‟s structure and function as well as the protein-protein interactions is critical for 
developing the most effective diagnostic techniques and disease treatments.  
Tumor markers or biomarkers are important indicators as they could provide 
information about the physiological status of the cell and changes during a disease process 
(Miles et al., 2006).  In cancer, the transformation of healthy into neoplastic cells brings 
about changes that can be followed distinctively at the protein level.  These changes affect 
the cellular function of the cell and can range from alteration of protein expression level to 
differential protein modification and aberrant localization (Srinivas et al., 2001).  Hence, 
the emergence of novel proteomics technologies allows for better understanding of the 
pathophysiology as well as etiology of various malignancies.  These proteomics approaches 
also contribute to the discovery of potential biomarkers to several diseased conditions 
(Srinivas et al., 2002).  Among the candidate tumor markers which have been identified 
using proteomics approaches are in the up-regulated expression of ceruloplasmin in sera of 
patients with nasopharyngeal carcinoma (Doustjalali et al., 2006) and the aberrant 
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expression of several secretory proteins, redox regulators and chaperonins in eutopic 
endometrium of women with endometriosis (Fowler et al., 2007). 
At present, the basis of drug design is to find drugs with the ability to inactivate 
proteins (Ivanov et al., 2007; Archakov et al., 2003).  This new approach relies on the 
genome and proteome information involved in a disease.  One of the approaches that is 
widely applied is the structure-based drug design.  In this approach, once the protein 
associated with a disease is identified, usually via 2-DE, the computer software will then 
use it as a target for development of new drugs.  The computer simulation will attempt to fit 
millions of small molecules to the three-dimensional structure of the particular protein and 
rate the quality of the fit to various sites in the protein.  The goal is either to enhance or 
disable the function of the protein, so as to interfere with its action.  Example of this 
approach is in the identification of new drugs to target and inactivate the HIV-1 protease 
(Wlodawer and Vondrasek, 1998).  
Application of proteomics techniques especially the 2-DE and mass spectrometry, 
have also been widely used for clinical microbiological research.  The 2-DE-MS approach 
has been used to analyze global protein synthesis and provide new insights that 
complement genomic-based investigations.  Other than providing a basic understanding of 
microbial gene expression, proteomics has also played a role in investigating the 
epidemiology and taxonomy of human microbial pathogens, identification of novel 
pathogenic mechanisms and analysis of drug resistance.  Progress has been made with the 
use of these techniques to characterize and compare proteomes of pathogenic bacteria 
(Schmidt et al., 2004; Vandahl et al., 2001; Langen et al., 2000) and has recently found 
applications in the field of parasitology (Parodi-Talice et al., 2004; Drummelsmith et al., 
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2003; Rout and Field, 2001) as more genome sequences of protozoan parasites become 
available.  
 
1.5.3.1  Multiplex immunoassay 
The development and application of a multiplex immunoassay that measures 
multiple proteins in complex matrices is becoming a significant tool for quantitative 
proteomic studies, diagnostic discovery and biomarker-drug development.  Currently two 
broad categories of multiplex assay formats are available; direct labeling with single 
antibody experiment (Kingsmore and Patel, 2003) and sandwich immunoassay, in which 
dual antibodies are used (Schweitzer et al., 2002).  In addition, a variety of microarray 
substrates  (plastic microwells, nylon membranes, planar glass slides, gel-based arrays and 
beads) and signal generation strategies have been employed in the effort to optimize the 
performance of multiplex immunoassays (Perlee et al., 2004).  Among the signaling 
platforms employed are the colorimetry, radioactivity, fluorescence, chemiluminescence, 
quantum dots, resonance light scattemide signal amplification, enzyme-linked assays and 
rolling circle amplification techniques.  Each of these formats has distinct advantages and 
disadvantages relating broadly to their sensitivity, specificity, precision, throughput, ease of 
use and multiplexing power (Nielsen and Geierstanger, 2004; Haab, 2003; Kingsmore and 
Patel, 2003; Schweitzer and Kingsmore, 2002). 
One of the multiplex immunoassay formats which is gaining popularity is the 
microsphere bead-based assay that utilizes the xMAP technology (Luminex Corporation, 
Austin, TX, USA).  The multiplex suspension array is built around three core technologies.  
First is the family of fluorescently dyed microspheres, or beads which act as a solid support 
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that allows covalent coupling of antigens.  Second is a flow cytometer with two lasers and 
associated optics to detect and measure the reactions based on the internal fluorescent ratio 
of the microspheres, and third is a high-speed digital signal processor to efficiently manage 
the fluorescent output.  The Bio-plex multiplex suspension array system uses polystyrene 
microbeads which are internally colored with differing ratios of two spectrally distinct 
fluorophores.  Each fluorophore can have any of ten possible levels of fluorescent intensity, 
thereby creating a family of 100 spectrally addressed bead sets. These dyed beads can be 
conjugated with different monoclonal antibodies, specific for a target protein or peptide.  
Hence, when these sets of antibody-conjugated beads are combined together in a single 
assay, it allows for simultaneous detection and quantitation of many target proteins in a 
single sample and a single run.  This is possible as the array reader can identify each 
specific reaction based on the bead color and quantitates it, whilst the magnitude of the 
reaction is measured using fluorescently labeled reporter molecules which are also specific 
for each target protein. 
At present, high throughput analysis of proteins has moved to a new level with the 
introduction of the multiplex immunoassay.  With multiplexing, researchers today is given 
the opportunity to dramatically increase the amount of useful information from rare or 
volume-limited samples such as the rat serum (Rodriguez et al., 2009), human tear 
(VanDerMeid et al., 2012), aqueous humor (Takai et al., 2012) and even proteins from 
formalin-fixed paraffin embedded tissues (Strathmann et al., 2012) and frozen archived 
muscle biopsies (Baird and Montine, 2008).  In addition, the convenience and consistency 
of this approach is complemented by the availability of commercially prepared cytokines, 
chemokines and growth factor assays.  To date, there has been a lot of work carried out 
using these commercial assays especially for differential diagnosis purposes (Elomaa et al., 
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2012; Gerritzen and Brandt, 2012; Guest et al., 2011; Hanly et al., 2010), for translating 
complex inter-relationships among proteins involved in signal transduction (Fauriat et al., 
2010), as well as for evaluation on the safety and efficacy of candidate drugs (Ray et al., 
2005).  Aside from the commercially available beads, the feasibility of this immunoassay 
method has also allowed for in-house designed beads to be applied in different diagnostic 
areas including serodiagnosis and allergy as well as cancer diagnosis.  Reactants attached to 
the beads can include antibodies (Schipper et al., 2010; Lindau-Shepard and Pass, 2010), 
peptides (van der Wal et al., 2012; Drummond et al. 2008) and antigenic proteins (Awan et 
al., 2012; Smits et al., 2012). 
Hence, based on the robustness and high-throughput method offered by the 
immunoassay, it is of interest to develop an in-house multiplex assay targeted at several 
high-abundance serum proteins; α1-antitrypsin (AAT), α1-antichymotrypsin (ACT), α2-HS-
glycoprotein(AHS), anti-thrombin III (ATR), clusterin (CLU), ceruloplasmin (CLP), 
kininogen (KNG) and zinc-α-2-glycoprotein (ZAG).  Selection of the respective proteins 
was made based on a recent report associating the differential patterns of these acute-phase 
proteins with several types of cancers (Pang et al., 2010).  To date there is limited number 
of commercially available assays for serum proteins in the market and none are specific to 
the list of proteins stated earlier.  Some of the protein assay kits which are available 
commercially are for ferritin, fibrinogen, procalcitonin, serum amyloid A, α-2-
macroglobulin, C-reactive protein, haptoglobin and serum amyloid P (Bio-Plex Pro Human 
Acute Phase Assays, BioRad Laboratories, Inc., USA).  
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1.6 LECTINS 
Currently, most serum proteome investigations are discovery driven, in which a 
large number of proteins are identified with the hope that one or more proteins are uniquely 
associated with a specific disease state.  However, blood serum is a difficult sample to 
characterize on account of the large amount of its protein constituents as well as their vast 
differences of concentrations.  Therefore, it might be difficult to use such profile in the 
search for novel tumor markers.  Alternatively, by targeting at selective proteins, which 
shares specific characteristics, investigation could be narrowed down to a subset of the 
whole proteome.  Hence, the development and application of techniques to fractionate the 
proteome has become an emerging field with one of the selection approaches currently used 
is by utilizing lectins.  
 
1.6.1 Definition of lectin 
The term lectin was first introduced by Boyd in 1954, which was coined from the 
Latin word legere, which means to pick-up or choose.  Lectins by definition are multivalent 
proteins of non-immune origin that bind to sugars rather specifically, agglutinate cells and 
display no catalytic activity.  The history of lectin was traced back to more than a century 
ago with the discovery of the actions of lectin by Herman Stillmark (1888).  He discovered 
that the extracts of castor bean (Rinucis communis) and four other Euphorbiaceae plants 
agglutinated erythrocytes from rabbits, cats, dogs and horses.  From there, lectins were 
regarded as phytohaemagglutines due to their plant origin and their capability to agglutinate 
erythrocytes.  Later, the terminology was ruled out once it was discovered that other agents 
such as tannins and certain lipids or bivalent cations at high concentration could also trigger 
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agglutination of human and animal erythocytes (Rudiger, 1988).  Furthermore, animals 
especially the invertebrates were also found to harbor lectins and not all lectins 
demonstrated agglutination activity towards erythocytes (Rudiger, 1981).  Therefore, with 
the expansion in the field of lectin research, there was a need to determine the boundaries 
of the term lectin.  Goldstein et al. (1980) proposed that lectin is a sugar-binding protein or 
glycoprotein of non-immune origin, which agglutinates cells and/or precipitates 
glycoconjugates.  Later in 1983, Kocourek and Horejsi formulated a broader definition of 
lectin in which they are proteins of non-immunoglobulin nature capable of specific 
recognition and reversible binding to carbohydrate moieties of complex carbohydrates 
without altering the covalent structure of the recognized glysosyl ligands.  A more 
simplified definition was later put forward by Barondes.  It is his simple but concise   
definition of lectin as a carbohydrate-binding protein other than an enzyme or an antibody 
(Barondes, 1988) which many accept till today.   
 
1.6.2 Source of lectin 
The source of lectin is vast.  Lectins have been found in plants, animals and even in 
microorganisms.  Table 1.2 exhibits a list of commercially available lectins derived from 
the various sources.  In the animal kingdom, lectins are widely dispersed among the phylas 
(Cohen, 1984).  They have been successfully isolated from the hemolymph, tissue, serum, 
venom, egg and body fluid of some invertebrates (Kilpatrick, 2002; Cohen, 1984).  In 
microrganisms, lectins have been detected on their cell surfaces or in their periplasm or 
cytoplasm (Giollant et al., 1993).  However, the major contributor of lectin is from the 
plant kingdom.  Lectin-containing plants include the mono- and dicotyledons, molds and 
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lichens, as demonstrated in Table 1.2.  However, most frequently they have been detected 
in the Leguminoseae and Euphorbiaceae groups of plants.  
 
Table 1.2: Examples of commercially available lectins, their origins and carbohydrate 
binding specificity(ies) 
 
Data derived from Wu, 1988 and Doyle, 1994. 
 
 
Source Common name Taxonomic name Carbohydrate 
specificity 
    
Plant Jackfruit (jacalin) Artocarpusheterophyllus Gal 
 Onion Allium  cepa Man and/or Glc 
 Jack bean (ConA) Canavaliaensiformis Man and/or Glc 
 Watermelon Citrullus vulgaris Man and/or Glc 
 Rice Oryza sativa GlcNAc 
 Soy bean Glycine max GlcNAc 
 Mushroom Psathyrellavelutina GlcNAc 
 Asparagus pea Lotus tetragonolobus L-Fuc 
 Wheat Triticum vulgaris Sialic acid 
 
Microorganism       - Pseudomonas aeruginosa Gal 
 Green algae Codium fragile GlcNAc 
 Red marine algae Ptilota plumose Gal 
 
Animal Electric eel Electrophorus electricus Gal 
 Japanese beetle Allomyrinadichotoma GlcNAc 
 Garden snail Helix aspersa GlcNAc 
 Saharan scorpion Biomhalariaglabrata Sialic acid 
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1.6.2.1 Plant lectin  
Plant lectins are the largest and best categorised group of lectins with more than a 
thousand plant species have been reported to possess lectin.  Most of the plant lectins are 
harboured in the seeds or more generally in their storage organs (Rudiger 1988). 
Nevertheless, they can also be found in other tissues such as the leaves and roots (Lis and 
Sharon, 1973).  For instance, species like the Aloe plant stores their lectin in leaves vesicles 
(Suzuki et al., 1979), while garlic plant harbours lectin in its leave and root bulb (Smeets, 
1997).  However, not all plant lectins are stored.  Hevein, lectin from rubber tree (Hevea 
brasiliensis) for example, is released in latex upon wounding of the bark (Giordani et al., 
1999).  Within the cell, lectins are localized in protein bodies, which are special cell 
organelles, derived from the cell vacuoles.  It is also present in the cytoplasm and 
intercellular spaces (Rudiger and Gabius, 2001). 
 Purification of lectin was initially established using methods such as precipitation 
by salts, acids and organic solvents (Rudiger and Gabius, 2001).  Of course, by using these 
approaches, the purity of the yielded lectin was not satisfactory, and as such, results 
obtained from its usage have to be interpreted with caution.   With advancement in the area 
of lectinology, preparative chromatographic methods using ion exchangers, gel filtration 
media and affinity adsorbents further improved the purity of lectins (Rudiger and Gabius, 
2001).  At present, the common purification employed in isolating plant lectins is via 
means of immobilized affinity adsorbent in a one-step purification scheme.  By selecting 
suitable glycoproteins or sugars as ligands, an affinity matrix presenting carbohydrate 
epitopes as ligands for the lectin can be devised.   Examples are in the use of natural 
polysaccharides such as agarose or cyanogen bromide containing galactose (Gal) to isolate 
Gal-binding lectin such as the champedak galactose binding lectin (CGB) and ricin.  For 
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eluting the immobilized lectin, the common method is by exploiting the sugar that acts as a 
competitive inhibitor.  Alternatively, elution can be performed by lowering the pH of buffer 
with immediate neutralization of the eluant in cases whereby the lectin binds to 
oligosaccharides which are not readily accessible or are very expensive. 
 
1.6.3 Binding specificity of lectin 
The nature of lectin in which it exhibits considerable specificity in binding 
oligosaccharides and at the same time hold enormous structural diversity creates much 
debate on its basis of classification (Komath et al., 2006).  At present, lectin could be 
classified using three approaches.  The first method of classification is based on the 
specificities of the lectins.  Based on this classification, lectins are categorised into six 
small groups according to their carbohydrate binding specificities i.e.; galactose (Gal), 
mannose and/or glucose (Man and/or Glc), N-acetylgalactosamine (GalNAc), N-
acetylglucosamine (GlcNAc), L-fucose (L-Fuc) and sialic acid (Wu and Sugii, 1991; Lis 
and Sharon, 1986).  
In the second approach, lectins are categorized based on their structural similarities 
(Van Damme et al., 1998).  The lectins are grouped based on the similarity of their 
molecular structure, sequence identity and specificity.  Four families namely legume 
lectins, type-2 ribosome-inactivating proteins, chitin-binding lectins and monocot mannose 
binding lectins comprise the majority of currently known plant lectins.  Aside from the four 
major groups, there are also smaller groups consisting of jacalin-related lectins, amarithin 
and Cucurbitaceae lectin which consisted of small numbers of lectins. 
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The last method of classification takes into account the structural features of the 
lectins.  Therefore, they are categorized into three groups i.e., simple, mosaic and 
macromolecular assemblies (Lis and Sharon, 1998).  Most plant lectins are classified as 
simple lectins.  This type of lectin possesses small number of subunits, each with a 
carbohydrate recognition domain with possible additional domains for other types of 
ligands.  In contrast, the mosaic types of lectins have multi-functional domains and only a 
single carbohydrate recognition domain.  Lectins with macromolecular assemblies consist 
of filamentous proteins with several different subunits assembled together forming a 
defined complex (Ofek and Doyle, 1994). 
 
1.6.4 Applications of lectin 
 The specificity of lectins in recognizing and interacting with carbohydrate moieties 
have allowed them to be utilized extensively in biomedical and biological studies.  Lectins 
have found extensive applications for differentiating between cells, elucidation of the 
architecture and dynamics of cell surface carbohydrates, glycoconjugate purification and 
structural characterization.  The reason behind the application of lectins across a broad 
spectrum is due to three reasons i.e., they are ubiquitously distributed in nature and they 
exhibit a wide repertoire of carbohydrate specificities as well as in the ease of their 
purification to homogeneity.  It is therefore not surprising that lectins find extensive 
applications in many aspects of biology and medicine. 
The earliest application of lectin was as a blood typing reagent and is still in wide 
use today.  As many lectins display blood-group specificity, they provide an alternative to 
human sera in the field of transfusion medicine.  Examples of useful lectins are the crude 
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extracts of  Lotus tetragonolobus that agglutinate the type O erythrocytes (Renkonen, 
1948), lectin extracted from Phaseolus limensis that specifically agglutinate type A 
erythrocytes (Boyd, 1949), lectin from Dolichos biflorus that agglutinate the type A1 
erythrocytes (Bird, 1951) and lectin from Ulex europaeus, which agglutinates the type H 
erythrocytes (Cazal and Laularie, 1952).  Other than blood typing, lectins are frequently 
used together with other parameters in the attempt to detect and classify polyagglutination 
of erythocytes (Judd, 1980).  The principal lectins employed for this task are isolated from 
Arachis hypogaea (anti-T/Tk), Dolichos biflorus (anti-A1/Tn/Cad), Salvia sclarea (anti-
Tn), Salvia horminium (anti-Tn + Cad) and Glycine max and Bandeiraea simplicifolia 
(anti-Tk) (Judd, 1980).   
Another attractive property of many lectins is in their ability to induce mitosis.  
Several plant lectins have mitogenic characteristics on certain cells such as T and B cells, 
macrophages and neutrophils (Goldstein et al., 1980).  Mitogenicity of lectins on T 
lymphocytes have been displayed by Con A (Powell and Leon, 1970) while pokeweed 
lectin had demonstrated mitogenic activity on both T and B cells (Janossy et al., 1976). 
Example from a more recent study was the finding of the mitogenecity of champedak 
mannose binding lectin on murine T cells by Lim et al. (1997).  Based on their mitogenic 
activity, lectins had therefore opened up a new technique in the field of lymphocyte 
research.  For example, Con A and PHA have been used to stimulate rat spleen cells to 
produce interleukin-2 (Gillis et al., 1980) while jacalin, another plant lectin, has been used 
to produce human -interferon from T-cell hybridoma (Crane et al., 1984).  Lectins have 
also been used for the treatment of cancer via utilizing them in mitogenic lectin therapy, 
anti-tumor therapy and targeted therapy (Mody et al., 1995).  Examples of these types of 
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lectins are abricin and ricin A which have been shown to be potent antitumor cytotoxins 
(Abdullaev and de Mejia, 1997). 
Lectins have also been used in the separation of cells into biologically distinct 
subpopulations.  One of the earliest usage of lectin was in the separation of mouse 
lymphocytes into B and T cells via soybean agglutinin (Reisner et al., 1976).  
Subsequently, the lectin was used to separate the cells responsible for graft-versus-host 
reaction from human marrow cells (Reisner, 1990).  Another example is in the ability of 
peanut agglutinin to separate germ cells from somatic cells in mouse testis (Maekawa and 
Nishimune, 1985) 
The ability of lectins to detect subtle variations in carbohydrate structures found on 
glycoproteins and glycolipids has paved way for the separation of closely related 
glycoproteins (Sharon, 1993).  It is a known fact that the great variation of carbohydrate 
moieties on a protein has created difficulties in its purification.  Thus, glycoproteins are 
among the most challenging of products to characterize because of the extreme and fine 
nature of the sample micro-heterogeneity.  Due to the narrow specificity of the lectins, they 
have been successfully used for fractionation of this type of glycoproteins.  An example is 
in the use of lentil affinity column that has been used to demonstrate the presence of L-
fucose residue attached to the innermost GlcNAac residue (Kornfeld et al., 1981).  In 
addition, the microheterogeneity of 1-acid glycoprotein fucosylation has also been 
previously investigated using lectin from Aleuria aurentia (Liljeblad et al., 2001). 
Lectins are also widely used in biomedical and clinical research areas.  They have 
been used not only for purification but also for determining the structure of glycoprotein-
derived oligosaccharides and glycopeptides.  Characterization of glycans in some of the 
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altered glycoproteins, that manifest in clinical conditions, are of importance for 
understanding disease generation as well as finding candidate tumor markers for the 
diagnosis, prognosis and treatment of the pathological condition.  Uses of lectins in the 
detection of glycosylation alteration associated with pathological manifestation of diseases 
were already reported.  To date, they have been applied in several approaches, such as 
chromatography, array and blotting as well as probes for histological and cytological 
analyses (Haab et al., 2010; Zeng et al., 2010; Zhao et al., 2007).   
The fact that sugars have an affinity for lectins, which is not as high as that for the 
carbohydrate-specific antibodies, is of immense practical utility in the purification of 
glycoproteins via affinity chromatography.  If antibodies are immobilized as the affinity 
ligand, harsh conditions need to be employed to elute the glycoproteins that were adsorbed 
onto the matrix (Satish and Surolia, 2001).   In doing so, there is probability of the isolated 
glycoprotein losing their biological activities.  In contrast, when lectins are employed as the 
affinity ligand for purification of a glycoprotein, only mild conditions are needed for 
elution.  Moreover, the task of isolating the lectins is not as arduous as raising 
carbohydrate-specific antibodies.  As such, lectin affinity chromatography has been used to 
aid in the investigation of several diseased conditions.  The use of champedak mannose-
binding lectin affinity chromatography prior to 2-DE has successfully been employed in the 
search for aberrantly expressed serum glycoproteins in patients with nasopharyngeal 
carcinoma (Seriramalu et al., 2010).  This approach has also made significant contribution 
to the isolation of several candidate tumor markers in patients with prostate cancer 
(Jayapalan et al., 2012; Tabares et al., 2006).  Recently, the use of multiple lectin affinity 
chromatography in a serial fashion has been gaining popularity.  Example is in the work of 
Zeng et al. (2011).  Their group has reported on the use of a multi-lectin affinity 
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chromatography to study glycosylation changes in patients with breast cancer.  
Immobilization of lectin onto solid support could also be performed on magnetic beads as 
described by Lee (2006).  In addition, various lectin conjugates, such as enzymes, biotin, 
fluorescent dyes or colloidal gold as well as radioactive labeled lectins have been utilized as 
specific and sensitive reagents for detection of glycoproteins (Mohamed et al., 2008 (this 
thesis); Abdul-Rahman et al., 2007; Abdul Rahman et al., 2002; Hashim et al., 2001; Li et 
al., 1993; Kijimoto-Ochiai et al., 1985).  
 
1.7 Champedak lectin: lectin of interest 
The study on the champedak (Artocarpus integer) lectin started in the early nineties 
with the discovery of an IgA1-reactive and D-galactose-binding lectin from the seeds of our 
local champedak (Hashim et al., 1991).  It was later discovered that this lectin was 
structurally and functionally similar to jacalin (Hashim et al., 1991 & 1992), which is also 
an IgA1-reactive and D-galactose-binding lectin isolated from the jackfruit (Artocarpus 
heterophyllus) seeds (Roque-Barreira and Campos-Neto, 1985).  
Champedak galactose binding (CGB) lectin is a lectin that binds to the galactose 
residues of the O-linked oligosaccharide moietes.  The CGB lectin comprises two types of 
non-covalently linked subunits with Mr of 13,000 and 16,000. And unlike the 
heterogeneous jacalins of distinctive origins, which were shown to have diverse specificity 
(Hashim et al., 1991; Kobayashi et al., 1988; Kondoh et al., 1987), the CGB lectin isolated 
from several clones demonstrated uniform reactivity (Hashim et al., 1993).  Interaction of 
the CGB lectin with human immunoglobulins demonstrated reactivity with IgA1 but not 
with IgA2, IgD, IgG and IgM (Hashim et al., 1991).  The lectin was also found to consume 
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complement and decrease the complement-mediated hemolytic activity of sensitized sheep 
red blood cells (Hashim et al., 1994).  The use of CGB lectin to probe for glycoproteins has 
been performed using immunodiffusion, affinity chromatography and enzyme-conjugated 
lectin approaches. The lectin has been successfully used in the study on the 
etiopathogenesis of IgA nephropathy (Shuib et al., 1998; Hashim et al., 2001 a & b).  This 
lectin has also been used to identify aberrantly expressed serum proteins, in relation to 
various cancers, by applying it to probe for the glycoproteins that had been separated by 2-
DE and transferred onto nitrocellulose membranes (Jayapalan et al., 2012; Mu et al., 2012; 
Abdullah-Soheimi et al., 2010; Mohamed et al., 2008 (this thesis); Abdul-Rahman et al., 
2007).  
Apart from CGB lectin, champedak seeds also harbour a D-mannose-binding lectin, 
which was termed champedak mannose binding (CMB) lectin (formerly known as 
champedak lectin M).  The lectin was discovered in 1997 by Lim et al. and was shown to 
have high specificity and affinity for the core-mannosyl residues of the N-glycans of 
glycoproteins.  The isolated CMB lectin was later discovered to be structurally quite similar 
but not totally identical to artocarpin (Lim et al., 1997).  Artocarpin is the CMB lectin‟s 
counterpart that was isolated from jackfruit (Miranda-Santos et al., 1991 a & b).  Structural 
studies of the CMB lectin demonstrated it to be a 64 kDa protein (Lim et al. 1997).  The 
lectin shows strong interaction with human IgE and IgM but displays weak interaction with 
IgA2 (Lim et al., 1997).  It also possesses selective mitogenic activity towards T 
lymphocytes (Lim et al., 1998; Hashim et al., 1992).  On the other hand, in the absence of 
T cells and macrophages, CMB lectin was incapable of activating the murine B cells for 
secretion of immunoglobulins (Lim et al., 1998).  The CMB lectin has also been shown to 
selectively bind to a group of glycoproteins collectively known as the N-linked 
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glycoproteins (Hashim et al., 2001a).  The use of enzyme-conjugated CMB lectin on 2-DE 
separated proteins of patients with congenital hypothyroidism has managed to demonstrate 
differences in the carbohydrate structure of haptoglobin ß-chain of the patients, relative to 
their control subjects (Yong et al., 2006).  Meanwhile, recent proteomics investigation on 
serum of patients with nasopharyngeal carcinoma using CMB lectin affinity 
chromatography demonstrated reduced expression of α-2 macroglobulin and complement 
factor B in sera of patients (Seriramalu et al., 2010). 
 
1.8 Research approaches and objectives of study 
 Previous report by Abdul-Rahman et al. has highlighted the enhanced expression of 
a protein, termed LDP1 that interacted with the CGB lectin probe (2007).  This protein, 
which was not detected earlier in the silver-stained 2-DE gels, was found to be over-
expressed in the sera of patients with endometrial adenocarcinoma (EACa) compared to 
control subjects.  In this regard, it is of interest to identify LDP1.  Since the protein was 
earlier detected on nitrocellulose membranes, an alternative approach was adopted to 
isolate LDP1, so as it may be identified by mass spectrometry.  The pooled sera of EACa 
patients would instead be subjected to an immobilized CGB lectin affinity chromatography. 
Following the identification of the LDP1, its expression in cancer and non-cancer 
conditions was assessed using the well-established enzyme conjugated-CGB lectin-probed 
2-DE electrophoretic approach.  Five groups of patients who were newly diagnosed with 
breast carcinoma (BrCa), epithelial ovarian carcinoma (EOCa), germ cell ovarian 
carcinoma (GOCa), nasopharyngeal carcinoma (NPCa) and osteosarcoma (OsSa) were 
subjected to analysis.  Groups of women with normal pregnancy (NP) and hydatidiform 
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mole (HM) as well as menopausal women who were under the hormone replacement 
therapy (HRT) were also recruited for the determination of its expression level in non-
cancer conditions. 
 In the second part of the study, an attempt was made to study the expression patterns 
of serum proteins in the sera of women with NP and HM.  The study was performed via the 
gel-based 2-DE approach that was followed either by the enzyme-conjugated CGB lectin 
detection of O-glycosylated proteins or silver staining.  Identities of all protein spots which 
showed differential expression were established by mass spectrometry and search of 
databases, and their aberrant expression was further validated using the immunoblotting 
technique.  In the final part of the study, an attempt to simultaneously detect the differential 
expression of candidate protein tumor markers in the groups of women with NP and HM 
was performed using a multiplex immunoassay.   
 
Objectives of the study 
The present study was performed: 
1. to identify the LDP1 in sera of women with EACa using immobilized CGB lectin 
affinity chromatography, followed by 2-DE and mass spectrometry analysis. 
2. to analyze the expression of LDP1 in sera of patients with BrCa, EOCa, GOCa, NPCa 
and OsSa using the HRP-CGB lectin-probed 2-DE electrophoretic approach. 
3. to analyze the expression of LDP1 in serum samples of women with NP, HM and 
HRT using the enzyme-conjugated CGB lectin-probed 2-DE electrophoretic approach.  
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4. to develop the O-glycosylated serum protein profiles of women with NP and HM as 
well as that of the normal non-pregnant women using the HRP-CGB lectin-probed 2-DE 
electrophoretic approach. 
5. to develop the high abundance serum protein profiles of women with NP and HM as 
well as the control subjects using the 2-DE and silver staining of gels. 
6. to analyze the differences in protein expression in the 2-DE profiles generated by 
lectin detection as well as silver staining by image analysis between two different groups of 
pregnant women and their control subjects. 
7. to identify the aberrantly expressed proteins detected in the study using mass 
spectrometry analysis. 
8. to validate the aberrant expression of the differentially expressed proteins using 
immunoblotting technique. 
9. to develop a multiplex assay for the simultaneous determination of eight candidate 
serum proteins 
10. to test the viability of the multiplex assay in detecting aberrantly expressed serum 
proteins in relation to the studied pregnancy conditions.   
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CHAPTER 2: 
MATERIALS AND METHODS 
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2.1 Champedak lectin 
 Previous study by Hashim et al, in 1993, had established that lectins obtained from 
seeds of six different cultivars of champedak (Artocarpus integer) did not vary in terms of 
their structure and glycoprotein binding specificity.  Thus, in this study, champedak fruits 
that were used for isolation of champedak galactose binding (CGB) lectin were purchased 
from a local market. 
 
2.2 Human Serum Samples 
Sera were collected from newly diagnosed patients of the University of Malaya 
Medical Centre (UMMC) and University Malaya Specialist Centre (UMSC), Kuala 
Lumpur.  Serum samples were collected from nine different groups of patients: sera from 
patients with endometrial adenocarcinoma (EACa; n=3), localized osteosarcoma (OsSa; 
n=10), nasopharyngeal carcinoma (NPCa; n=13), breast carcinoma (BrCa; n=10), germ cell 
ovarian carcinoma (GOCa; n=10), epithelial ovarian carcinoma (EOCa; n=10), women with 
normal pregnancy (NP; n=20), women with complete hydatidiform mole (HM;   n=20) and 
menopausal women under hormone replacement therapy (HRT; n=10).  Venous blood 
samples were taken from patients with cancer prior to surgery or treatment.  Samples from 
the groups of women with NP and HM were collected from women in their first trimester 
of pregnancy while women with HRT were recruited from the Obstetrics and Gynecology 
Clinic, UMMC. 
All serum samples from carcinoma patients were confirmed histopathologically for 
stage 1 or 2 whilst for the OsSa serum samples, they were from patients showing no 
evidence of metastasis.  For comparison, sera from normal healthy non-pregnant 
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individuals (n=20) were obtained from age matched volunteers  (range of 21-45 years old) 
from the Department of Molecular Medicine, Faculty of Medicine, University of Malaya. 
Samples were obtained with patients‟ consent and approval, granted by the Ethical 
Committee (Institutional Review Board) of the Medical Centre in accordance to the ICH 
GCP guideline and the Declaration of Helsinki. 
 Blood samples were collected in fresh 1.5 ml plain blood collection tubes and were 
centrifuged at 3000g for 10 minutes (Centrifuge 5403, Eppendorf).  Recovered serum were 
collected and stored in aliquots of 100 µl at -80° until used. 
 
2.3 General Materials 
 The materials used during the course of this project and their respective suppliers 
are as listed. 
 
2.3.1 Chemicals 
All chemical used were of analytical grade and were supplied by Sigma Chemical 
Company, St. Louis, USA with exceptions of the following: 
i. British Drug House Ltd. (BDH), Poole, England 
Sodium thiosulphate-5-hydrate 
Sodium dihydrogen phosphate 
Sucrose 
Glutaraldehyde 
Formaldehyde  
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ii. BioRad Laboratories, Hercules, USA 
Bis N,N‟-methylene-bis-acrylamide 
 
iii. ICN Biomedicals Inc., USA 
Tris(hydroxymethyl)aminomethane (Tris) 
Sodium dodecyl sulphate (SDS) 
Glycine 
Glycerol 
 
iv. Merck, Darmstadt, West Germany 
Potassium dihydrogen phosphate 
Sodium acetate-trihydrate 
Acetic acid 
Hydrochloric acid 
Tween 20  
Methanol  
 
v. Pharmacia Biotech,Uppsala, Sweden 
N,N,N‟,N‟-tetramethylethylenediamine 
 
vi. Supelco, USA 
Amberlite  
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2.3.2 Enzymes and substrates  
i. Sigma Aldrich Company, St. Louis, USA 
Activated horseradish peroxidase (HRP)  
3,3‟- Diaminobenzidine (DAB)  
 
ii. Promega, Madison, WI, USA 
Trypsin Gold, mass spectrometry grade  
 
2.3.3 Chromatographic support 
i. GE Health Biosciences, Uppsala, Sweden 
Sepharose 4B  
 
ii. Sigma Aldrich Company, St. Louis, USA  
Cyanogen bromide-activated gel (CNBr)  
 
2.3.4 Membrane 
i. Schleicher and Schuell, Dassel, Germany 
Nitrocellulose membrane 
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2.3.5 Materials for two-dimensional electrophoresis 
i. GE Health Biosciences, Uppsala, Sweden 
IEF immobiline dry strips 11 cm (pH 4-7)  
IPG buffer(pH 4-7) 
Drystrip cover fluid 
Dithiothreitol (DTT)  
Iodoacetamide  
 
2.3.6 Materials for SELDI-MS 
i. Ciphergen Biosystems Inc., Fremont, CA, USA 
ProteinChip array NP20 
Sinnapinic acid 
 
2.3.7 Materials for MS/MS analysis 
i. Sigma Aldrich Company, St. Louis, USA  
α-cyano-4-hydroxycinnamic acid 
 
ii. Millipore, MA, USA 
ZipTip
® 
pipette tips 
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2.3.8 Commercial kits and materials for Bioplex analysis 
i. Pierce, Rockford Illinois, USA 
N-hydroxysulfosuccinimide (S-NHS)  
1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC)  
 
ii. BioRad Laboratories Inc.,USA 
Bio-Plex Amine Coupling Kit 
Bio-Plex COOH Beads (COOH Beads 5, 12, 22, 34, 55, 62 and 91) 
Bio-Plex Cytokine Reagent Kit 
Bio-Plex Human Serum Diluent Kit 
 
2.3.9  Serological Reagents 
2.3.9.1Proteins and antibodies used in the Bioplex analysis  
i. Abcam, Cambridge, USA 
Human α1-antitrypsin  
Human α2-HS-glycoprotein  
Human ceruloplasmin  
Human clusterin 
Biotin conjugated goat anti-human α-1-antitrypsin 
Biotin conjugated rabbit anti-human α-1-antichymotrypsin  
Biotin conjugated rabbit anti-human ceruloplasmin  
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ii. Abnova, Taipei, Taiwan 
Human kininogen 
Human zinc α2 -glycoprotein  
 
iii. Meridian Life Science Inc., Santa Cruz, USA 
Human α-1-antichymotrypsin  
 
iv. RnD system, Minneapolis, USA 
Human antithrombin III  
Biotin conjugated goat anti-human antithrombin III 
Biotin conjugated rabbit anti-human α2-HS-glycoprotein 
Biotin conjugated goat anti-human clusterin  
Biotin conjugated rabbit anti-human kininogen 
Biotin conjugated rabbit anti-human zinc α2 -glycoprotein  
 
 
2.3.9.2 Proteins and antibodies used in the immunoblotting assay   
i. Abcam, Cambridge, USA 
Rabbit anti-human α-1-antichymotrypsin 
 
ii. Abnova, Taipei, Taiwan 
Mouse anti-human leucine rich glycoprotein 
Mouse anti-human zinc α2 -glycoprotein  
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iii. Pierce, Rockford Illinois, USA 
Peroxidase conjugated goat anti-rabbit IgG  
Peroxidase conjugated rabbit anti-mouse IgG 
 
 
METHODS 
2.4 Purification of champedak lectin 
2.4.1 Preparation of crude extracts of champedak seeds 
Collection of crude extracts from champedak seeds were performed using the 
protocol established by Hashim et al. (1991).   
 
Standard solutions 
Phosphate-buffered saline (PBS) 
NaCl     9.360 g 
KCl     0.253 g 
Na2HPO4    0.245 g 
KH2HPO4    1.420 g 
The solution was made up to 1 L with distilled water and the pH was adjusted to pH 7.2 
using HCl.  Solution was stored at room temperature.  For preparation of PBS-azide, 
sodium azide was added at 0.1% (w/v) and stored at 4°C. 
   
 54 
The champedak seeds were cleaned with distilled water and dried at 37°C for 24 
hours.  Dried seeds were ground to powder form using a blender and 150 g of the powdered 
seeds were suspended overnight in PBS at 10% (w/v) with constant stirring at 4°C.  The 
suspension was later centrifuged at 8000 x g for 15 minutes (7000 r.p.m. for 20 minutes) 
also at 4°C using a Sorvall R2B centrifuge.  Resulting supernatant was collected and 
subjected to ammonium sulphate precipitation to remove impurities thus resulting in a 
semi-pure extract.  Ammonium sulphate was added gradually to 60% (w/v) saturation at 
4°C and suspension was left to stir for 2 to 3 hours.  Stirred solution was later centrifuged at 
8000 x g for 15 minutes also at 4°C.   
The resulting pellets were redissolved with cold PBS before being dialyzed 
extensively with PBS to remove the ammonium sulphate.  After 4 changes of buffer, the 
crude extract of champedak seeds was stored at –20°C. 
 
2.4.2 Preparation of sugar affinity columns 
2.4.2.1  Activation of Sepharose 4B with Divinylsulfone  
Activation of Sepharose 4B was performed using method of Hermanson et al. 
(1992).  The use of Divinylsulfone (DVS) was to introduce reactive vinyl groups in the 
sepharose which enables immobilization of sugars via their hydroxyl groups. 
In this step, 50 ml of settled Sepharose 4B was washed with 1 L of distilled water in 
a sintered glass funnel and suction-dried to a wet cake.  The moist gel was transferred to a 
beaker and was suspended in 50 ml of 0.5 M sodium carbonate.  Mixture was stirred slowly 
in a fume cabinet.  5 ml of DVS was added drop-wise over a period of 15 minutes followed 
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by another hour of continuous stirring at room temperature.  The activated gel was washed 
extensively with distilled water until pH of the filtrate reached that of distilled water.  At 
this point of time, the activated sepharose was ready for ligand coupling. 
 
2.4.2.2  Coupling of sugar to DVS-activated Sepharose 4B 
DVS activated gel was suspended in an equal volume of 20% (w/v) of D-galactose 
in 0.5 M sodium carbonate.  The mixture was allowed to react overnight at room 
temperature with constant stirring.  The sugar-coupled gel was washed successively with 2 
L of distilled water and 2 L of 0.5 M sodium bicarbonate.  Gel was later suspended in 50 ml 
of 0.5 M sodium bicarbonate containing 2.5 ml of 2-mercaptoethanol in a fume cabinet to 
block excess reactive vinyl groups.  Suspension was left to stir for 2 hours at room 
temperature before washing with 2 L each of distilled water and PBS.  The resulting 
galactose-coupled Sepharose 4B were then used to isolate the CGB lectin.  Unused gel was 
stored in PBS azide at 4°C. 
 
2.4.3 Purification of CGB lectin 
CGB lectin was purified from the crude champedak seeds extract using the prepared 
galactose affinity column. 
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2.4.3.1  Isolation of CGB lectin 
Fifty ml of settled galactose-Sepharose gel was suspended in 5 ml of crude extract.  
Suspension was left overnight at 4°C with gentle stirring to allow maximum coupling of 
CGB lectin to the immobilized galactose.  The mixture was then loaded into a 100 cm 
polypropylene column and was allowed to pack at room temperature. 
Once the column was packed, fractions of 3 ml were collected and absorbance was 
monitored at 280 nm using a Shimadzu UV-1201 spectrophotometer.  The column was 
washed extensively with PBS until the absorbance reached baseline (A280 is less than 0.005) 
and leveled off.  The wash fractions collected were unbound fractions which were free from 
CGB lectin.  Bound CGB lectin was then eluted out with 0.8 M galactose in PBS and 
fractions with high absorbance were pooled together.  After elution, the column was 
regenerated by extensive washing with PBS.  Similar steps were repeated several times to 
obtain enough CGB lectin to be used in this study. 
 
2.4.3.2  Purification of extracted CGB lectin 
Collected bound fractions were pooled and dialysed against six changes of diluted 
PBS to remove sugar and salt.  Resulting dialysate was freeze-dried using a freeze-drier 
(Virtis Research Equipment) to concentrate the CGB lectin.  Aliquots of the lectin were 
then stored at –20°C.  
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2.5 Assessment of purified CGB lectin  
2.5.1 Assessing purity of CGB lectin using SDS-PAGE 
To access the purity of the isolated CGB lectin, SDS-PAGE was performed based 
on the discontinuous buffering system by Laemmli (1970).  In this experiment, reduction of 
the CGB lectin was performed by addition of 2% (w/v) DTT. 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
method widely used in protein science to determine sample purity and molecular weight.  
In SDS-PAGE separation, migration is determined by molecular weight of polypeptides.  
SDS is an anionic detergent that denatures protein by wrapping around the polypeptide 
backbone conferring a negative charge to the polypeptides.  When treated with SDS and a 
reducing agent such as dithiothreitol, the polypeptides become rods of negative charges and 
after separation and staining, the position of a protein along the lane gives a good 
approximation of its size.  The band intensity is an indicator of the amount of protein 
present in the sample.   
 
Standard solutions  
30% acrylamide; 0.8% N,N’-methylenebisacrylamide (Solution A) 
 Acrylamide     60.0 g 
 N,N‟- methylenebisacrylamide  1.8 g 
 Deionised distilled water   topped up till 200 ml 
The solution was deionised using amberlite MB-1, filtered and stored in a dark bottle at 
4°C. 
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1.5M Tris-HCL, pH 8.8 (Solution B) 
Tris base      36.2 g 
 Deionised distilled water   150.0 ml 
The solution was corrected to pH 8.8 using HCL and was topped up till 200 ml.  The 
solution was stored at 4°C. 
 
10% (w/v) SDS (Solution C) 
 SDS      10.0 g 
 Deionised distilled water   100.0 ml 
The solution was stored at room temperature. 
 
10% (w/v) ammonium persulphate (Solution D) 
 Ammonium persulphate (APS)  2.0 g 
 Deionised distilled water   20.0 ml   
The solution was kept in aliquots of 200 µl and stored at -20°C.  Solution was thawed prior 
to use. 
 
N,N,N’,N’-tetramethylethylenediamine (TEMED) (Solution E) 
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0.5 M Tris-HCl, pH 6.8 (Solution F) 
Tris base      6.1 g 
 Deionised distilled water   50.0 ml 
The solution was corrected to pH 6.8 using HCl and was topped up till 100 ml.  The 
solution was stored at 4°C. 
 
SDS-PAGE sample buffer (62.5 mM Tris-HCl, pH 6.8; 10% (w/v) glycerol; 2% (w/v) 
SDS; 1% (w/v) DTT; 0.01% (w/v) bromophenol blue) 
0.5M Tris-HCl, pH 6.8   2.5 ml  
Glycerol     2.0 ml 
SDS      400.0 mg 
Bromophenol blue    a few grains 
DTT (added prior to use)   
Solution was topped up to 20 ml with deionised distilled water and stored at -20°C. 
Solution was thawed and added with 1% (w/v) of DTT prior to use. 
 
Cathode buffer (25 mM Tris; glycine 198 mM; SDS 0.1% (w/v), pH 8.3) 
 Tris-HCl     1.2 g 
 Glycine     5.9 g 
 SDS        0.4 g 
The buffer was made up to 1 L with distilled water. 
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Coomassie Blue Stain  
Coomassie Blue Stain  10% (v/v) acetic acid;0.1% Coomassie Brilliant Blue 
Staining solution was kept at room temperature and was re-used for up to 3 times.  
 
Destaining solution  
10% (v/v) acetic acid solution  
 
2.5.1.1  Preparation of stacking and separating gel  
The separating gel mixture was prepared according to Table 2.1 and was carefully 
pipetted into the glass plate sandwich.  Subsequently, the gel was overlaid with a layer of 
distilled water to achieve an even gel surface.  Once the gel polymerized, the overlay was 
removed and was replaced by the stacking gel.  A comb was inserted into the stacking gel 
layer and gel was left to polymerize completely.  
 
2.5.1.2  SDS-PAGE electrophoresis  
Samples and sample buffer were mixed at a ratio of 1:1 and were boiled at 100°C 
for 5 minutes.  5 l of molecular weight marker and 5 l of each sample were filled into the 
wells.  Electrophoresis was performed at 70 V until the blue dye front entered the 
separating gel.  Voltage was then increased to 100 V and was stopped once the dye front 
was approximately 1 cm from the gel bottom.  Gel was later stained using the Coomassie 
Blue method.  
   
 61 
 
Table 2.1: Volumes of stock solutions for stacking and separating gels 
 
Stock solution 
Volumes of stock solutions for 
Stacking gel 18 % separating gel 
Solution A (ml) 0.65 12.00 
Solution B (ml) - 5.00 
Solution C ( l) 50.00 200.00 
Solution D ( l)* 25.00 100.00 
Solution E ( l)* 5.00 6.60 
Solution F (ml) 1.25 - 
Distilled water (ml) 3.05 2.69 
Total volume (ml) 5.03 20.00 
*added prior to use 
 
 
2.5.1.3 Staining with Coomassie Blue 
Gel was soaked in Coomassie Blue staining solution and left overnight with 
continuous shaking.  Staining solution was later replaced with destaining solution and left 
to shake until the gel background was clear.  A piece of clean sponge or KimWipe tissue 
was placed on top of the solution to accelerate the destaining procedure.  Gel was later 
rinsed in distilled water and scanned.  
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2.5.2 Assessing purity of CGB lectin using SELDI-MS 
To substantiate data obtained from the SDS-PAGE analysis, purity of the CGB 
lectin was further evaluated using surface-enhanced laser desorption/ionization mass 
spectrometry (SELDI-MS).  Analysis of the prepared CGB lectin by SELDI-MS was 
performed on pre-activated surfaces of NP20 array using the protocol recommended by the 
manufacturer reader (Bio-Rad Laboratories, California, USA).   
 
2.5.2.1  Immobilization of CGB lectin 
Prior to analysis, saturated matrix solution of sinnapinic acid (SPA) was dissolved 
in the matrix solution (50% aqueous ACN and 0.5% TFA).  1.0 µl of the SPA solution was 
applied onto each spot on the NP20 array and left to dry for 5 min, at room temperature.  
Once dried, 1 μl of 1 mg/ml CGB lectin at dilution of 1:50 was added onto the SPA spots.  
Finally, 1 μl of matrix was again applied onto the same spot thus, forming a sandwich 
preparation within the array spot.  The array was left to dry completely for approximately 
20 min at room temperature and was ready for analysis. 
 
2.5.2.2  SELDI-MS analysis of CGB lectin 
 Mass analysis of the bound CGB lectin was performed using a ProteinChip SELDI 
reader (Bio-Rad Laboratories, California, USA).  Optimization range was set between 10 to 
60 kDa.  MS time of flight spectra were generated by averaging 130 laser shots collected in 
25kV Positive Ions mode.  Initial arrays were read at three laser intensities before 
optimization at 1300 nJ.  The protocol averaged 10 laser shots per pixel with a focus mass 
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of 15 kDa, a matrix attenuation of 1 kDa and a range of 0–20 kDa.  Calibration was 
performed externally using the Proteinchip All-in-One Peptide Standard (Bio-Rad 
Laboratories, California, USA).  Spectra obtained were analyzed using the ProteinChip 
SELDI reader (Bio-Rad Laboratories, California, USA).   
 
2.5.3 Determination of CGB lectin concentration 
Concentration of the purified lectin was estimated using a Protein Assay ESL kit 
(Roche, Germany).  The protein assay kit utilizes a biuret-like reaction.  Concentration 
estimation was performed according the manufacturer‟s instruction using the micro 
method.  A standard curve was constructed based on the standard solution of bovine serum 
albumin (BSA).  The BSA standard was diluted in PBS to achieve protein concentrations 
ranging from 25 to 800 g/ml.  CGB lectin sample was also serially diluted to ensure 
accurate estimation.  Determination of the CGB lectin concentration was later made by 
referring to the BSA standard curve obtained. 
 
2.5.4 Determination of CGB lectin binding activity using double diffusion test  
Double diffusion test also known as Ouchterlony double immunodiffusion is a 
simple but rather dated assay for detecting antigen-specific antibodies.  In the double 
diffusion test, both antigen and antibody are loaded into wells in a bed of agar and allowed 
to diffuse into the gel.  The visual signature of reactivity between antigen and antibody is 
by formation of a thin white line called the precipitin line at their equivalence zone 
(Ouchterlony, 1949).    
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In this assay, 0.5% (w/v) of agarose was prepared in distilled water.  Approximately 
4 ml of warm agarose was pipetted onto a microscope slide placed on leveled surface. 
Several slides were prepared (assay was run in duplicate) and the coated slides were dried 
at 40°C.  Precoating the slides provides an adhesive surface to support the analytical gel.  
Subsequently, 8 ml of buffered 1% (w/v) agarose in PBS-azide was pipetted onto each 
precoated slide and were allowed to solidify.  Once the gel solidifies, holes were punched 
using a 7-well gel puncher (LKB 6808A, Sweden).  Plugs of agar were removed using a 
Pasteur pipette attached to a water pump.  
CGB lectin and all proteins used were prepared at 1 mg/ml in PBS.  20 l of lectin 
was pipetted into the center well followed by 20 l of proteins into the surrounding wells as 
shown in Figure 2.1. Gels were incubated overnight at room temperature in a humid 
chamber to develop.  Unprecipitated excess proteins were removed from the gels by 
extensive dialysis against PBS.  The precipitin lines were stained with Coomassie Blue for 
better visualization. 
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Figure 2.1:  Double diffusion test of CGB lectin. Test was carried out on a 5% (w/v) 
agarose bed.  20 l of the CGB lectin and glycoproteins were pipetted into their respective 
wells.  Gel was then incubated overnight in a humid chamber. 
 
 x : CGB lectin 
 a : 2-HS-glycoprotein (AHS)    
 b : IgA    
 c : IgA2  
 d : IgM    
 e : albumin   
 f : PBS  
 
 
 
 
 
 
 
 
x 
a 
d 
c
b 
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e 
b 
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2.6 CGB lectin affinity chromatography 
2.6.1 Preparation of CGB-CNBr activated gel 
Cyanogen bromide (CNBr) activated gel was used in the preparation of the CGB 
lectin affinity column.  4 g of the activated gel was stirred overnight in ice-cold distilled 
water.  Approximately 12 ml of rehydrated gel was then washed successively with 2 L of 
cold distilled water and 1 L of cold 0.1 M sodium bicarbonate, pH 8.5.  The gel was later 
sucked into a moist cake and was incubated with 12 ml of the purified CGB lectin at a 
concentration of 4 mg/ml. 
Incubation was carried at 4°C with gentle stirring for 20 hours.  Later, the lectin 
immobilized gel was washed with 200 ml of 1.0 M sodium chloride and 200 ml of distilled 
water.  The volume of filtrate collected was measured and its protein concentration was 
estimated based on the protocol in Section 2.5.3.  The gel was then sucked dry and stirred 
in 100 ml of 1.0 M ethanolamine pH 9.0 for 1 hour followed by extensive washing with 1.0 
M NaCl and distilled water. 
 
2.7 Interaction of CGB lectin with intact human serum glycoproteins  
2.7.1 CGB lectin column preparation  
2.5 ml of settled CGB lectin-CNBr gel was packed in a minicolumn and was 
equilibrated with several washes of PBS. 
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2.7.2 Human serum sample preparation 
50 l of serum from each donor or patient were pooled according to their respective 
disorders. 
 
2.7.3 Separation of CGB lectin-bound fractions 
500 l of sample was loaded into the CGB lectin column.  Column was washed 
with PBS and fractions of 2 ml were collected.  Absorbance was monitored at 280 nm using 
a Shimadzu UV-1201 spectrophotometer.  Washing was done extensively with PBS and 
once the absorbance reached baseline, bound fractions were eluted with 0.1 M melibiose.  
Upon elution, bound fractions were pooled together. 
 
2.7.4 Purification of CGB lectin-bound fractions  
The affinity-separated fractions were dialysed against 6 changes of distilled water to 
remove both sugar and salt.  The resulting dialysate were concentrated to 90% of the initial 
volume using a freeze-drier (Virtis Research Equipment).  Aliquots of the fractions were 
stored at –20 C.  
 
2.8 HRP conjugated CGB lectin  
2.8.1 Conjugation of CGB lectin to HRP 
Another application of CGB lectin in this study was to detect O-glycosylated serum 
proteins that were separated via 2-DE.  The 2-DE separated  human serum proteome was 
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electrophoretically transferred to nitrocellulose membranes which were then probed with 
enzyme conjugated lectin to form lectin-glycoprotein complexes.  The complexes were then 
detected using colorimetric reaction of specific substrate towards the enzyme.  In this study, 
CGB lectin was conjugated to horseradish peroxidase (HRP).  The protocol for conjugation 
was adopted from that described in Hudson and Hay (1989). 
 
Stock solutions  
0.1 M Sodium periodate 
Sodium periodate    21.4 mg 
Sodium salt was dissolved in 1 ml of deionized distilled water.  The solution was prepared 
fresh prior to use. 
 
1mM Sodium acetate buffer, pH 4.4 
Sodium acetate    8.2 g/L 
Acetic acid     6.0 g/L 
Sodium acetate solution was mixed with acetic acid solution at a ratio of 1:2.  The solution 
was diluted with distilled water to a final concentration of 1 mM. 
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0.1 M Sodium carbonate buffer, pH 9.5 
Sodium carbonate    10.6 g/L 
Sodium hydrogen carbonate   8.4 g/L 
Sodium carbonate solution was added to the sodium hydrogen carbonate solution until pH 
9.5 was obtained. 
 
0.4% (w/v) Sodium borohydride 
 Sodium borohydride    4.0 mg 
Sodium borohydride crystal was dissolved in 1 ml of distilled water. 
 
0.1 M Borate buffer, pH 7.4 
Disodium tetraborate    9.54 g/250 ml 
Boric acid     42.73 g/L 
Approximately 115 ml of borate solution was added to 4L of boric acid to obtain pH 7.4. 
 
4 mg of HRP was dissolved in 1 ml of distilled water.  Once dissolved, 200 µl of 
freshly prepared 0.1 M sodium periodate solution was added to the HRP solution.  The 
solution was stirred for 20 minutes at room temperature after which it was dialyzed 
overnight against 0.1 mM sodium acetate buffer, pH 4.4 at 4°C.  The pH of the recovered 
HRP dialysate was later raised to 9.5 by adding approximately 25 µl of 0.1 M sodium 
carbonate, pH 9.5.  This was immediately followed by addition of 1 ml of CGB lectin at a 
concentration of 2 mg/ml.  The mixture was left to stir at 4°C for 2 hours.  Free enzyme 
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was reduced by addition of 100 µl of fresh sodium borohydride and left to stand for another 
2 hours at 4°C.  The HRP conjugated product was later dialyzed overnight against 2 L of 
0.1 M sodium borate, pH 7.4, at 4°C with 2 changes of buffer.  The HRP-CGB lectin 
coupled product was then diluted in equal volume with 60% glycerol in the same borate 
buffer and stored at 4°C. 
 
2.9 Two-dimensional electrophoresis 
Two-dimensional electrophoresis (2-DE) is a powerful gel-based proteomics 
approach for the analysis of complex protein mixtures extracted from cells or other 
biological samples.  This technique sorts proteins according to two different properties in 
discrete steps.  In the first dimensional electrophoresis, isoelectric focusing (IEF) will 
separate complex mixture of proteins according to their isoelectric points (pI).  In the 
second dimensional run, SDS-polyacrylamide gel electrophoresis will further separate the 
proteins based on their molecular weights.  
In this study, 2-DE was performed using the apparatus from Amersham Pharmacia 
Biotech.  The first dimension separation was carried out using a Multiphor Flatbed 
electrophoresis system and Immobiline Drystrip (IPG) strips with pH 4-7.  For the second 
step, strips were transferred the Hoefer SE 600 Ruby system for separation on gradient 
SDS-PAGE gels.  
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2.9.1 First dimensional electrophoresis 
Standard solutions 
Sample buffer 
 Urea      13.5 g 
DTT      0.15 g 
IPG buffer (pH 4-7)    0.5 ml 
Triton X-100     0.13 ml 
Mixture was made up to 25 ml with double distilled water and kept in 250 l aliquots at  
–20 C. 
 
Rehydration solution 
 Urea      12.0 g 
IPG buffer (pH 4-7)    0.13 ml 
Triton X-100     0.13 ml 
DTT  
Mixture was made up to 25 ml with double distilled water. Solution was stored in 1250 l 
aliquots at –20 C.  Prior to use, DTT was added into the rehydration solution (0.2 g /1250 
l of rehydration solution). 
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2.9.1.1  Sample preparation 
Samples were added to the sample buffer according to Table 2.2 and were left at 
room temperature an hour. 
 
Table 2.2:  Volume of sample and sample buffer for sample preparation 
Sample Volume of  
sample  ( l) sample buffer ( l) 
   
Serum      7 21 
Bound fractions*    50 100 
* Bound fractions from the CGB lectin affinity chromatography 
 
 
2.9.1.2  Rehydration of immobiline dry strip 
For an 11 cm IPG strip with pH of 4-7, a total volume of 200 l solution was 
required per slot of the reswelling tray.  Thus, mixture of sample and sample buffer was 
made up to 200 l with the rehydration solution.  Prior to use, the reswelling tray was 
treated with hot water and air-dried.  200 l of mixture was loaded into each slot of the 
tray.  The IPG strip was carefully lowered with the gel side facing downwards into the 
sample concoction.  Subsequently, 1 ml of IPG cover fluid was pipetted onto the gel strip to 
minimize evaporation and to prevent urea crystallization.  The rehydrated strips were left to 
stand overnight or for 18 hours at room temperature to ensure complete uptake of sample 
by the IPG strip. 
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2.9.1.3  First dimensional run 
The setting up of apparatus and procedure for isoelectric focusing was conducted 
according to the protocol supplied by the manufacturer.  3 ml of dry cover fluid was 
pipetted on the center of the cooling plate.  The drystrip tray was positioned on the cooling 
plate and 10 ml of dry cover fluid was poured on it.  A drystrip aligner was placed inside 
the tray, on top of the dry cover fluid, to position the rehydrated IPG strips.  Swelled IPG 
strips were then placed in the center of the drystrip aligner with the gel side facing upwards. 
Moistened electrode strips were placed across the cathodic and anodic ends of the aligned 
IPG strips and the electrodes were positioned on the electrode strips.  Each IPG strip was 
overlaid with dry cover fluid to ensure good thermal contact.  The temperature of the 
apparatus was maintained at 20 C using a thermostatic circulator.  Running conditions were 
as stated below.  
 
Table 2.3:  Running conditions for the first dimension run 
Phase Voltage mA W Time 
(hour) 
V/ hr 
      
1 300 5 5 0.30 - 
2 3500 2 5 - 15 000 
 
Once the first dimension run was completed, the focused strips can either be used 
immediately for the second dimension separation or can be stored individually in screw-cap 
tubes at –80 C.  
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2.9.2 Second dimensional electrophoresis 
Standard solutions 
SDS equilibration buffer 
 1.5 M Tris-HCl   pH 8.8   6.7   ml 
Glycerol     69.0 ml 
Urea      72.07 g  
SDS      4.0 g 
Mixture was made up to 200 ml with double distilled water. 
 
4 X Resolving buffer (1.5 M Tris-HCl, pH 8.8)   
 Tris-HCl      36.3 g 
Solution was made up to 200 ml with double distilled water.  HCl was used to adjust the pH 
to 8.8.  
 
Monomer solution  
 30% acrylamide 
 0.8% N,N‟- methylenebisacrylamide 
The solution was deionised using amberlite MB-1, filtered and stored in a dark bottle. 
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Anode buffer (0.37 M Tris-HCl, pH 8.8) 
 Tris-HCl     136.2 g 
Solution was made up to 3 L with double distilled water.  HCl was used to adjust the pH. 
 
Cathode buffer (25 mM Tris, 198 mM glycine, 0.1% SDS) 
 Tris-HCl     6.04 g 
 Glycine     29.73 g 
SDS      2.0 g 
Mixture was made up to 2 L with double distilled water and was prepared fresh. 
 
2.9.2.1  Preparation of 8-18% gradient SDS-PAGE gel 
A 1 mm thick gradient gel was prepared according to the recipe in Table 2.4.  Gel 
was prepared using a gradient maker (model SG 30. Hoefer, USA) connected to a 
peristaltic pump and a gel caster. Casting procedure was done according to the 
manufacturer‟s manual.  Both solutions were placed in the mixing chamber connected to 
the pump by a tube with a canula at one end.  Mixed light and heavy solution was pumped 
into the glass plate sandwich at a constant rate of 2.5 ml/ min. 
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Table 2.4:  Volumes of light and heavy solution for 8-18% gradient SDS-PAGE gel 
 
 Solution light solution (8 %) heavy solution (18 %) 
 
  
4 X resolving buffer 3 ml 3 ml 
Monomer 3.2 ml 7.2 ml 
10 % SDS 120 l 120 l 
Sucrose - 1.8 g 
Distilled water 5.64 ml Made up to 12 ml 
*TEMED 3.96 l 3.96 l 
*10 % Ammonium persulphate 39.6 l 39.6 l 
     * Added just prior to use 
 
2.9.2.2  Equilibration of IPG strips 
Equilibration of IPG strips was carried out using SDS equilibration buffer in two 
separate steps.  The first equilibration step required 1% (w/v) of DTT to be dissolved in 
SDS equilibration buffer.  Once completely dissolved, 5 ml of solution was pipetted into 
each tube containing the IPG strips.  Tubes were shaken gently for 15 minutes.  The second 
equilibration step was similar to the first with the exception of using 4.5% (w/v) of 
iodoacetamide instead of DTT.  Also added was a few grains of Bromophenol Blue. 
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2.9.2.3  Second dimensional run 
Application of the equilibrated IPG strip onto the second dimension gel and setting 
up of the Hoefer SE 600 was carried out according to the procedures proposed by the 
manufacturer.  Thermostatic circulator was set at 16 C.  Electrophoresis was performed at 
constant current in two steps as shown below. 
 
Table 2.5:  Running conditions for the second dimension run 
Phase Voltage mA W Time (minutes) 
     
1 50 80 50 30 
2 600 40mA/ gel 25 mA/ gel - 
     
 
Electrophoresis was stopped once the dye front was approximately 1 mm from the 
bottom of gel.  After electrophoresis, gel was removed from its cassette in preparation for 
Western blotting (for HRP-CGB lectin probing) or silver staining.  Prior to removal, gel 
was marked at the upper corner nearest to the pointed end of the IPG strip to identify the 
acidic end of the first-dimension separation.  All samples were analyzed in duplicates. 
 
 
 
 
   
 78 
2.10 Detection of 2-DE separated proteins using HRP-CGB lectin  
2.10.1 Western blotting of 2-DE gels 
To further analyze the isolated serum O-glycoprotein profiles, western blotting 
followed by incubation with HRP-CGB lectin solution was conducted.  This involved a 
procedure of transferring the resolved serum proteins onto nitrocellulose membrane 
(Schleicher and Schuell, Dassel, Germany) using a semidry transfer system (Novablot Kit 
for the Multiphor II Electrophoresis System, GE Healthcare Biosciences, Uppsala, 
Sweden).  The membranes were then probed with the HRP-CGB lectin to form lectin-
glycoprotein complexes followed by detection using 3,3'-diaminobenzidine 
tetrahydrochloride (DAB).  
 
Standard Solutions  
Transfer buffer (40 mM glycine, 0.1 M Tris, 0.038% (w/v) SDS, 20% (v/v) methanol) 
 Glycine     2.93 g 
Tris      5.81 g 
SDS      0.375 g 
Methanol     200 ml 
Chemicals were dissolved and made up to 1 L with double distilled water. 
 
Tris buffered saline-Tween (TBS-T) (TBS with 0.1% (v/v) Tween-20) 
 TBS      1 L 
 Tween-20     1 ml 
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A piece of nitrocellulose membrane and 6 pieces of filter paper was carefully cut 
according to the size of the 2-DE derived gel.  The graphite anode plate was saturated with 
distilled water while 3 pieces of the filter paper as well as the nitrocellulose membrane 
were soaked with transfer buffer before being placed on the anode plate.  The gel piece, 
which was also pre-equilibrated with the transfer buffer, was carefully placed on top of the 
membrane followed by another 3 pieces of filter paper that were already soaked in the 
transfer buffer.  A roller was carefully rolled on the sandwich of filter papers, membrane 
and gel to remove any trapped air bubbles.  The cathode tray was placed on top of the 
sandwich and transfer was performed for 2 hours at a constant current of 0.8 mA/cm
2
.  
 
2.10.2 HRP-CGB lectin blotting 
The electroblotted membrane was subsequently blocked using 3% gelatin in TBST 
for 1 hour at room temperature with constant shaking.  It was then washed trice with TBST 
for 10 minutes each.  The washed blot was later incubated overnight with the prepared 
CGB-HRP in TBST at a concentration of approximately 1 µg/ml at 4°C.  Washing step was 
repeated again before the membrane was developed using freshly prepared substrate 
solution, a solution containing 25 mg of DAB and 50 µl of 3% H2O2 in 50 ml TBS.  The 
developed reaction was stopped by washing the membrane 3 times with double distilled 
water.  Finally, the membrane was air dried before being scanned using the Image Master 
2D-Platinum software, version 5.0 (GE Healthcare Biosciences).  
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2.10.3 Image analysis of HRP-CGB lectin detected blots 
Captured images of the respective blots were then analyzed using Image Master 2D 
platinum software, version 5.0 (GE Healthcare Biosciences, Uppsala, Sweden).  Automatic 
spot detection was performed with default parameters, whereas spot editing and removal of 
artifacts were done manually.  Glycoprotein spots were analyzed in terms of percentage of 
volume contribution.  The percentage volume contribution refers to the volume percentage 
of a protein taken against the total spot volume of all proteins in each gel.  A minimum 
difference of two folds between differentially regulated proteins of controls and tests 
(represented by ratios of above 2.0 or below 0.5), was taken as the cutting point for the 
variation to be considered significant. 
All values are presented as mean ± SEM (standard error mean).  Data were analyzed 
by Student's t-test to determine differential expression between healthy and test samples.  A 
false discovery rate (FDR) correction was applied to correct for multiple comparisons and 
finally a p value of less than 0.01 in all the tests was considered significant.   
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2.11 Detection of 2-DE separated proteins using silver staining  
Silver staining was conducted according to the method by Heukeshoven and 
Dernick (1985) with some modifications.  
 
Staining solutions 
Fixing solution (40% (v/ v) ethanol, 10% (v/v) acetic acid) 
 Ethanol     400 ml 
 Acetic acid     100 ml 
Mixture was made up to 1 L with distilled water. 
 
Incubation solution (30% (v/v) ethanol, 0.5 M sodium acetate, 8 mM sodium thio-
sulphate, 0.13% (v/v) glutaraldehyde) 
Ethanol     300 ml 
Sodium acetate trihydrate     68 g 
Sodium thiosulphate 5-hydrate    20 g 
Solution was made up to 1 L with distilled water and 1.30 ml of glutaraldehyde was added 
prior to use. 
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Silver solution (5.9 mM silver nitrate, 0.02% (v/v) formaldehyde) 
 Silver nitrate     1.0 g 
Dissolved and made up to 1L with distilled water.  Prior to use, 200 l of formaldehyde 
was added.  
 
Developing solution (0.24 M sodium carbonate, 0.2% (v/v) formaldehyde) 
 Sodium carbonate    15.0 g 
Dissolved and made up to 1L with distilled water.  100 l of formaldehyde was added prior 
to use. 
 
Stopping solution (40 mM EDTA-Na2.2H2O) 
EDTA-Na2.2H2O    14.6 g 
Dissolved and made up to 1L with distilled water. 
 
Preserving solution (10% (v/v) glycerol) 
 Glycerol     100 ml 
Made up to 1 L with distilled water. 
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2.11.1 Staining of gels 
After completion of the second-dimension electrophoresis, gel slab was immersed 
in fixing solution for 30 minutes to precipitate the proteins and to allow SDS to diffuse out. 
Gel was later left in incubation solution for 30 minutes to overnight incubation.  After 
incubation, the gel was washed three times with distilled water for 5 to 10 minutes each. 
Staining with silver stain was done for another 40 minutes.  The gel was then rinsed with 
approximately 50 ml of developing solution before subjecting it to further incubation in 
fresh developing solution.  Once protein spots were developed, gel was soaked in stopping 
solution for 30 minutes to block further color development.  Stopping procedure was done 
twice followed by washing with distilled water.  Incubation was carried out in a shaker as 
all steps in the staining technique required gentle shaking.  Developed gel was stored in 
preserving solution at room temperature.  
 
2.11.2 Image analysis of silver stained 2-DE gels 
2-DE profiles of protein spots from sera of controls and women with NP and HM 
were performed using the Image Master 2D platinum software, version 5.0 (GE Healthcare 
Biosciences, Uppsala, Sweden).  Automatic spot detection was performed with default 
parameters, whereas spot editing and removal of artifacts were done manually.  Analysis 
was restricted to the protein spots with Mr of greater than 30,000 which were distinctively 
separated in the silver stained 2-DE gels.  Albumin and serum polypeptides having 
idiotypic and/or allotypic variations (such as the heavy and light chains of all isotypes of 
immunoglobulins and the α-chains of haptoglobin) and the low Mr protein spots, which 
were not well resolved under the settings of our experiment, were not assessed. 
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Spots were analyzed in terms of percentage of volume contribution and all values 
are presented as mean ± SEM (standard error mean).  The percentage volume contribution 
refers to the volume percentage of a protein taken against the total spot volume of all 
proteins in each gel.  To determine the significance of the differential expression obtained 
from the comparative analysis conducted between healthy and test samples, a minimum 
difference of two folds, as represented by ratios of above 2.0 or below 0.5, was taken as the 
cutting point.  In addition, when subjected to statistical analysis using the Student's t-test, 
the comparison should demonstrate a p value of less than 0.01 to be considered statistically 
significant.   
 
2.12  Mass spectrometry analysis 
Identification for aberrantly expressed proteins obtained from the comparative 
analysis between groups of test individuals with their control subjects were carried out 
using mass spectrometry (MS).  Gel plugs containing the LDP1 protein was sent to the 
Biomolecular Research Facility, University of Newcastle, Callaghan, Australia for mass 
spectrometry analysis.  As for the aberrantly expressed proteins detected in the serum 
samples of women with NP and HM, MS analyses were performed at the Proteomics 
Research Facility, Faculty of Medicine, University of Malaya.  
For both MS analysis, 2-DE gel runs of serum samples were repeated.  However, 
the resolved gels were stained with a different recipe of Commassie Blue stain.  Following 
staining of the gels with Coomassie Blue, gel plugs containing protein spots of interest 
were excised from the gels.  The gel pieces were then kept in HPLC grade water, in clean 
microfuge tubes.  This was to ensure that the gel plugs remained hydrated until analysis is 
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carried out.  The gel plugs were then either sent out for an out-sourced MS analysis or 
subjected to a series of procedures in preparation for an in-house MS analysis. 
 
2.12.1 Coomassie Blue staining for MS analysis 
Standard solution:  
Staining solution 
 0.1% Coomassie Brilliant Blue (R250) 
   50% methanol 
 5% acetic acid glacial  
 
Destaining solution 
 50% methanol 
 5% acetic acid glacial 
 
Storage solution 
 5% acetic acid glacial 
 
For each gel, 250 ml of each solution was prepared.  All solutions were prepared in 
double distilled water.  Gels were soaked in Coomassie staining solution either for 20-30 
minutes or left overnight with continuous shaking.  Staining solution was later replaced 
with destaining solution and left to shake until the gel background was clear.  A piece of 
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clean sponge or KimWipe tissue was placed on top of the solution to accelerate the 
destaining procedure.  All steps were carried out at room temperature.  
  
2.12.2 Destaining of Coomassie-stained gel plugs 
For identification of the proteins of interest, the selected clusters of protein were 
manually excised from the Commassie stained gels.  The gel plugs were washed and 
destained by adding 100 µl of 25 mM ammonium bicarbonate/5% ACN to each piece of gel 
plug.   Following a 15-minute incubation, the supernatant was removed and 100 µl of 25 
mM ammonium bicarbonate/50% ACN was added.  The washing and destaining steps were 
repeated twice.   
 
2.12.3 Preparation of peptides 
Following destaining of the gel pieces, the proteins in the gel plugs were reduced 
with 10 mM DTT in 100 mM ammonium bicarbonate solution for 30 minutes at 60ºC.  
After which alkylation was performed using 55 mM iodoacetamide in 100 mM ammonium 
bicarbonate for 20 minutes at room temperature and protected from light.  After incubation, 
the gel pieces were washed thoroughly for 3 times with 50% ACN to dehydrate the gels.  
Plugs were then subjected to vacuum centrifugation (Speed Vac
®
) at room temperature to 
remove as much ACN as possible.  
Once dried, the gel plugs were digested with 10 ng/µl trypsin (Promega, Madison, 
WI, USA) in 50 mM ammonium bicarbonate at 37°C for 18 hours.  Extraction of the 
peptides from the gel plugs was carried out using 50% ACN and 100% ACN followed by   
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lyophilisation in a vacuum centrifuge.  The lyophilised peptides were then reconstituted 
with 0.1% formic acid and purified using reversed phase ZipTip® pipette tips containing 
C18 resin (Millipore, MA, USA). 
 
2.12.4 Tryptic peptide analysis 
Equal amount of peptide sample and α-cyano-4-hydroxycinnamic acid (5 mg/ml) 
were mixed together and 0.7 µl of each mixture was spotted onto the Opti-ToF® 384 well 
MALDI plate insert (AB SCIEX, Foster City, California).  The wells were then allowed to 
dry under ambient conditions and once dried the plate was loaded into the 4800 Plus 
MALDI ToF/ToF™ analyzer (AB SCIEX, Foster City, California).   In this study, the MS 
and MS/MS spectra were calibrated using the mass standard kit (Applied Biosystems/ MDS 
Sciex, Toronto, Canada).  
 
2.12.5 Database search 
Data obtained from the MS/MS analysis was generated using the peaklist software 
4000 Series Explorer (release version 3).  The data was then exported for search using the 
MASCOT search engine (Matrix Science Ltd, London, UK; release version 2.2).  Search 
was performed against all entries in the NCBI non redundant database (updated April 25, 
2007, containing 192489 sequences).  The following parameters were used in the 
MASCOT Ion Search: enzyme: trypsin; allowed missed cleavage-1; variable modification – 
2; (i) carbamidomethylation of cysteine, and (ii) oxidation of methionine; MS precursor ion 
mass tolerance – 100 ppm; MS/MS fragment ion mass 2.2.4. 
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2.13 Immunodetection of aberrantly expressed proteins 
The subsequent validation of the differentially expressed serum proteins in sera of 
women with NP and HM were performed by subjecting SDS-PAGE separated proteins to 
western blotting followed by immunodetection using antibodies.   
Prior to the SDS-PAGE separation, serum samples were diluted to a 1/20 final 
dilution using double distilled water.  Diluted samples were added to equal volume of SDS-
PAGE sample buffer prior to boiling for 10 minutes.  After boiling, 10 µl of each sample 
was loaded into a 12.5% SDS-PAGE gel.  Alternatively, for serum proteins with high 
molecular weight, 7.5% gels were used.  Electrophoresis was carried out as described in 
section 2.5.1.2.  Upon completion of SDS-PAGE, blotting of gels was performed as 
described in section 2.10.1.  Following protein transfer, blots were stained with Ponceau S 
so as the protein lanes became visible.  The blots were then cut vertically into strips using a 
scissor.   This was followed by decolorization of the stain using double distilled water. 
 
2.13.1 Immunodetection using antibodies 
Staining of blots with antibodies by an immunoperoxidase technique was performed 
as instructed by the manufacturers of the antibodies used in this part of the study.  In the 
initial part of the work, the membrane strips were first blocked with either non-fat milk or 
BSA to saturate any unoccupied sites on the membranes.  Strips were incubated with 
blocking buffer for 2 hours at room temperature with gentle agitation.  Following blocking, 
the strips were then washed 3 times for 5 minutes per wash using their respective buffers 
and incubated with the desired antibodies overnight at 4°C.  Prior to use, the antibodies 
were diluted with their respective blocking buffers into various concentrations as suggested 
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by the manufacturer.  After incubation, strips were washed again in 3 changes (10 minutes 
each) of buffer.  Subsequently, peroxidase conjugated goat anti-rabbit and rabbit anti-
mouse secondary antibodies were diluted 1:100,000 and 1:200,000, respectively.  Strips 
were incubated with the secondary antibody conjugates for 2 hours at room temperature 
with agitation followed by a washing step.  After washing in 3 changes of buffer, the strips 
were developed with DAB substrate solution as described in section 2.10.2. 
 
2.13.2 Image analysis of blots 
To quantify the intensity of the resolved bands, stained strips were analyzed using 
the Image Master 2D-platinum software version 5.0 (GE Healthcare Biosciences, Uppsala, 
Sweden).  Automatic spot detection was performed with default parameters, whereas spot 
editing and removal of artifacts were done manually. 
All values are presented as mean ± SEM (standard error mean).  Data were analyzed 
by Student's t-test to determine differential intensity between the bands of test and control 
samples.  A false discovery rate (FDR) correction was applied to correct for multiple 
comparisons and a p value of less than 0.01 was considered significant. 
 
 
2.14 Development of a multiplex assay for simultaneous detection of proteins 
In the present part of the study, an attempt was made to develop a multiplexed 
immunoassay which allows for simultaneous quantification of multiple proteins in a single 
sample.  Aside from evaluating the viability of the multiplex assay to simultaneously detect 
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the aberrantly expressed serum proteins, results derived from the assay would further 
corroborate the earlier findings of this study.  Protocols employed in the preparation and 
validation of the multiplex immunoassay were as described by the manufacturer. 
In the present study, an indirect competitive multiplex assay was developed to 
detect the differential regulation of the aberrantly expressed serum proteins.  Unlike a 
customized bioplex immunoassay, whereby the beads are immobilized with antibodies to 
the protein of interest (section 1.5.3.1), the developed in-house design involved conjugation 
of the beads with the protein of interest.  Hence, the detector antibodies were antibodies 
specific to the respective proteins on the beads.   In this format, the protein conjugated 
microbeads were mixed with the serum sample in the microtiter wells.  When the detector 
antibodies were added into the wells, immobilized proteins will compete with free serum 
proteins for binding sites on their corresponding detector antibodies.  The serum protein-
antibody complexes and any unbound proteins were then removed by the washing step.  
Hence, only the protein-conjugated bead-antibody complexes were detected and 
enumerated by the array reader.  
 
2.14.1 Development of protein conjugated beads 
In this study, Bio-Plex carboxylated (COOH) polystyrene beads numbered 5, 12, 
22, 34, 55, 62, 79 and 92 with distinct emitting fluorescence patterns were chosen. 
Commercially available antibody and protein pairs that comprised of AAT, ACT, AHS, 
ATR, CLU, CLP, KNG and ZAG were purchased from commercial sources.  The coupling 
process was performed following the procedures supplied in the Bio-Plex Amine Coupling 
Kit (BioRad Laboratories, Inc., USA).  In the coupling step, proteins would be covalently 
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coupled on to the surface of the beads via carbodiimide reactions which involved the 
protein primary amino groups and the functional groups bound on the surface of the 
polystyrene beads. 
 
2.14.1.1  Protein preparation 
Prior to the coupling process, proteins must be free of sodium azide, BSA, glycine, 
Tris or any amine-containing additives and must be suspended in PBS, pH 7.4.  Protein 
purification and buffer exchange were performed using Micro Bio-Spin
™
 6 Tris 
chromatography columns (Bio-Rad Laboratories, Inc., USA).  The protein of interest (20-
75 µl) was carefully applied into the column, which was then spun for 5 minutes at 1000 
xg.   Purified protein sample, now in PBS, pH 7.4, was placed on ice and protein recovery 
was determined using the Protein Assay ESL kit (Roche, Germany) as stated in section 
2.5.3. 
 
2.14.1.2  Protein coupling 
 Optimal protein-coupling conditions must be established by determining the 
amount of protein that is required to promote optimal binding between the protein and the 
ligand on the beads.  As such, each of the purified proteins was reconstituted in PBS, pH 
7.4 to several concentrations ranging from 2-12 µg/ml.  The beads stock solutions were 
vortexed for 30 seconds followed by sonication in a bath sonicator (Ultrasonik, NeyTech) 
for another 30 seconds.  This step was to ensure that the beads were completely 
resuspended as single monodisperse particles.  The microbeads are light-sensitive, thus, 
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throughout the process, beads were protected from light as much as possible by covering 
the tubes with aluminum foil.  For a single coupling reaction, an aliquot of 1.25 x 10
6 
beads 
was transferred into the coupling reaction tube.  The beads were centrifuged at 14 000 x g 
for 4 minutes and the supernatant was carefully removed from the bead pellet.  This was 
followed by a washing step using 100 µl of wash buffer.  The beads were then resuspended 
in 80 µl of bead activation buffer and were sonicated until a homogeneous distribution of 
microspheres was observed.   
Solutions of N-hydroxy-sulfosuccinimide (S-NHS) and 1-ethyl-3-(3-
dimethlaminopropyl)-carbodiimide hydrochloride (EDC), both at 50 mg/ml, were prepared 
in bead activation buffer.  Ten µl of each freshly-made solution was then added to the 
beads. Suspension was incubated for 20 minutes at room temperature with agitation to 
allow activation of the carboxyl groups on the beads.  Then, 150 µl of PBS, pH 7.4 was 
added followed by centrifugation to remove the supernatant from the activated beads.  The 
bead pellet was then resuspended with 100 µl of PBS, pH 7.4.   Each of the protein 
samples, which were prepared into various concentrations, was added into the bead 
suspension.  The volume of the mixture was adjusted to a final volume of 500 µl   and was 
left on an agitator for 2 hours at room temperature or alternatively overnight at 4°C.  After 
incubation, beads were washed with 500 µl PBS, pH 7.4.  Further reaction was blocked 
using 250 µl of blocking buffer. The coupled beads were later enumerated with a 
haemacytometer and stored in the dark at 4°C. 
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2.14.1.3  Validation of coupling 
Once the coupling reaction has been completed and the approximate numbers of 
protein-coupled beads have been counted, the functionality of the coupling reaction needs 
to be validated.  In this step, the protein-coupled beads were reacted with its corresponding 
biotinylated antibody followed by activation of the biotin by streptavidin-PE 
(phycoerythrin).  The intensity of the resulting fluorescent signal is directly proportional to 
the amount of coupled protein available on the surface of the beads. 
Coupling efficiency was determined by incubating 5000 beads with 50 µl of its 
biotinylated antibody in staining buffer for 30 minutes.   Fifty µl of diluted streptavidin-PE 
was added to the beads and mixture was incubated for another 10 minutes.  This was 
followed by centrifugation to remove the supernatant and the resulting pellet was 
resuspended in 125 µl of storage buffer.  Beads were vortexed at medium speed and 125 µl 
of sample was transferred to a single well of a 96-well 1.2 µm PVDF filter bottom 
microtiter plate (Millipore, Schwalbach, Germany).  Beads were analyzed with the Bio-
Plex array system (BioRad Laboratories Inc.,USA).  A successful coupling would typically 
yield a fluorescent intensity signal greater than 2,000 median fluorescent intensity (MFI). 
 
2.14.2 Determination of multiplex assay characteristic 
The developed multiplex immunoassay was subjected to various tests to evaluate its 
performance.  All evaluation assays were carried out at room temperature and protected 
from light as much as possible. 
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2.14.2.1  Evaluation of assay’s specificity  
In order to determine the specificity of the developed immunoassay, the degree of 
cross-reactivity between the various sets of beads was evaluated.  The beads were put to 
challenge by the various biotinylated antibodies involved in the multiplex assay (Ling et 
al., 2007).    
In this assay, a bead working solution was prepared by calculating the volumes 
required from the a single set of bead, so as in each well of the microtiter plate there would 
be approximately 5000 beads/50 µl of assay buffer.  Next, 50 µl of the working bead 
solution was added into each well.  This was followed by three times washing with 100 µl 
of wash buffer.  All tests were run in duplicates and blank wells were devoid of any 
microbeads.  Each of the biotinylated antibodies (detector antibodies) was dissolved in the 
Bio-plex detection antibody diluent to a final concentration of 2 µg/ml.  The freshly 
prepared detector antibody solution was vortexed and 25 µl of the solution was added into 
each well.  The microtiter plate was then sealed with a sealing tape before covering it with 
aluminum foil.  The plate was vigorously mixed on a shaker at 1100 rpm for 30 seconds 
followed by 30 minutes incubation with shaking at 300 rpm on a microplate shaker 
(Eppendorf, Westbury, NY).   Following incubation, the plate was washed three times with 
100 µl of Bio-plex wash buffer. 
 For the detection step, 50 µl of 2 µg/ml streptavidin-PE, freshly prepared using the 
Bio-plex assay buffer, was added into each well.  The plate was covered with a new sheet 
of sealing tape followed by aluminum foil before being placed on the shaker.  Incubation 
was carried out for 10 minutes at room temperature with quick but vigorous shaking 
followed by gentle shaking at 300 rpm.  At the end of the 10 minutes incubation, the buffer 
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was removed via vacuum filtration and plate was washed 3 times.  This was followed by 
the addition of 125 µl of assay buffer into each well and plate was shaken at 1,100 rpm for 
30 seconds to resuspend the beads.  Finally, plate was placed on a calibrated Bio-Plex
 TM
 
array instrument (BioRad Laboratories Inc.,USA).   
Percentage of cross-reactivity for a particular set of protein conjugated beads was 
calculated as the ratio of the fluorescence intensity in response to an antibody compared 
with the maximum intensity derived from the interaction of the protein on the beads to its 
corresponding detector antibody.  
 
2.14.2.2  Optimization of sampel dilution 
To determine the optimal serum dilution to be used in combination with the 
multiplexed immunoassay, serum samples were diluted with the Bio-Plex human serum 
diluent using dilution factors of 1/4, 1/50, 1/100 and 1/200.  A working solution was 
prepared by mixing 1500 beads from each set of beads into 50 µl of assay buffer.  
Likewise, a cocktail of detector antibodies was also prepared by mixing each of the 
antibodies to a final concentration of 2 µg/ml.   
Aliquots of 50 µl of bead mixture were pipetted into each well after which the beads 
were washed with 100 µl of wash buffer.  Subsequently 50 µl of diluted serum samples 
were added into the wells and mixture were incubated for 30 minutes.  25 µl of freshly 
prepared detection antibody working solution was added into each well and this was 
followed by another 30 minutes of incubation.  Beads were then washed and drained using 
a vacuum manifold.  For detection, 50 µl of 2 µg/ml streptavidin-PE was added into each 
   
 96 
well.  Beads were then incubated for 10 minutes followed by 3 times of washing using the 
wash buffer.  Finally, the beads were resuspended using 125 µl of assay buffer.   The plate 
was later loaded into the Bio-Plex
 ™ 
 array system. 
 
2.14.2.3  Evaluation of assay’s sensitivity 
In this part of the study, the ability of the developed immunoassay to specifically 
detect differences in the concentration of serum proteins was investigated.   The assay was 
run using the indirect competitive approach and the serum samples were spiked with 
different concentrations of proteins.   
In the present study, each of the protein at initial concentrations of 2 µg/ml, was 
serially diluted to final concentrations of 0.2, 0.02, 0.002 and 0.0002 µg/ml.  Test samples 
were prepared by mixing 45 µl of diluted serum with 5 µl of each serially diluted protein.  
The beads mixture was prepared as described earlier. 
Aliquots of 50 µl of bead mixture were pipetted into each well after which the beads 
were washed with 100 µl of wash buffer.  Subsequently 50 µl of test sample was added into 
the wells along with 25 µl of the detection antibody working solution.  The mixture was 
then incubated with vigorous shaking for 30 seconds followed by gentle shaking at 700 rpm 
for 60 minutes. The incubation period is to allow free proteins i.e., serum proteins and the 
spiked proteins to compete with the bead conjugated proteins for binding sites on the 
detector antibodies.  After the incubation period, the plate was placed on the vacuum 
manifold to remove buffer, serum sample and free protein-antibody complexes produced 
during the incubation.  Wells were then washed 3 times with 100 µl of Bio-plex wash 
buffer as previously stated.  For detection, 50 µl of streptavidin-PE (2 µg/ml) was added 
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into each well.  Plate was then washed and beads were resuspended and analysed as 
described earlier.  
 
2.14.2.4  Evaluation of assay’s reproducibility  
Reproducibility of the multiplex assay was assessed by determining the level of 
both intra- and inter-assay variation.  Intra-assay variation within a plate was determined by 
assaying 10 control samples in duplicates.  For each protein, the coefficient of variation 
(%CV) for each duplicate result was calculated and averaged (van Gageldonk et al., 2008).   
Inter-assay variation (plate to plate variation) was assessed by testing 10 control 
samples in two separate assays.  The %CV between each of the results for each protein was 
calculated and averaged. 
 
2.14.3 Profiling of proteins using the competitive multiplex assay  
A bead mix and serum samples were prepared as described in the earlier sections.  
50 µl each of the prepared bead mix and diluted serum samples were added into the wells 
of the microtiter plate.  Also added was 25 µl of the detector antibody mixture.   This was 
followed by 30 minutes incubation on a plate shaker (700 rpm) at room temperature.  All 
controls and samples were assayed in duplicates and blank wells were treated similarly to 
tests except for the absence of serum sample.   
Following incubation, the plate was subsequently washed three times prior to 
addition of 50 µl of Streptavidin-PE as previously described.  125 µl of assay buffer was 
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then added to resuspend the beads.  Finally, plate was placed on a calibrated Bio-Plex
 TM
 
instrument (BioRad Laboratories Inc.,USA) for analysis.  Statistical analysis was 
performed by applying Student's t-test to the MFI values for each of the protein tested in 
the different groups of women studied.  A p value of less than 0.01 was considered 
significant.  All values were presented as mean ± SEM (standard error mean).   
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CHAPTER 3: 
RESULTS 
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3.1 Identification of LDP1 
Previous report by Abdul-Rahman et al. has highlighted the enhanced expression of 
a protein termed LDP1 that interacted with the CGB-HRP probe (2007).  This protein, 
which was not detected earlier in the silver-stained 2-DE gels, was found to be over-
expressed in the sera of patients with endometrial cancer (EACa) compared to control 
subjects.  In the initial part of this study, an attempt was made to identify LDP1.  Since the 
protein was earlier detected on nitrocellulose membranes, an alternative approach was 
adopted to isolate LDP1 and separate the protein by 2-DE so as it may be identified by 
mass spectrometry.  Hence, pooled serum samples from EACa patients were subjected to 
CGB lectin affinity chromatography. 
 
3.1.1 Isolation and purification of CGB lectin 
In the present study, the CGB lectin affinity column was prepared initially by 
isolation and characterization of the lectin.  The CGB lectin was purified by subjecting 
crude extracts of champedak (Artocarpus integer) seeds to galactose-Sepharose affinity 
separation.  The CGB lectin‟s affinity towards galactose promotes its isolation from other 
lectins and compounds within the champedak seed extract. 
Figure 3.1 demonstrates a typical elution pattern of the galactose affinity 
chromatography of the champedak seed extract.  The column was first washed with PBS to 
ensure removal of all substances that did not bind to the galactose.  The flow-through 
fractions are represented by the first peak of the elution profile.   The galactose-bound CGB  
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Figure 3.1: Elution profile of CGB lectin.  A crude extract of the champedak seed was 
applied into a galactose-Sepharose affinity chromatography column.  Fractions collected 
were monitored by measuring the absorbance at 280 nm.  The column was washed 
extensively with PBS, pH 7.2 until the absorbance fell to less than 0.05.  Bound CGB lectin 
was eluted using 0.8 M D-galactose in PBS until absorbance of the effluent returned to less 
than 0.05.  Arrow denotes the point of application of the galactose solution.  
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lectin was then displaced from the column using 0.8 M D-galactose and appeared as the 
second peak in the elution profile.    
 
3.1.2 Assessment of purified CGB lectin 
The CGB lectin fractions collected from the galactose-Sepharose affinity 
chromatography were pooled, extensively dialysed and freeze-dried.  To ensure that the 
CGB lectin obtained from the isolation process was highly purified, assessment for its 
purity and reactivity was performed. 
 
3.1.2.1  Purity of CGB lectin 
In order to assess its purity, the CGB lectin was subjected to SDS-PAGE 
electrophoresis.  Figure 3.2 demonstrates the electrophoretic profile of the CGB lectin.  The 
reduced lectin contained a protein which migrated as two highly resolved bands with 
relative molecular weights of approximately 16.5 and 14.0.  These were the two typical 
bands of the CGB lectin as reported by other researchers (Abdul Rahman et al., 2002; 
Hashim et al., 1991).  No other bands were detected in the SDS-PAGE profile of the 
isolated CGB lectin, thus, indicating that the prepared lectin was free from any 
contaminants. 
To substantiate the data obtained from the SDS-PAGE analysis, purity of the CGB 
lectin was further evaluated using surface-enhanced laser desorption/ionization mass 
spectrometry (SELDI-MS).  Analysis of the prepared CGB lectin by SELDI-MS was  
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Figure 3.2:  Analysis of CGB lectin by SDS-PAGE.  The affinity purified CGB lectin 
was subjected to 18% SDS-PAGE electrophoresis and Coomassie-blue staining.  Gel was 
calibrated with molecular weight markers for SDS-PAGE consisting of 
triosephosphateisomerase (26.6kDa), myoglobin (17.0 kDa), -lactalbumin (14.4 kDa) and 
aprotinin (6.5 kDa). The lectin was resolved into two distinct bands.  The arrow indicates 
the direction of sample migration. 
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performed on a ProteinChip NP20 array and resulted in a mass spectrum profile that is 
shown in Figure 3.3.  Two pairs of successive sharp peaks of approximately 14 and 16 kDa 
were observed.  These peaks correspond closely to the subunits of the CGB lectin and 
comparable with those that were previously established by Abdul-Rahman, (2007).  The 
other pair of peaks was detected at the lower region, with masses of approximately 7 and 8 
kDa, were the doubly charged subunits of the lectin.  There was no other peak detected in 
the profile.  And this reflects the high purity of the CGB lectin preparation. 
 
3.1.2.2  Concentration of CGB lectin 
The protein concentration of the CGB lectin prepared in this study was determined 
using the Protein Assay ESL kit (Roche, Germany).    The overall yield of the concentrated 
CGB lectin was estimated to be approximately 6.34 mg/ml, which corresponds to 1.7 mg/g 
of dried champedak seed weight.  Figure 3.4 demonstrates the calibration curve used to 
estimate the concentration of the purified lectin. 
 
3.1.2.3  Specificity of CGB lectin 
The binding specificity of the CGB lectin was assayed using the double diffusion 
test.  In this study, interactions of the CGB lectin with various human serum proteins and 
isotypes of immunoglobulins were investigated.  Figure 3.5 demonstrates the binding 
interaction of the purified CGB lectin towards selective proteins. 
 A positive reaction between the CGB lectin and a glycoprotein was reflected by 
formation of a precipitin line between the respective wells.  Based on the observation made,  
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Figure 3.3: Analysis of CGB lectin by SELDI-MS.  The prepared CGB lectin was 
analyzed using SELDI-MS.  Four peaks were detected within the spectrum profile, at 
masses of approximately 7, 8, 14 and 16 kDa. 
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Figure 3.4: BSA standard curve.  A typical standard curve was constructed based on 
standard solutions of BSA with concentrations of 0, 50, 100, 300, 500 and 750 µg/ml.  
Estimation of the CGB lectin was made by referring to this standard curve. 
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(a)                                                                     (b) 
                                        
 
Figure 3.5:  Interaction of CGB lectin with human proteins using double diffusion assay.   
The purified CGB lectin was tested with several human proteins and immunoglobulins.  
Positive reactivity is represented by formation of a precipitin line between adjacent wells.  
The center well (x) was filled with 20 µl of CGB lectin while the surrounding wells were 
filled with various proteins as listed below: 
     a : IgA1  
b : AHS 
c : IgA2 
d : IgM 
e : Albumin 
f  : PBS   
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positive reactivity was exhibited for wells containing IgA1 and α2-HS glycoprotein (AHS), 
which are known to have O-linked oligosaccharide structures.  However, no precipitin lines  
were detected for the non-O-glycosylated IgA2 and IgM.  Similarly, wells containing 
albumin and PBS, which served as negative controls, did not exhibit any reactivity with the 
CGB lectin. 
 
3.1.3 CGB lectin affinity separation of O-glycosylated serum proteins 
The highly purified CGB lectin was then used in the development of a CGB lectin 
affinity column, as previously described by Abdul Rahman et al., 2002.  Subsequent to its 
development, the lectin column was used to isolate O-glycosylated proteins from serum 
samples of patients with EACa, which are known to contain substantial amount of LDP1.   
The serum samples of EACa patients were pooled and applied into the CGB lectin 
affinity column.  Bound O-glycoproteins were displaced from the lectin using 0.1 M 
melibiose in PBS.  Figure 3.6 demonstrates the elution profile of the O-glycosylated serum 
proteins using the developed CGB lectin affinity chromatography column.  Fractions from 
the first peak consisted of serum proteins which did not interact with the CGB lectin.  The 
CGB lectin reactive serum proteins were then eluted in the fractions that form the second 
peak of the elution profile.  
 
3.1.4 2-DE profile of lectin purified O-glycosylated serum proteins 
The bound fractions from the CGB lectin affinity chromatography were pooled, 
dialyzed and freeze-dried.  However, the pooled fractions obtained comprised a cocktail of  
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Figure 3.6:  Isolation of O-glycosylated serum proteins.  Pooled serum samples from 
three patients with EACa were subjected to CGB lectin affinity chromatography.  Fractions 
collected from the column were monitored by measurement of absorbance at 280 nm.  
Column was washed extensively with PBS, pH 7.2 until the absorbance fell to less than 
0.05.  Arrow indicates start of elution of bound glycoproteins using 0.1 M melibiose in 
PBS.  Elution was performed until absorbance of the effluent returned to less than 0.05.   
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CGB lectin reactive serum O-glycoproteins, including the LDP1 protein.  To isolate the 
LDP1 protein spot cluster, the pooled concentrated protein mixture was subjected to 2-DE 
separation. 
When the pooled lectin bound fractions were separated by 2-DE and stained with 
Coomassie Blue, several protein spots were resolved.  Profiles obtained were found to be 
generally comparable to the HRP-CGB lectin blots previously generated by Abdul-Rahman 
et al. (2007) from sera of patients with EACa, except for presence of an intensely stained 
line of immunoglobulin light chains (Figure 3.7).  Spots that were visually identified 
included IgA α-heavy chains, immunoglobulin light chains, α1-antichymotrypsin (ACT), 
α2-HS glycoprotein (AHS), hemopexin (HPX), cleaved high molecular weight kininogen 
light chain (KNG), leucine rich glycoprotein (LRG) and the LDP1 protein spot cluster.   
 
3.1.5 MS/MS Identification of LDP1 
To identify LDP1, its Coomassie-stained protein spot cluster was excised from the 
2-DE gel prior to analysis by mass spectrometry.  *The MS/MS results obtained from the 
Biomolecular Research Facility, University of New Castle, Australia were then exported 
for search using the MASCOT search engine.  The information regarding its database 
search using the NCBInr database is summarized in Table 3.1, while the list of peptide 
sequences derived from the MS/MS analysis is presented in Table 3.2.  Based on the 
MS/MS data and the MASCOT database search, the LDP1 protein spot cluster was 
identified as inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4).   
_________________________________________________________________________
*Due to malfunction of the MS instrument at the University of Malaya during the period of time of the 
experiment, analysis was out-sourced.   
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Figure 3.7: Profile of O-glycosylated serum proteins of pooled EACa patients.  Bound 
fractions from the CGB lectin column was separated by 2-DE and stained with Coomassie 
Blue.  The acidic side of the gel is to the left and relative molecular mass declines from the 
top.  
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Table 3.1: MS identification of LDP1 protein 
 
 
 
 
 
 
 
a)
 Accession number is from the MASCOT database (www.matrixscience.com) 
b)
 Percentage of sequence coverage was calculated against the ITIH4 fragment 
 
 
 
Table 3.2: List of peptide sequences identified from MS/MS analysis of LDP1 
 
Peptide sequence 
 
Amino acid 
 
  
R.LLLRDTDR.F 858-867 
R.VQGNDHSATR.E 898-909 
K.ETLFSVMPGLK.M 815-827 
R.MNFRPGVLSSR.Q* 657-668 
K.VTIGLLFWDGR.G 842-854 
K.AGFSWIEVTFK.N 777-789 
R.TLRVQGNDHSATR.E 894-909 
K.WKETLFSVMPGLK.M 812-827 
K.NPLVWVHASPEHVVVTR.N 788-806 
R.RLDYQEGPPGVEISCWSVEL.- 909-930 
R.QGPVNLLSDPEQGVEVTGQYER.E 752-776 
K.TGLLLSDPDKVTIGLLFWDGR.G 831-854 
R.QGPVNLLSDPEQGVEVTGQYEREK.A 752-778 
R.VMNMKIEETTMTTQTPACPSCSR.S 709-733    
R.FSSHVGGTLGQFYQEVLWGSPAASDDGR.R 865-895 
  
Sequences of peptide were checked against the Swiss-Prot database for ITIH4 (Q14624).  With exception  
of the sequence denoted by an asterisk, all other sequences correlate with the fragment region of ITIH4 
(amino acids 696-930) 
 
Accession 
number 
a)
 
 
Protein 
matched 
 
No. of peaks 
matched 
 
MASCOT 
score 
 
Sequence  
coverage 
b) 
 
 
gi│7770149 
 
 
ITIH4  
 
 
15 
 
165 
 
75.2% 
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ITIH4 is a 120 kDa, single chain, plasma acute-phase glycoprotein.  However, the 
LDP1 spot cluster detected in the 2-DE gel demonstrated relative molecular mass of 
approximately 35 kDa.  Hence, this suggests that the LDP1 is only a cleavage fragment of 
ITIH4, and not the intact protein.  This notion is further substantiated by the MS/MS 
derived amino acid sequences. 
 
3.2 Prevalence of the ITIH4 fragment 
In the preceding sections, the LDP1 has been identified as a fragment of ITIH4 
(ITIH4f).  Subsequent to its identification, it seemed interesting to study the expression of 
ITIH4f in other cancers.  Hence, analysis of the expression of the fragment was extended to 
groups of patients with different types of malignancies.  
 
3.2.1 Analysis of ITIH4f in sera of patients with different cancers 
In the present work, the expression of ITIH4f in sera of patients with five different 
types of cancers was investigated.  The study involved groups of patients with localized 
osteosarcoma (OsSa), nasopharyngeal carcinoma (NPCa), breast carcinoma (BrCa), germ 
cell ovarian carcinoma (GOCa) and epithelial ovarian carcinoma (EOCa).  Serum proteins 
were initially separated by 2-DE before being transferred electrophoretically onto 
nitrocellulose (NC) membranes.  Detection of the transferred ITIH4f along with the rest of 
the O-glycosylated serum proteins was performed using HRP-conjugated CGB lectin. 
Figure 3.8 demonstrates representative profiles of the CGB lectin detected blots from the 
five different types of malignancies.   
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Figure 3.8:  Separation and detection of ITIH4 fragment in five different groups of 
cancer patients.  Unfractionated serum samples were subjected to 2-DE, blotting and 
detection with HRP-conjugated CGB lectin.  Panels demonstrate typical profiles of (a) 
control subjects and patients with (b) BrCa , (c) EOCa, (d) GOCa, (e) NPCa and  (f) OsSa.  
Up-regulated expression of the ITIH4 fragment (ITIH4f) is exhibited in profiles of patients 
with BrCa, EOCa and GOCa.   For all panels, the acidic side of the blot is to the left and 
relative molecular mass declines from the top.  
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In general, all the resolved blots demonstrated specific differential expression of 
their O-glycosylated proteins.  When analysis was focused on the expression of ITIH4f, 
significantly enhanced expression was detected in patients with BrCa, GOCa and EOCa, 
relative to the control subjects.  However, the differential expression was not significantly 
detected in NPCa and OsSa patients.  Figure 3.9 summarizes the results of the densitometry 
analysis which showed the over expression of ITIH4f in patients with BrCa (+10.9-fold; 
p<0.0001), EOCa (+4.4-fold; p<0.0001) and GOCa (+8.5-fold; p<0.0001) compared to the 
controls. 
The question of why the enhanced expression of the fragment is selective to certain 
cancers is rather intriguing.  One possibility is that the phenomenon may be hormonally 
correlated.  BrCa, EOCa, GOCa, EACa are unlike NPCa and OsSa such that the former is 
generally associated with estrogen dysregulation.  In such a case, however, the abundance 
of the particular fragment is also likely to be enhanced in other diseases associated with 
increased levels of estrogen. 
 
3.2.2  Analysis of ITIH4f in sera of non-cancer patients 
At this stage, the results of the present study appear to link the up-regulated 
expression of ITIH4f specifically with cancers that are associated with estrogen 
dysregulation.  Therefore, it would be interesting to determine if the fragment is also over-
expressed in other non-cancer conditions that are associated with enhanced levels of 
estrogen.  This notion was then investigated in groups of women who were known to have 
high levels of plasma estrogen.  Included in this study were women who were with a 
normal form of pregnancy (NP) and those associated with an abnormal pregnancy condition  
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Figure 3.9:  Relative expression of ITIH4 fragment in sera of five different groups of 
cancer patients.  Analysis was performed on sera of healthy controls and patients with 
BrCa, EOCa, GOCa, NPCa and OsSa.  Volume of ITIH4f was analyzed using Image 
Master 2D-Platinum software, version 5.0.  All values are presented as mean ± SEM.  Data 
were analyzed by Student's t-test and a p value of less than 0.01 was considered significant.  
Asterisks denote significantly different values as compared to controls. 
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referred to as hydatidiform mole (HM).  To determine the influence of exogenous estrogen 
on the expression of ITIH4f, experiments were also performed on serum samples from 
menopausal women who were under the hormone replacement therapy (HRT). 
In this part of the work, similar lectin-based electrophoretic approach was adopted.  
Representatives of the CGB lectin resolved NC membranes are shown in Figure 3.10.  
When densitometric analysis was performed on ITIH4f, up-regulated expression was 
observed for both groups of women with NP (+8.7-fold; p=0.0002) as well as HM (+5.6-
fold; p<0.0001) compared to their non-pregnant controls.  In contrast, the patients with 
HRT possess ITIH4f expression that was comparable to that of the control subjects.  Figure 
3.11 summarises the results of the densitometry analysis.  Therefore, the data of this study 
suggest that ITIH4f was also over-expressed in normal and benign conditions that are 
associated with estrogen dysregulation. 
 
3.3 Profiling of O-glycoproteins in sera of women with NP and HM  
 In the earlier sections, the enzyme conjugated CGB lectin was used to resolve the 
ITIH4f, as well as other O-glycosylated serum proteins that were separated by 2-DE.  By 
using a similar approach, the aberrantly expressed high-abundance serum glycoproteins in 
sera of patients with BrCa (Doustjalali, 2004), EOCa (Chen, 2007), GOCa (Chen, 2007), 
EACa (Abdul-Rahman et al., 2007), NPCa (Doustjalali, 2004) and OsSa (Wan Ibrahim, 
personal communication, 2010) were also detected.  However, the serum O-glycoproteins 
of women with NP and HM have not been previously profiled.  Thus, an attempt was made 
to study their expression patterns in relation to the different types of pregnancies.   
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Figure 3.10:  Separation and detection of ITIH4f in women with estrogen dysregulation.  
Unfractionated serum samples were subjected to 2-DE, blotting and detection with enzyme-
conjugated CGB lectin.   Panel (a) demonstrates a typical profile of healthy non-pregnant 
controls while panels (b), (c) and (d) are representative profiles of women with NP, HM 
and HRT, respectively.  The cleavage fragment of ITIH4 appears to be over-expressed in 
profiles of patients with NP and HM.  For all panels, the acidic side of the blot is to the left 
and relative molecular mass declines from the top.  
 
 
 
 
ITIH4f  ITIH4f  
ITIH4f  ITIH4f  
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Figure 3.11: Relative expression of ITIH4 fragment in sera of women with estrogen 
dysregulation.  Analysis was performed on sera of healthy controls and women with NP, 
HM and HRT.  Volume of ITIH4f was analyzed using Image Master 2D-Platinum 
software, version 5.0.  All values are presented as mean ± SEM.  Data were analyzed by 
Student's t-test and a p value of less than 0.01 was considered significant.  Asterisks denote 
significantly different values as compared to controls. 
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When the 2-DE separated serum proteins of the NP and HM patients and controls 
were exposed to HRP-conjugated CGB lectin, different profiles comprising just the O-
glycosylated proteins were obtained.  Figure 3.12 (a) demonstrates the representative 
profile of a normal female control while figures (b) and (c) represent typical examples of 
protein profiles of women with NP and HM, respectively.  Resolved glycoprotein spots 
were initially identified through visual comparison with the HRP-CGB lectin detected 
profiles developed by previous researchers (Abdul-Rahman et al., 2007; Abdul Rahman et 
al., 2002).  Spots that were visually identified included ACT, AHS, HPX, KNG, LRG and 
ITIH4f.   Also noted was that, by using the lectin detection method, spots of HPX and KNG 
appeared to be well resolved in the absence of albumin streak that usually obscures their 
presence.  Since the expression of ITIH4f had been studied in the preceding section, 
densitometry analysis was performed on the other O-glycoproteins resolved on the 
nitrocellulose membranes.  
 
3.3.1  Profiling of O-glycoproteins in sera of women with NP 
The present part of the study was aimed at the identification of O-glycosylated 
serum proteins that were aberrantly expressed in women with NP compared to non-
pregnant controls.  When the 2-DE separated O-glycoprotein profiles of NP women and 
controls were subjected to densitometry analysis, a striking difference in glycoprotein 
expression was observed.  Figure 3.13 and Table 3.3 demonstrate the differential 
expression of the various glycoproteins released in the serum, in response to pregnancy.  In 
addition to the aberrantly expressed ITIH4f, which was detected in the earlier section of the 
study, expression of ACT (+2.9-fold; p=0.0037) and LRG (+2.0-fold; p=0.0008) were also 
found to be significantly higher than their negative controls.   
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 (c) 
                       
 
Figure 3.12: Typical CGB-lectin detected serum protein profiles of control individual and 
women with NP and HM.  Whole serum samples of normal healthy females and women 
with NP and HM were subjected to 2-DE and HRP-CGB lectin detection.  Panels (a), (b) 
and (c) are representative serum glycoprotein profiles of control subjects and women with 
NP and HM, respectively.  The O-glycosylated protein spots resolved on the blots included 
ACT, AHS, CLU, HPX, KNG, LRG and ITIH4f.  For all panels, the acidic side of the 2-
DE blot is to the left and relative molecular mass declines from the top.  Aberrantly 
expressed glycoproteins are marked in bracket. 
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Figure 3.13:  Mean percentage of volume contribution of O-glycoproteins of women with 
NP and control subjects.  Volumes of O-glycosylated protein spots resolved in sera of 
women with NP and controls were analyzed using Image Master 2D-Platinum software, 
version 5.0.  Analyses were restricted to high abundance serum proteins including ACT, 
AHS, HPX, KNG, LRG and ITIH4f.  Asterisk denotes significantly different values when 
compared to that of control. 
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Table 3.3: Relative expression of O-glycoproteins in sera of women with NP  
Serum proteins 
Statistical analysis 
*fold changes **p  
   
ACT 
≠
 +2.9231 0.0037 
AHS +1.1054 0.4326 
HPX +1.0556 0.0872 
ITIH4f 
≠
 +8.6612 0.0002 
KNG –0.8351 0.5176 
LRG +2.0262 0.0009 
   
 
*fold changes measures the degree of change in percentage volume of the respective glycoprotein 
in test individuals compared to controls.  A minimum difference of two folds was 
taken as the cutting point for the variation to be considered significant 
**p  Student t-test was used to analyze the significance of differences and p<0.01 was 
considered significant 
+/–   increased/decreased in expression level 
≠ 
  
glycoprotein showing significant differential expression  
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Figure 3.14: Profiles of isoforms of O-glycosylated proteins. Panel (a) demonstrates the 
position of the glycoproteins on a CGB lectin-detected blot.  Panel (b) consisted of profiles 
of isoforms of the respective proteins.  Isoforms were abbreviated using numbers in 
ascending order starting from the acidic side of the blot.  
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Aside from changes in a glycoprotein‟s abundance, alteration in serum constituents 
has also been linked to changes of the structures of its carbohydrate chains.  And this may 
be reflected by alteration in the expression pattern of its isoforms (Sàez-Valero et al., 
2001).  Hence, in addition to the densitometry analysis performed on the lectin resolved 
glycoproteins, the study was also extended to the expression of well resolved isoforms of 
the protein clusters.  For the purpose of this study, isoforms were abbreviated using 
numbers in ascending manner starting from the acidic to the basic sides of the nitrocellulose 
membrane (Figure 3.14).   
When isoforms of individual glycoproteins in the O-glycosylated protein profiles of 
women with NP were compared to those of the controls, none of the isoforms demonstrated 
alteration in their relative distribution patterns.  Table 3.4 demonstrates the summary of the 
volume analysis, which indicated high similarities in the relative distribution of the 
isoforms in all the six glycoproteins, between the two groups studied.  However, 
glycoproteins which were found to be over-expressed, such as ITIH4f and ACT, 
demonstrated significant difference in terms of abundance of their isoforms, relative to that 
of the controls.  Densitometry analysis performed on the isoforms of ITIH4f demonstrated 
that all of its isoforms were highly expressed, especially isoforms 3, 4 and 5 which were not 
detected in the membranes of the control subjects.  As for ACT, marked increase of 
expression appeared to be contributed mainly by three of its isoforms, i.e., isoform 1 
(+13.7-fold; p<0.0001), isoform 2 (+4.9- fold; p=0.0009) and isoform 3 (+3.8-fold; 
p=0.0051).  Also observed was the over-expression of the other three isoforms of ACT, 
compared to those exhibited by the control women.  However, the difference in abundance 
appeared to be not statistically significant. 
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Table 3.4: Relative expression of isoforms of O-glycoproteins in serum profiles of 
women with NP 
 
Serum 
proteins 
 
*Isoform 
number 
Statistical analysis 
**fold changes ***p 
    
ACT 
 
 
 
1
≠
 +13.7295 <0.0001 
2
≠
 +4.9689 0.0008 
3
≠
 +3.7505 0.0051 
4 +2.8239 0.0202 
5 +2.0120 0.1676 
6 +1.4461 0.4292 
    
AHS 
 
1 +1.8773 0.0156 
2 +1.5771 0.0032 
3 –0.9328 0.8082 
4 +1.3489 0.3314 
    
HPX 
 
 
 
1 +1.8034 0.0356 
2 +1.5621 0.0236 
3 +1.2823 0.2365 
4 +1.3671 0.1546 
5 +1.4115 0.1135 
 6 +1.0190 0.9415 
 
ITIH4f 1
≠
 +5.6882-fold 0.0047 
 2
≠
 +5.9756-fold 0.0055 
 3
≠
 # 0.0015 
 4
≠
 # 0.0002 
 5
≠
 # 0.0001 
      continued on next page… 
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Serum 
proteins 
 
*Isoform 
number 
 
Statistical analysis 
**fold changes 
***p 
    
KNG 1 –0.4975 0.3428 
 2 –0.6782 0.5340 
 3 –0.6220 0.3133 
 4 –0.6505 0.3422 
    
LRG 1 +2.4478 0.0208 
 2 +1.9562 0.0339 
 3 +1.7304 0.0792 
 4 +1.9544 0.0900 
 
*Isoform number numbering of the isoform starts from the acidic side of the glycoprotein (as shown 
in Figure 3.14) 
**fold changes measures the degree of change in percentage of volume contribution of each 
isoform over the total volume of its protein in test individuals as compared to 
controls.  A minimum difference of two folds was taken as the cutting point for the 
variation to be considered significant  
***p  Student t-test was used to analyze the significance of differences and p<0.01 was 
considered significant 
+/–   increased/ decreased in expression level 
#   not detected in serum protein profiles of negative controls 
≠ isoform showing significant differential expression compared to that of the control 
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3.3.2  Profiling of O-glycoproteins in sera of women with HM 
In the previous section, several O-glycosylated proteins from the sera of women 
with NP were found to be differentially expressed.  Hence, a similar volume analysis was 
performed on the profiles of the O-glycoproteins of women with HM compared to that of 
non-pregnant subjects.  Figure 3.11(c) demonstrates a typical representative of the 2-DE 
serum protein profiles of patients with HM.  When the lectin detected membranes were 
analyzed, most of the O-glycoproteins in the sera of the HM patients appeared to exhibit 
comparable expression patterns to those of the control subjects (Figure 3.15).  Out of the 
six O-glycoproteins analyzed, ITIH4f was the sole glycoprotein found to be significantly 
over-expressed, relative to the controls.  The expression levels of the other O-glycosylated 
proteins including ACT, AHS, HPX, KNG and LRG were not significantly different 
between the HM patients and control women (Table 3.5).  
In this study, the isoforms of the six O-glycosylated proteins detected in the 
membranes of HM patients were also subjected to densitometry and statistical analysis. 
Analysis performed on the isoforms of the glycoprotein clusters demonstrated that their 
expression patterns were generally similar to those of the controls (Table 3.6).   As such, no 
significant alteration in the glycosylation pattern of the serum glycoproteins was detected.  
Observed from the densitometry analysis, however, was the isoforms of ITIH4f, which 
were notably different for their abundance but not for their relative isoform distribution, 
compared to those of the controls.  As for the rest of the analyzed glycoproteins, none of 
them demonstrated significant difference in the levels of expression of their isoforms. 
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Figure 3.15: Mean percentage of volume contribution of O-glycoproteins of women with 
HM and control subjects.  Volumes of O-glycosylated protein spots resolved in sera of 
control and women with HM were analyzed using Image Master 2D-Platinum software, 
version 5.0.  Analyses were conducted on the high abundance serum proteins such as ACT, 
AHS, HPX, KNG, LRG and ITIH4f.  Asterisk denotes significantly different values when 
compared to that of control. 
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Table 3.5:  Relative expression of serum O-glycoproteins of women with HM  
 
 
Serum proteins  
 
Statistical analysis  
*fold changes **p 
   
ACT +1.4159 0.3012 
AHS –0.8839 0.3930 
HPX +1.2465 0.0872 
ITIH4f
≠
 +5.6139 < 0.0001 
KNG +1.4081 0.4357 
LRG +1.2359 0.3552 
   
*fold changes measures the degree of change in percentage volume of the respective protein in 
test individuals compared to controls.  A minimum difference of two folds was 
taken as the cutting point for the variation to be considered significant   
**p  Student t-test was used to analyze the significance of differences and p<0.01 was 
considered significant. 
+/–   increased/decreased in expression level 
≠ glycoprotein showing significant differential expression compared to that of 
control 
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Table 3.6: Relative expression of isoforms of O-glycoproteins in serum profiles of 
women with HM 
  
 
Serum 
proteins 
*Isoform 
number 
Statistical analysis 
**fold change ***p 
 
ACT 
 
 
 
   
1 +3.2937 0.0159 
2 +2.8039 0.0196 
3 +2.6992 0.0213 
4 +1.4895 0.4304 
5 –0.5225 0.7641 
6 –0.4774 0.3069 
    
AHS 
 
1 +2.8636 0.1009 
2 –0.8725 0.5458 
3 –0.5663 0.0471            
4 –0.6700 0.1444 
    
HPX 
 
 
 
1 –0.9938 0.9812 
2 +1.4479 0.1352 
3 +1.0011 0.9957 
4 –0.9448 0.6188 
5 +1.1791 0.3408 
6 +0.8599 0.5155 
    
ITIH4f 1
≠
 +4.9582 0.0025 
 2
≠
 +4.5647 0.0032 
 3
≠
 # 0.00015 
 4
≠
 # 0.00026 
 5
≠
 # 0.000038 
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*Isoform number numbering of the isoform starts from the acidic side of the glycoprotein (as 
demonstrated in Figure 3.14) 
**fold changes measures the degree of change in percentage of volume contribution of each isoform 
over the total volume of its protein in test individuals as compared to controls. A 
minimum difference of two folds was taken as the cutting point for the variation to 
be considered significant  
***p values Student t-test was used to analyze the significance of differences and  p<0.01 was 
considered significant 
+/– increased/ decreased in expression level 
# not detected in serum protein profiles of negative controls 
≠ isoform showing significant differential expression compared to that of the control 
3.3.3 Comparison of the expression of serum O-glycoproteins between women with 
NP and those with HM  
In this study, the expression of the O-glycoproteins in sera of women with NP and 
HM was investigated using a lectin-based electrophoretic approach.  Figure 3.16 
 
Serum 
proteins 
 
*Isoform 
number 
 
 
Statistical analysis 
**fold change ***p 
    
KNG 1 +1.0787 0.8638 
 2 +1.0680 0.8927 
 3 +1.0546 0.9459 
 4 +1.1825 0.8439 
    
LRG 1 +2.8636 0.3869 
 2 +1.6871 0.1421 
 3 –0.9492 0.8304 
 4 +1.1942 0.5814 
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demonstrates the mean percentages of volume contribution of the glycoproteins resolved 
from serum samples of three groups of women.  Densitometry and statistical analyses were 
performed on the six O-glycosylated serum proteins of women with NP and HM in order to 
identify disease-associated changes in the glycoproteins of women with HM.  When the 
CGB lectin resolved glycoproteins were analyzed, the only significant difference detected 
was in the reduced expression of ACT (–0.5-fold; p=0.0023) in the serum samples of HM 
patients, relative to that of the NP women (Table 3.7).  The expression levels of the other 
five O-glycosylated proteins, i.e., AHS, HPX, KNG, LRG and ITIH4f, appeared to be 
unaffected by the abnormal pregnancy condition of the women with HM.   
When the isoforms of the glycoprotein clusters were analyzed, their distribution 
patterns were not significantly different between the HM patients and those with NP for 
most of the proteins (Table 3.8).  In addition, their abundance was also not significantly 
different with exception of one isoform spot of ACT.  The expression of isoform 5 of ACT 
appeared to be significantly reduced (–0.5-fold; p=0.0055) in the sera of women with HM 
as compared to those of NP women.  
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Figure 3.16:  Mean percentage of volume contribution of O-glycoproteins of women with 
NP and HM.  Volume of O-glycosylated protein spots resolved in sera of women with NP 
and HM were analyzed using Image Master 2D-Platinum software, version 5.0.  Analyses 
were performed on the high abundance serum proteins resolved on the blots including 
ACT, AHS, HPX, KNG, LRG and ITIH4f.  Asterisk denotes significantly different values 
when compared to that of control. 
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Serum proteins 
Statistical analysis  
*fold changes **p  
   
ACT
≠
 –0.4843 0.0023 
AHS –0.7996 0.0715 
HPX –0.9293 0.3613 
ITIH4f –0.8346  0.3449 
KNG +1.6863 0.1305 
LRG –0.6099 0.0041 
   
*fold changes measures the degree of change in percentage volume of the respective protein in 
test individuals compared to controls.  A minimum difference of two folds was 
taken as the cutting point for the variation to be considered significant   
**p values Student t-test was used to analyze the significance of differences and p<0.01 was 
considered significant. 
+/–   increased/decreased in expression level 
≠ glycoprotein showing significant differential expression compared to that of 
control 
 
 
 
 
 
 
 
Table 3.8: Relative expression of isoforms of O-glycoproteins in serum profiles of 
women with HM as compared to women with NP 
Serum 
proteins 
*Isoform number Statistical analysis 
 * 
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**fold change ***p  
 
ACT 
 
 
 
   
1 –0.4584 0.0123 
2 –0.5643 0.0321 
3 –0.7197 0.1847 
4 –0.5274 0.0273 
 5
≠
 –0.4613 0.0055 
6 –0.3301 0.0103 
    
AHS 
 
1 +1.5254 0.3855 
2 –0.5533 0.0023 
3 –0.6071 0.0659           
4 –0.4967 0.0299 
    
HPX 
 
 
 
1 –0.5511 0.0042 
2 –0.9269 0.7099 
3 –0.7807 0.1547 
4 –0.6911 0.0388 
5 –0.8353 0.2963 
6 –0.8439 0.4019 
    
ITIH4f 1 –0.6938 0.6173 
 2 –0.7639 0.3507 
 3 –0.6876 0.2545 
 4 –0.3775 0.1974 
 5 –0.4977 0.0191 
Serum 
proteins 
*Isoform 
number 
Statistical analysis 
**fold change ***p 
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*Isoform number numbering of the isoform starts from the acidic side of the glycoprotein 
(refer to Figure 3.14) 
**fold changes measures the degree of change in percentage of volume contribution of 
each isoform over the total volume of its protein in test individuals as 
compared to controls. A minimum difference of two folds was taken as 
the cutting point for the variation to be considered significant  
***p values Student t-test was used to analyze the significance of differences and  
p<0.01 was considered significant 
+/–    increased/ decreased in expression level 
#    not detected in serum protein profiles of negative controls 
≠ isoform showing significant differential expression compared to that of 
the control 
 
    
    
3.4 Profiling of serum proteins of women with NP and HM 
When the 2-DE separated serum proteins of women with NP and HM as well as 
their non-pregnant controls were subjected to Western blotting and HRP-CGB lectin 
    
KNG 1 +1.5399 0.4471 
 2 +1.0062 0.9919 
 3 +1.1110 0.8519 
 4 +1.0729 0.9047 
    
LRG 1 +1.0439 0.2979 
 2 –0.8624 0.6284 
 3 –0.5485 0.0435 
 4 –0.6111 0.1547 
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detection, different serum O-glycoprotein expression patterns were obtained.  However, by 
using the CGB lectin electrophoretic approach, only serum proteins carrying the O-linked 
moieties would interact with the lectin and able to be detected.  Hence, to complete the 
analysis on the serum protein profiles of the two groups of pregnant women, the expression 
of other high abundance serum proteins were studied using whole serum samples.  
In the present part of the study, whole serum samples of women with NP and HM, 
along with their age-matched female controls, were subjected to 2-DE separation.  Figure 
3.17 demonstrates typical representative high resolution 2-DE profiles of serum proteins 
obtained from the non-pregnant controls (panel a) and women with NP (panel b) and HM 
(panel c).  Obviously, more protein spots were detected in the present work as compared to 
the CGB lectin generated profiles.  The silver-stained protein spots were initially identified 
by visual comparison with the standard SWISS ExPASy reference map (Sanchez et al., 
1995).  Among the high abundance serum proteins which were not resolved in the O-
glycosylated protein profiles but were detected in the present gels were albumin (ALB),  
α1-antitrypsin (AAT), α1-ß-glycoprotein (ABG), antithrombin-III (ATR), clusterin (CLU 
and CLU2), haptoglobin (HAP), zinc-α2-glycoprotein (ZAG) and the heavy and light 
chains of immunoglobulins.  However, in contrast to the serum O-glycoprotein profiles, the 
ITIH4f protein spot cluster was not seen.  In addition, serum ALB was detected as a streak 
which obscured detection of other proteins of similar masses in this study mainly due to its 
high abundance. 
  
(a) 
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(c) 
 
           
 
 
Figure 3.17: Typical serum protein profiles of control women and patients with NP and 
HM.  Whole serum samples of non-pregnant females and pregnant patients were subjected 
to 2-DE and silver staining.  Panel (a) demonstrates a typical serum protein profile of a 
healthy control individual.  Clusters of protein spots clearly resolved include AAT, ABG, 
ACT, AHS, ALB, ATR, CLU, HAP, HPX, KNG, LRG and, ZAG.  Panels (b) and (c) 
demonstrate typical profiles of women with NP and HM, respectively.  The aberrantly 
expressed proteins are marked in brackets.  For all panels, the acidic side of the 2-DE gel is 
to the left and relative molecular mass declines from the top.  
 
 
 
                 
Under the settings of the 2-DE experiments, ALB usually appears as a horizontal 
streak in the 2-DE profiles of serum samples.  The immunoglobulin polypeptide chains, on 
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the other hand, are normally resolved as hundreds of spots, either in scattered- or train-like 
patterns.  In addition, the idiotypic and/or allotypic variation of the immunoglobulin 
molecules lead to inconsistencies in the resolution of the polypeptide chains.  Because of 
these reasons, the proteins were excluded from the analyses in this study.  Hence, 
densitometry and statistical analysis were focused only on the twelve main clusters of well-
resolved high abundance serum proteins.  
 
3.4.1 Profiling of serum proteins of women with NP 
In this study, whole serum samples from women with NP were subjected to 2-DE 
and followed by silver staining.  The resulting silver stained serum protein profiles of the 
women with NP were then compared quantitatively to those obtained from control subjects.  
Analysis of the twelve proteins revealed presence of four proteins that were differentially 
expressed (Figure 3.18 and Table 3.9).   
Among the serum proteins that were aberrantly expressed in the sera of women with 
NP relative to the non-pregnant controls were ACT, CLU, LRG and ZAG.  In the present 
study, the expression of ACT (+4.3-fold; p=0.0001) and LRG +2.6-fold; p<0.0001) were 
confirmed to be enhanced as reported earlier from the analysis of the O-glycosylated serum 
protein profiles.  In addition to these findings, CLU (+3.5-fold; p=0.0009) and ZAG (2.2-
fold; p<0.0001) were also found to be highly expressed in the normal pregnant women 
compared to the levels in control subjects.   
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Figure 3.18: Analysis of serum protein expression of women with NP and control subjects.  Silver stained 2-DE serum protein profiles were 
scanned using a densitometer and resulting protein spots were then analyzed using Image Master 2D platinum software (version 5.0).  The 
percentage of contribution of each protein was calculated based on the volume of a selected protein over the total volume of all the analyzed 
proteins in the protein map.  Asterisk denotes significantly different values when compared to controls. 
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Table 3.9:  Relative expression of serum proteins of women with NP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*fold changes measures the degree of change in intensities of proteins in patients compared to 
controls. A minimum difference of two folds was taken as the cutting point for the 
variation to be considered significant  
**p values Student t-test was used to analyze the significance of differences and p<0.01 
between cohorts was considered significant. 
+/- increased/decreased in expression level 
≠ 
  
protein showing significant differential expression 
 
 
 
 
Serum proteins 
Statistical analysis 
*fold changes **p  
   
AAT +1.0979 0.3746 
ABG +1.0333 0.7202 
ACT
≠
 +4.2718 0.0001 
AHS +1.5035 0.0042 
ATR +1.2891 0.0451 
CLU
≠
 +3.5095 0.0009 
CLU2 +1.9061 <0.0001 
HAP +1.3346 0.0574 
HPX +1.2091 0.2852 
KNG –0.8812 0.5209 
LRG
≠
 +2.5526 <0.0001 
ZAG
≠
 +2.2139 <0.0001 
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In this study, densitometry analysis was performed on the isoforms of the twelve 
high abundance serum proteins detected in the 2-DE protein profiles of women with NP.   
Figure 3.18 demonstrates the positions of the isoforms analyzed while Table 3.10 
summarizes the result of the statistical analysis conducted between the groups of NP 
women and controls.  Amongst the serum proteins that were analyzed, the isoform 
expression patterns of CLU and ZAG were significantly different compared to the patterns 
demonstrated by the control subjects.  The abundance of CLU in the sera of women with 
NP seems to be attributed by the up-regulated expression of isoform 2 (+3.9-fold; 
p=0.0038) and isoform 3 (+3.4-fold: p=0.0034) of the CLU spot cluster.  In the case of 
ZAG, the densitometry analysis performed on its isoform cluster demonstrated that isoform 
1 (+2.5-fold; p<0.0001) was the sole isoform which was differentially expressed, as 
opposed to that of non-pregnant controls.  As for the other ten serum proteins, including 
ACT and LRG, their isoforms demonstrated comparable expression pattern to that of the 
controls.  Thus, the results of the isoform analysis performed on ACT and LRG were not in 
agreement with the earlier findings demonstrated by the respective proteins. 
 
 
 
 
 
 
 (a) 
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(b) 
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Figure 3.19: Profiles of isoforms of silver stained serum proteins. Panel (a) demonstrates 
the position of the proteins on a 2-DE silver stained gel.  Panel (b) shows the isoform 
profiles of the respective proteins.  Isoforms were abbreviated using numbers in ascending 
order starting from the acidic side of the blot.  
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Table 3.10:  Analyses of isoforms of serum proteins in profiles of women with NP  
 
Serum 
proteins 
*Isoform 
number 
 
Statistical analysis  
**fold changes ***p 
 
AAT 
 
 
   
1 +1.3452 0.4801 
2 –0.9734 0.7651 
3 +1.0273 0.8782 
4 +1.0501 0.8934 
   
 
ABG 
 
   
1 +1.8353 0.0018 
2 +1.2175 0.1851 
3 +1.0109 0.9334 
4 –0.8186 0.0304 
   
 
ACT 
 
 
   
1 +1.5133 0.7932 
2 +3.5478 0.5954 
3 +5.6435 0.4261 
4 +2.732 0.5022 
5 +5.4133 0.3350 
   
 
AHS 
 
   
1 +1.8901 0.0469 
2 +1.8850 0.0566 
3 +1.7643 0.0178 
4 +1.2376 0.1654 
 
Serum 
proteins 
*Isoform 
number 
 
Statistical analysis 
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**fold changes ***p 
 
ATR 
 
   
1 –0.6193 0.0115 
2 +2.0130 0.0236 
3 +1.8797 0.0127 
   
 
CLU 
 
   
1 +1.3515 0.2854 
2
≠
 +3.9794 0.0039 
3
≠
 +3.4181 0.0034 
   
CLU2 1 +1.8121 0.0164 
 2 +1.9362 0.0157 
 3 +1.8023 0.0113 
 4 +1.6217 0.2718 
    
HAP 1 +2.5060 0.0207 
 2 +1.7609 0.0414 
 3 +1.4684 0.1690 
 4 +1.5695 0.1378 
 5 +1.4875 0.3831 
    
HPX 1 +1.2781 0.6341 
 2 –0.7819 0.9784 
    
KNG 1 +1.1375 0.6647 
 2 –0.9341 0.8285 
 3 –0.7844 0.4214 
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Serum 
proteins 
*Isoform 
number 
Statistical analysis 
**fold changes ***p 
    
LRG 1 +4.8425 0.0112 
 2 +2.4774 0.0523 
 3 +2.0559 0.0652 
    
ZAG 1
≠
 +2.5812 <0.0001 
 2 +1.5020 0.0177 
 3 +3.0242 0.2109 
    
 
*Isoform number numbering of the isoform starts from the acidic side of the glycoprotein which 
is to the left of the diagram 
**fold changes measures the degree of change in percentage of volume contribution of each 
isoformover the total volume of its protein in patients as compared to controls. 
A minimum difference of two folds was taken as the cutting point for the 
variation to be considered significant  
***p values Student t-test was used to analyze the significance of differences and  p<0.01 
between groups was considered significant 
+/– increased/ decreased in expression level. 
# not detected in serum protein profiles of negative controls. 
≠ isoform showing significant differential expression 
 
 
 
 
3.4.2 Profiling of serum proteins of women with HM 
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Similar to the earlier profiling studies of the sera of women with NP, the whole 
serum samples of the patients with HM were subjected to 2-DE.  The resulting silver 
stained protein profiles of patients with HM were then visually analyzed and compared to 
those of the control subjects.  Figure 3.17(c) demonstrates a typical representative of the 2-
DE serum protein profiles of patients with HM.  When densitometry and statistical analyses 
were performed between the two groups, the protein profiles obtained from the sera of HM 
women appeared to be slightly different compared to the controls.  Several proteins were 
found to be significantly altered as shown Figure 3.20 and Table 3.11.  The expression of 
LRG, which was not significantly altered in the lectin derived profiles of patients with HM, 
was found to be up-regulated (+3.5-fold; p<0.0001) in the silver stained profiles.  In 
addition, the expression of CLU was found to be significantly higher (+3.8-fold; p=0.0013) 
than that exhibited by the controls.  The expression levels of AAT, ABG, ACT, AHS, ATR, 
CLU2, HAP, HPX, KNG and ZAG, on the other hand, appeared to be comparable to those 
of the control subjects.  
Similarly the detected proteins were also analyzed for their relative distribution of 
isoform clusters.  Table 3.12 demonstrates that the expression of isoforms of individual 
serum proteins of women with HM.  The relative distribution of most of the protein 
isoforms of HM women was generally comparable with those of the non-pregnant controls.  
However, LRG demonstrated significantly altered expression although the relative 
distribution of its isoform clusters was maintained.  The change in the abundance of LRG in 
sera of patients with HM seems to be attributed by the highly expressed isoform 1 (+5.3- 
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Figure 3.20:  Analysis of serum protein expression of women with HM and control subjects.  Silver stained protein profiles were scanned using 
a densitometer and resulting protein spot clusters were then analyzed using Image Master 2D platinum software (version 5.0).  The percentage of 
contribution of each protein was calculated based on the volume of a selected protein over the total volume of all the analyzed proteins in the protein 
map.  Asterisk denotes significantly different values when compared to controls. 
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fold; p=0.0009), isoform 2 (+3.9-fold; p=0.0007) and isoform 3 (+3.4-fold; p=0.0035) 
compared to that of non-pregnant controls.  On the other hand, CLU was the sole protein 
showing altered distribution of its isoforms.  The up-regulated expression of CLU appeared 
to be mainly contributed by the over-expression of its isoform 1 (+3.8-fold; p=0.0066) and 
isoform 2 (+5.2-fold; p=0.0029), relative to the others.   
 
Table 3.11:  Relative expression of serum proteins of women with HM  
 
Serum proteins 
Statistical analysis  
fold changes **p  
   
AAT +1.4392 0.0020 
ABG +1.1798 0.1367 
ACT +1.5696 0.1869 
AHS +1.2673 0.0531 
ATR +1.0794 0.5974 
CLU
≠
 +3.8695 0.0013 
CLU2 +1.7639 0.0007 
HAP +1.1187 0.4246 
HPX +1.1568 0.4608 
KNG +1.2912 0.2730 
LRG
≠
 +3.5991 <0.0001 
ZAG +0.4246 0.1836 
   
*fold changes measures the degree of change in intensities of proteins in patients compared to 
controls. A minimum difference of two folds was taken as the cutting point for the 
variation to be considered significant and is highlighted in red 
**p values Student t-test was used to analyze the significance of differences and an FDR-
corrected p<0.01 between cohorts was considered significant. 
+/- increased/decreased in expression level 
≠ 
  
isoform showing significant differential expression 
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Table 3.12:  Analyses of isoforms of serum proteins in profiles of women with HM  
Serum 
proteins 
 
*Isoform 
number 
Statistical analysis  
**fold changes ***p 
 
AAT 
 
   
1 +1.4474 0.3971 
2 +1.044 0.8612 
3 +1.039 0.8331 
4 +1.4210 0.1409 
   
 
ABG 
 
   
1 +1.4951 0.5351 
2 –0.8547 0.5351 
3 +1.0877 0.6019 
4 +1.3510 0.0912 
   
 
ACT 
 
 
   
1 # 0.4291 
2 # 0.1245 
3 +4.5010 0.2011 
4 +1.2881 0.7319 
5 +1.7709 0.8364 
   
 
AHS 
 
   
1 +2.0490 0.0574 
2 +1.9185 0.0678 
3 +1.2197 0.5338 
4 –0.7625 0.8417 
   
 
      continued on next page… 
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…continued from previous page 
 
Serum 
proteins 
 
*Isoform 
number 
Statistical analysis 
**fold changes ***p 
    
ATR 1 +1.2271 0.3597 
 2 +1.1036 0.6087 
 3 +1.4583 0.8435 
    
CLU 1
≠
 +3.833 0.0066 
 2
≠
 +5.2894 0.0029 
 3 +1.7886 0.1710 
    
CLU2 1 +1.4611 0.2046 
 2 +1.8038 0.0738 
 3 +1.5428 0.0799 
 4 +1.5735 0.2474 
    
HAP 1 +2.2706 0.0186 
 2 +1.2439 0.4086 
 3 +1.2277 0.4153 
 4 +1.1709 0.4873 
 5 +1.0900 0.8527 
    
HPX 1 +1.5631 0.1327 
 2 +1.0600 0.9100 
    
KNG 1 +1.1302 0.7483 
 2 –0.8832 0.3431 
 3 –0.9304 0.4131 
    
        continued on next page… 
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…continued from previous page 
 
 
 
Serum 
proteins 
 
*Isoform 
number 
Statistical analysis 
**fold changes ***p 
    
    
LRG 1
≠
 +5.3097 0.0009 
 2
≠
 +3.9392 <0.0001 
 3
≠
 +3.3536 0.0035 
    
ZAG 1 +1.8012 0.0326 
 2 +1.2694 0.1018 
 3 –0.9995 0.9990 
*Isoform number numbering of the isoform starts from the acidic side of the glycoprotein which 
is to the left of the diagram 
**fold changes measures the degree of change in percentage of volume contribution of each 
isoformover the total volume of its protein in patients as compared to controls. 
A minimum difference of two folds was taken as the cutting point for the 
variation to be considered significant and is highlighted in red 
***p values Student t-test was used to analyze the significance of differences andan FDR-
corrected p<0.01between groups was considered significant  
  +/– increased/ decreased in expression level. 
   #  not detected in serum protein profiles of negative controls. 
   ≠ isoform showing significant differential expression 
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3.4.3 Comparison of protein expression in sera of women with NP and HM 
 In this section, the expression of serum proteins that were detected by silver staining 
of the 2-DE gels of women with HM was compared to those of women with NP.  Figure 
3.20 demonstrates the results of the volume analysis performed on the protein spot clusters 
of the studied groups.  When subjected to statistical analysis, ACT was the sole protein 
found to be significantly down-regulated (–0.37-fold; p=0.0003) in the women with HM 
compared to the women with NP.  The expression of the other eleven protein spot clusters 
in the 2-DE gels appeared to be not significantly different between the two groups of 
pregnant women as shown in Table 3.13.  Subsequent analysis on the relative expression of 
isoforms of the protein clusters also demonstrated that none of the isoform of the analyzed 
proteins in the women with HM was differentially expressed, relative to those of NP 
women. 
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Figure 3.21:  Analysis of serum protein expression of women with NP and HM.  Silver stained 2-DE serum protein profiles were scanned using 
a densitometer and resulting protein spots were then analyzed using Image Master 2D platinum software (version 5.0).  The percentage of 
contribution of each protein was calculated based on the volume of a selected protein over the total volume of all the analyzed proteins in the protein 
map.  Asterisk denotes significantly different values when comparative analysis was performed between the two groups of pregnant women. 
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Table 3.13:  Relative expression of serum proteins of women with HM compared to 
women with NP  
Serum proteins  
Statistical analysis  
fold changes 
 
**p  
   
AAT +1.3108 0.6866 
ABG +1.1418 0.1629 
ACT
≠
 –0.3674 0.0003 
AHS –0.8429 0.1319 
ATR –0.7187 0.0035 
CLU +1.1026 0.7026 
CLU2 –0.9254 0.4779 
HAP –0.8383 0.1847 
HPX –0.9567 0.8059 
KNG +1.4653 0.0767 
LRG +1.4099 0.0359 
ZAG –0.5639 0.0003 
   
*fold changes measures the degree of change in intensities of proteins in patients compared to 
controls. A minimum difference of two folds was taken as the cutting point for the 
variation to be considered significant and is highlighted in red 
**p values Student t-test was used to analyze the significance of differences and an FDR-
corrected p<0.01 between cohorts was considered significant. 
+/- increased/decreased in expression level 
≠ 
  
isoform showing significant differential expression 
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Table 3.14:  Analyses of isoforms of serum proteins in profiles of women with HM 
compared to women with NP  
 
Serum proteins 
 
*Isoform 
number 
 
Statistical analysis  
**fold changes 
***p 
 
 
AAT 
 
   
1 +1.1024 0.6281 
2 +1.0115 0.9671 
3 +1.3533 0.3669 
4 +1.0760 0.6939 
   
 
ABG 
 
   
1 –0.8974 0.7169 
2 –0.8229 0.4871 
3 +1.1211 0.5531 
4 +1.7111 0.0791 
   
 
ACT 
 
 
   
1 # 0.1907 
2 # 0.2383 
3 –0.7976 0.4788 
4 –0.4715 0.2747 
5 –0.3271 0.1461 
   
 
AHS 
 
   
1 +1.0841 0.8088 
2 +1.0177 0.9669 
3 –0.6913 0.3289 
4 –0.7625 0.3881 
   
                     continued on next page…. 
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…continued from previous page 
Serum 
proteins 
 
*Isoform 
number 
Statistical analysis 
**fold changes ***p 
    
ATR 1 +1.9146 0.0049 
 2 –0.5733 0.0094 
 3 –0.5170 0.0119 
    
CLU 1 +2.8358 0.1292 
 2 +1.3292 0.3816 
 3 –0.5233 0.0500 
    
CLU2 1 –0.8663 0.4034 
 2 –0.8108 0.6283 
 3 –0.8559 0.5976 
 4 –0.9703 0.9296 
    
HAP 1 –0.9061 0.7876 
 2 –0.7064 0.3304 
 3 –0.8361 0.5719 
 4 –0.7460 0.3049 
 5 –0.7328 0.5849 
    
HPX 1 +1.5139 0.8179 
 2 +1.9991 0.5443 
    
KNG 1 +1.0065 0.9865 
 2 +1.0493 0.2883 
 3 –0.8431 0.1057 
    
 
      continued on next page… 
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…continued from previous page 
 
Serum 
proteins 
 
*Isoform 
number 
Statistical analysis 
**fold changes ***p 
    
    
LRG 1 +1.0965 0.8805 
 2 +1.5900 0.1868 
 3 +1.6312 0.2311 
    
ZAG 1 –0.6979 0.1756 
 2 –0.8452 0.3961 
 3 –0.3305 0.3964 
*Isoform number numbering of the isoform starts from the acidic side of the glycoprotein 
which is to the left of the diagram 
**fold changes measures the degree of change in percentage of volume contribution of each 
isoformover the total volume of its protein in patients as compared to 
controls. A minimum difference of two folds was taken as the cutting point 
for the variation to be considered significant and is highlighted in red 
***p values Student t-test was used to analyze the significance of differences andan 
FDR-corrected p<0.01between groups was considered significant 
+/– increased/ decreased in expression level. 
# not detected in serum protein profiles of negative controls. 
≠ isoform showing significant differential expression 
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3.5 Identification of aberrantly expressed proteins 
 In the preceding sections, the serum proteins were generally identified based on 
visual comparison either with the already established CGB lectin resolved protein maps or 
the standard SWISS ExPASy plasma protein reference map.  The aberrantly expressed 
protein spots which were visually identified in this study included ACT, CLU, LRG and 
ZAG.  In the present study, the four protein spot clusters were subjected to mass 
spectrometry analysis for confirmation of their identities. 
  For the identification of the ACT and LRG spots that were detected on the 
nitrocellulose membranes, a similar approach to that employed for the identification of the 
ITIH4f was performed.  Pooled serum samples of women with NP were subjected to CGB 
lectin affinity chromatography prior to 2-DE separation.  Subjecting the spots of interest to 
MS/MS analysis and NCBInr database search identified them as ACT and LRG.  Table 
3.15 (panel a) provides the information regarding the number of matching peaks, MASCOT 
score, sequence coverage and accession numbers as listed in the NCBInr database for each 
of the identified proteins.  
In order to validate the identities of ACT, CLU, LRG and ZAG which showed 
significant statistical difference after analysis of their silver stained serum protein profiles, 
2-DE run was repeated using pooled sera of women with NP.   However, in this 
experiment, the 2-DE gel was stained with Coomassie Blue staining since it was the 
preferred method of staining for mass spectrometry analysis.  Similarly, the peptide 
sequences obtained from the MS/MS analysis were searched against the NCBInr database 
and the results obtained from the MASCOT search gave positive identification for ACT, 
CLU, LRG and ZAG.  Information regarding the number of matching peaks, MASCOT 
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score, sequence coverage and accession numbers as listed in the NCBInr database are 
shown in Table 3.11 (panel b).  
 
Table 3.15: Mass spectrometric identification of aberrantly expressed serum proteins 
Accession 
number
*
 
Protein 
matched 
No. of peaks 
matched 
MASCOT 
score 
 
Sequence  
coverage 
 
 
    
P01011 ACT
(a)
 2 128 10% 
P02750 LRG
(a)
 4 326 18% 
 
    
P01011 ACT
(b)
 8 522 35% 
P10909 CLU
(b)
 5 249 24% 
P02750 LRG
(b)
 6 414 29% 
P25311 ZAG
(b)
 4 284 13% 
 
*   Accession number is from the MASCOT database (www.matrixscience.com) 
(a)
 Isolated from gels of samples subjected to CGB lectin affinity chromatography prior to 2-DE  separation 
(b
) Isolated from gels of whole serum samples subjected to 2-DE separation 
 
 
3.6 Validation of aberrantly expressed serum proteins by immunoblotting 
 For confirmation of the aberrantly expressed proteins in the serum samples of 
women with NP and HM, an immunoblotting technique was employed.  Western blotting 
was performed using commercially available antibodies against four of the differentially 
expressed serum proteins.  In this study, proteins which were identified as significantly up-
regulated in the sera of women with NP were ACT, CLU, LRG and ZAG.  On the other 
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hand, CLU and LRG were the only proteins found to be abundantly expressed in the sera of 
women with HM.   
 The results obtained from the Western blotting and antibody detection of serum 
samples of the group of women with NP and HM and their non-pregnant controls are 
demonstrated in Figure 3.15a-d.  Panel (a) of Figure 3.21 demonstrates a representative 
nitrocellulose membrane with the transferred SDS-PAGE separated proteins that were 
probed with anti-ACT.  Following a reaction with anti-ACT, an intense band with a 
molecular weight of approximately 70 kDa was detected for each of three lanes which 
consisted of serum proteins from control, NP and HM women, respectively.  When the 
resolved bands were subjected to densitometry analysis, the expression of ACT in the 
pooled sera sample of women with NP seemed to be significantly higher (1.7-fold; 
p=0.005) than that of the control women. 
Panel (b) of Figure 3.21 represents an anti-CLU detected nitrocellulose membrane 
obtained from this study.  When the HRP conjugated antibody towards CLU was interacted 
to the electrophoretically transferred serum proteins on the blot, an intensely resolved band 
with a relative molecular weight of approximately 60,000 was detected.  Subsequent 
analysis performed on the bands resolved from the sera of control, NP and HM women 
managed to demonstrate the over-expression of CLU in the serum samples of women with 
NP (+2.2-fold; p=0.0039) as well as in women with HM (+2.7-fold; p=0.0028), relative to 
that of the controls. 
Similarly, the expression of LRG was analysed by Western blotting using anti-LRG. 
Observed from the reaction was a band resolved with a molecular weight of approximately 
38,000 [Figure 3.21 (c)].  From the analysis performed on the bands of the controls as well  
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Figure 3.22:  Representative Western blots for ACT, CLU, LRG and ZAG.  Pooled serum 
samples of controls (C), women with NP (NP) and HM (HM) at concentrations of 4 µg/ml 
were separated on 12.5% SDS-PAGE gels. Resulting bands were transferred to 
electrophoretically onto nitrocellulose membrane.  Immunodetection of the resolved protein 
bands were performed using their respective antibodies.  Panels (a), (b), (c) and (d) 
demonstrate the immunoblots for ACT, CLU, LRG and ZAG, respectively.   
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as the women with NP and HM,  the  expression of LRG appeared to be altered in both 
samples of  the NP (+1.5-fold; p=0.0096) as well as the HM (+1.5-fold; p=0.0094) women, 
relative to that of the control subjects. 
When the immunoassay was performed using anti-ZAG, the antibody detected 
serum ZAG was resolved as a band with a molecular weight of 34,000.  Higher levels of 
ZAG was significantly detected for women with NP (2.6-fold; p=0.0041) as compared to 
the controls [Figure 3.21 (d)].  
 
 
3.7 Development of a multiplex immunoassay 
The data of the present study demonstrates the different altered expression of serum 
proteins associated with the two different types of pregnancy.  These findings were shown 
by subjecting serum samples to 2-DE followed by detection of the separated proteins either 
via silver stain or enzyme conjugated CGB lectin.  These approaches, however, were 
suitable for the analysis of samples of small sizes.  In cases of larger sample populations, an 
assay platform which allows for high through-put analysis appeared to be more feasible.  
Amongst the high through-put assay platforms that are available today is the multiplex 
immunoassay.    
The multiplex immunoassay still maintains the traditional immunoassay principles 
which involved coupling of proteins with simple quantitative antibody-based assays.  
However, unlike other conventional immunoassay techniques, the multiplex assay is 
characterized by presence of multiple capture ligands which are immobilized in parallel.  
This permits simultaneous quantification of multiple serum proteins and at the same time, 
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eliminates multiple sample preparations.  Therefore, at this point of the study, it seemed 
interesting to test the viability of the multiplex assay in detecting aberrantly expressed 
serum proteins in relation to the studied pregnancy conditions.   
Hence, in the present work, an in-house competitive multiplex assay was designed 
using the four differentially expressed serum proteins, i.e. ACT, CLU, LRG and ZAG.  
Also included was four other target proteins comprising of AAT, AHS, ATR and 
ceruloplasmin (CLP), which acted as negative controls.  In the prepared multiplex assay, a 
target protein was conjugated to the surface of a set of color coded microbeads.  The 
different sets of protein-conjugated microbeads were then mixed together with the serum 
samples and the detector molecules.   The detector molecules, which were biotin labeled 
antibodies, reacted with their own proteins irrespective of whether they are proteins 
circulating in the serum or proteins immobilized on the microbeads.  Prior to detection, the 
antibody-serum protein complexes were removed from the reaction mixture, leaving the 
complexes on the beads to be enumerated by the array reader.  The array reader then 
identifies each specific reaction based on the bead color and quantitates it.  
 
3.7.1 Validation of conjugated beads functionality 
In the initial part of the study, the target proteins were coupled to the surface of the 
microbeads.  Once the coupling reaction has been completed, the functionality of the 
coupling reaction needs to be validated as described in section 2.14.1.3.  A successful 
coupling typically yields a fluorescent intensity signal greater than 2000 median fluorescent 
intensity (MFI). 
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Out of the eight sets of protein conjugated microbeads prepared in this study, only 
three sets of microbeads ie. ATR, CLP and CLU demonstrated successful protein-bead 
coupling (Table 3.16).  The other five proteins, however, were not successfully conjugated 
onto the beads, based on their low MFI values.  
 
 
Table 3.16:  Validation of microbeads analytical performance 
 
Assay 
 
Signal intensity (MFI) from different concentration of proteins 
2 µg 5 µg 7 µg 9 µg 10 µg 12 µg 
       
AAT 30 73 - - - - 
ACT 137.5 52 48.3 39.3 19.8 15 
AHS 20.9 56 - - - - 
ATR - 66.5 10783 - - - 
CLP - 6314.5 5160 5298.5 - - 
CLU 66 1745.8 - - 3132.5 - 
KNG 37 50 115 - - 179 
ZAG - 93 25 - - - 
 
(-) and signal intensity of less than 2000 MFI indicate unsuccessful conjugation  
 
 
3.7.2 Evaluation on the specificity of the multiplex assay 
Prior to multiplexing of the three sets of successfully coupled microbeads, each of 
the sets of beads was analyzed for their specificity.  In general, to determine the specificity 
of the beads, the protein conjugated beads were challenged to the various detector 
antibodies involved in the multiplex assay.  Specificity of the protein conjugated beads was 
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demonstrated by absence of any cross-reactivity between the beads and the detector 
antibodies of the other target proteins.  
Table 3.17 shows the MFI signals and percentages of cross-reactivity of the assay 
performed.  From the table, the three sets of beads appeared to display very low percentage 
of cross-reactivity (<1%) with antibodies directed against other proteins but exhibited 
strong reactivity with their own antibodies.  
 
 
Table 3.17:  Specificity of multiplex assay   
 
 
Assay 
Anti-ATR Anti-CLP Anti-CLU 
Signal 
intensity 
(MFI) 
Cross-
Reactivity 
(%) 
Signal     
intensity 
(MFI) 
Cross-
Reactivity 
(%) 
Signal 
intensity 
(MFI) 
Cross-
Reactivity 
(%) 
       
ATR 8165.3            100 5 0.13 3.5 0.22 
CLP 42                 0.51 3948.5 100 2 0.13 
CLU 45.5               0.55 1 0.03 1555.8 100 
Blank 4                    - 2 - 4 - 
 
Reactivity level of the beads to each antibody is demonstrated in terms of raw MFI values or represented as 
percentage of each MFI value over the MFI value generated from homologus protein-antibody interaction  
 
 
3.7.3 Optimization of sample dilution 
One of the essential issue that was addressed in the development of the multiplex 
assay was the selection of sample dilution factor.  Optimal dilution factor needs to be 
predetermined to enable measurement of each protein constituent within the assayed 
samples.  Therefore, pooled control sera were diluted using five different dilution factors.   
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In this study, the assay was conducted using a multiplex suspension of the three sets 
of microbeads and was run in a competitive assay manner.  Results from the multiplex 
assay are summarized in Table 3.18.  Based on the MFI values exhibited in the table, it 
appeared that diluting the serum samples using larger dilution factors (1/4 and 1/20) 
resulted in low MFI values.  In contrast, higher signal intensities were obtained when 
smaller dilution factors were employed.  From the MFI values exhibited in the Table 3.18, 
1/50 to 1/200 dilution factors appeared to be the appropriate factors to use for the study.  
However, since the assay runs in a multiplex format, the dilution factor of choice should 
give optimal MFI values for all the target proteins involved.  Hence, amongst the four 
ratios, 1:50 appeared to be the best ratio to be used in preparation of subsequent serum 
samples.   
 
 
Table 3.18:   MFI values in response to various dilutions of serum sample 
Assay 
 
Signal intensity in response to samples with different dilution factors 
(MFI) 
1/4 1/20 1/50 1/100 1/200 
 
ATR 
 
31 
 
74 
 
1717.5 
 
2336 
 
2139 
CLP 33 165.3 359.5 262 190 
CLU 92.5 329.3 427.3 316.5 225.5 
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3.7.4 Assay sensitivity evaluation 
To evaluate the sensitivity of the developed multiplex immunoassay, serum samples 
spiked with different concentrations of proteins were measured in duplicates using the 
competitive immunoassay method.  In the present study, the antibodies were incubated in 
the presence of their target proteins which were immobilized on the beads or within the 
serum samples.  The immobilized proteins compete for the antibody binding sites with the 
serum proteins.  Subsequent washing step will then remove any unbound antibodies as well 
as the serum antigen-antibody complexes.  Hence, the higher the serum protein 
concentration, the weaker the signal intensity produced by the developed assay. 
Figure 3.23 demonstrates the MFI values derived from the sensitivity test of the 
competitive multiplex assay.  Based on the results, the developed multiplex assay was 
shown to be capable of recovering the spiked protein samples and thus have appropriate 
accuracy to be used to detect corresponding proteins in the sera. 
 
 
3.7.5 Assay reproducibility evaluation 
Reproducibility of an assay refers to the degree of agreement between 
measurements conducted on replicate samples due to differences in operator behaviour.  
The reproducibility of a multiplex assay is reflected by its intra- and inter-assays coefficient 
of variation (%CV).  In this study, both the intra (within run) as well as inter (between run) 
variability were investigated using control samples and the results are shown in Table 3.19.    
Based on the %CV values obtained, the %CV for the intra-assay was found to range from  
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(a) 
 
 
(b) 
 
 
Figure 3.23: Analyses of MFI values derived from the multiplex assay sensitivity test.  The 
sensitivity of the developed multiplex immunoassay was performed with a competition 
step.  The MFI generated was from normal human sera spiked with ten-fold dilution of 
protein with initial concentration of 0.2 µg/ml.  Panel (a) demonstrates the MFI values from 
response of various concentrations of ATR to the assay.  Panel (b) demonstrates the MFI 
values obtained from response of various concentrations of CLU and CLP to the multiplex 
assay. 
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11.3 to 12.5% for the three target proteins.   The inter-assay %CV which indicates the plate 
to plate variation ranged from 3.9 to 28.3%.   And since the acceptable %CV for intra- and 
inter-assays should be <30% for the assay to be considered reproducible, the prepared 
multiplex assay appeared to be within acceptable limits.  
 
 
Table 3.19:  Reproducibility of the multiplex immunoassay 
Assay 
Intra-assay variation* 
Mean %CV 
Inter-assay variation# 
Mean %CV 
ATR 12.04 9.43 
CLP 11.28 3.93 
CLU 12.47 28.28 
          *
Intra-assay variation indicates variation within plates 
          #
Inter-assay variation indicates variation between assays  
 
 
3.7.6 Protein profiling of serum proteins using competitive multiplex assay  
The developed multiplex assay was used to profile the expression level of ATR, 
CLP and CLU in serum of controls as well as women with NP and HM.   For each serum 
sample, assay was performed in duplicates.  The signal intensities obtained reflect the 
serum protein levels and was compared to those of controls for differences in their signal 
intensity. 
Figure 3.24 demonstrates results of the competitive multiplex immunoassay 
performed with the protein conjugated microbeads.  The MFI values of ATR for both 
cohorts of pregnant women were found to be comparable to that of controls.  Statistical 
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analysis conducted on the MFI values yielded no significant differences in sera of NP and 
HM women as opposed to their non-pregnant controls.  When the MFI values of CLP from 
sera of women with NP and HM were compared with their non-pregnant controls, no 
significant differences were observed between the various groups to the controls.  
While in the case of CLU, there is a trend of lower MFI values in both groups of 
pregnant women.  Lower MFI values of CLU were significantly detected in women with 
NP (1.5-fold; p<0.0001) and HM (1.5-fold; p<0.0001), relative to the controls.  Taking note 
that this assay runs in a competitive mode, the decrease in MFI values would be interpreted 
as an increase in CLU expression level.  Thus, the over-expression of CLU demonstrated 
by the multiplex assay was in agreement with earlier results derived from analysis of 2-DE 
silver stained gels  
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(a) 
                        
(b) 
  
(c) 
   
 
Figure 3.24: Analysis of serum protein expression by competitive multiplex assay.  
Multiplex immunoassay was performed using sera of women with NP (NP) and HM (HM) 
as well as control subjects (C).  Panels (a), (b) and (c) demonstrate the results of the 
competitive multiplex assay for ATR, CLP and CLU, respectively.  
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CHAPTER 4: 
DISCUSSION 
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4.1 Champedak galactose binding lectin  
In 1991, Hashim et al had reported the discovery of a novel galactose binding lectin 
in the extract of the champedak (Artocarpus integer) seeds.  The lectin, termed as CGB 
(champedak galactose binding) lectin, was found to possess a similar general structure, and 
to a certain extent binding specificity to jacalin, a lectin purified from the seeds of jackfruit 
(Artocarpus heterophyllus).  The CGB lectin was observed to be capable of recognizing 
and binding to the O-linked Galß1-3GalNAc structure of IgA1 and C1 inhibitor molecules 
(Hashim et al., 1991, 1993 and 1994).  Based on its unique reactivity towards the O-
glycans, the CGB lectin has been extensively used to study the differential expression of 
serum O-glycoproteins in selective groups of patients with cancers as well as other diseases 
(Jayapalan et al., 2012; Mu et al., 2012; Abdullah-Soheimi et al., 2010; Mohamed et al., 
2008 (this thesis); Abdul-Rahman et al., 2007; Hashim et al, 2001a; Hashim et al, 2001b; 
Shuib et al., 1998).  
Amongst the several studies conducted using the CGB lectin, of interest was the 
work of Abdul-Rahman et al. (2007).  In their work, they have highlighted the enhanced 
expression of a CGB lectin-detected 35 kDa protein, termed LDP1, in the serum samples of 
patients with endometrial cancer (EACa) compared to the controls.  This protein was not 
detected when serum samples of the patients and control subjects were profiled using the 
conventional 2-DE approach which involved silver staining.  In this regard, it is of interest 
to identify the LDP1.  However, identification of a protein that has been electroblotted onto 
a nitrocellulose membrane and reacted with an enzyme conjugated lectin was not a 
straightforward task.  There were several shortcomings associated with the direct use of 
such protein, including low accessibility of digestive enzymes and reagents to the 
membrane-trapped protein.  In addition, presence of the HRP-CGB lectin and other 
   
 178 
reagents that were used earlier in the development of the blots may also interfere with the 
performance of the mass spectrometer.  Hence, in the present work, a different approach 
was adopted in the attempt to identify the protein of interest.  O-glycosylated fractions 
containing the protein of interest, LDP1, was thus isolated by subjecting pooled serum 
samples of patients with EACa to a CGB lectin affinity chromatography followed by 2-DE.  
 
 
4.1.1 Isolation and purification of CGB lectin 
In order to use the CGB lectin to isolate and identify LDP1 in the pooled sera of 
patients with EACa, the lectin had to be prepared from the seeds of Artocarpus integer.  
Therefore, in the initial part of the study, a crude extract of the champedak seeds was 
subjected to affinity separation on immobilized galactose.  The procedure for the isolation 
of the CGB lectin was essentially the same as that of Abdul Rahman et al. (2002).  In both 
studies (Abdul Rahman et al. (2002) and ours), the CGB lectin was purified using a 
galactose-Sepharose affinity chromatography column, which was a modification from an 
initial protocol that was used to isolate similar lectin.  Earlier, Hashim et al. (1991a and b) 
had purified their CGB lectin using an IgA1-Sepharose affinity column.  However, using 
galactose as a ligand to capture the CGB lectin offered a more cost-effective method 
compared to using IgA1. 
Similar to any extraction process of a plant lectin, the seeds must first be ground to 
the form of powder (Hermanson et al., 1992).  Therefore, the champedak seeds was dried 
and ground prior to ammonium sulphate precipitation.  Subsequent centrifugation and 
solubilisation of the seed precipitate yielded a yellowish supernatant containing a mixture 
of lectins and other compounds including the CGB lectin.  To isolate the lectin of interest, 
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its carbohydrate-binding specificity towards galactose was exploited in the use of a 
galactose-affinity chromatography column.  The prepared supernatant was passed slowly 
through a galactose-affinity column, allowing the CGB lectin to bind to the galactose 
ligands.  Subsequently, the bound CGB lectin was desorbed with an elution buffer.  The 
approach employed in this experiment involved displacement of the bound material by 
competition with a counter ligand.  The counter ligand is either the same as the ligand itself 
or of similar structure so as it will effectively compete for the binding sites on the adsorbed 
molecules (Hermanson et al., 1992).  Therefore, in our study, D-galactose was dissolved in 
PBS at a concentration of 0.8 M to break the CGB lectin-galactose interaction and elute the 
bound lectin off the column.  Following displacement of the lectin from the column, the 
purified CGB lectin, which was still in the elution buffer, was dialysed against PBS and 
later pooled and freeze-dried.  
 
 
4.1.2 Characterisation of CGB lectin 
Prior to the application of the purified CGB lectin, it was important to ascertain that 
the lectin was of high quality.  Hence, the prepared CGB lectin was analysed in terms of its 
purity and reactivity and compared with those reported from previous studies. 
In the present study, the CGB lectin, when subjected to SDS-PAGE, was found to 
comprise two subunits.  This is consistent with the earlier findings of Hashim et al. (1991).  
In their SDS-PAGE analysis of the purified CGB lectin, the lectin was demonstrated to 
consist of a combination of two types of non-covalently linked subunits with apparent 
molecular weights of 13.3 and 16 kDa.  However, noted was a slight discrepancy in terms 
of the molecular weights of the resolved bands.  In the present study, the CGB lectin 
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appeared to migrate into two bands with molecular weights of approximately 14 and 16.5 
kDa.  This minor molecular weight disparity may be attributed to the different percentage 
of polyacrylamide and/or differences in the chemicals and standards used during the run.    
The mass of a protein could also be determined using mass spectrometry approaches 
such as the MALDI, ESI and SELDI.  These techniques have been gaining popularity as 
they could accurately determine masses at the parts per million (ppm) levels (Dass, 2001).  
Therefore, to further corroborate the finding from the SDS-PAGE analysis, the molecular 
mass of the CGB lectin was also determined using SELDI-MS.  SELDI mass spectrum 
profile obtained from this study showed two successive sharp peaks within the mass range 
of approximately 14 and 16 kDa.  These peaks appeared to possess masses which correlate 
well with the masses of the two reported subunits of the CGB lectin.  In 2002, Abdul 
Rahman et al. had sequenced these two subunits and reported that there exists 95% 
sequence homology for the larger subunit of the CGB lectin with the α1 subunits of jacalin.  
The larger subunit was thus designated as α1, while the smaller subunit was termed as ß1 
(Abdul Rahman et al., 2002). 
The presence of the smaller peaks with masses of 7 and 8 kDa in the SELDI mass 
spectrum profile, may be linked to the formation of doubly charged molecules of the 
respective subunits during ionisation of the target molecule (Merchant and Weinberger, 
2000), and in this case, the CGB lectin.   Since there was no other bands or peaks observed 
in the SELDI-MS analysis, the CGB lectin that was prepared in this study can be concluded 
to be of high purity.  
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In view of the high purity of the CGB lectin that was isolated in the present study, it 
was therefore possible to crystallize the lectin.   As documented by Gabrielsen et al. (2009; 
this thesis), the highly purified solution of the CGB lectin managed to be crystallized at 
293K in two space groups, P21 and P212121.  In addition, the resulting crystals were found 
to diffract to resolutions of 1.65 and 2.6Ǻ, respectively.  And since a protein crystal plays a 
pivotal part in the structural and functional studies of the respective protein, 
crystallographic study had been further conducted comparing the CGB lectin crystal with 
that of jacalin.  The results of this study generally demonstrate that the CGB lectin is more 
specific in its binding to galactose than jacalin (Gabrielsen et al., personal communication).  
Determination of the functional property of the CGB lectin was assessed by putting 
it to challenge with a panel of different types of human serum proteins and 
immunoglobulins.  The panel that was chosen consisted of glycoproteins with established 
O- (such as IgA1 and AHS) and N-linked glycan moieties (such as IgA2 and IgM) as well 
as a non-glycosylated protein (albumin).  Simple double diffusion test showed that the 
purified CGB lectin interacted strongly with AHS and IgA1 but were completely non-
reactive with IgA2 and IgM.  The reactivity of the CGB lectin to these glycoproteins had 
also been described previously (Abdul Rahman et al., 2002; Hashim et al., 1993).  The 
preferential binding of the CGB lectin to AHS and IgA1 were not surprising as presence of 
O-glycan in the structures of these two glycoproteins had been documented (Van den Steen 
et al., 1998).  And since IgA2 and IgM do not possess any O-glycans but harbor N-linked 
oligosaccharide moieties instead (Arnold et al., 2007; Field et al., 1994), they were unable 
to interact with the CGB lectin.   
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4.2 Identification of the LDP1  
One of the primary requirements for protein identification using mass spectrometry 
approach is that the protein is of high purity.  Hence, to identify the protein of interest, the 
LDP1 had to be isolated from a cocktail of proteins in the serum samples of patients with 
EACa.   Based on the strong reactivity of the LDP1 to the CGB lectin (Abdul-Rahman et 
al., 2007), isolation of the protein was performed by subjecting pooled sera of patients with 
EACa to a CGB lectin affinity chromatography.   Hence, the purified CGB lectin was used 
in the preparation of a CGB lectin affinity chromatography column.   
The specific binding of CGB lectin to the Gal and GalNAc residues renders the 
affinity column capable of isolating serum proteins harbouring O-glycan moieties (Abdul 
Rahman et al., 2002).  Therefore, when the pooled serum samples were loaded into the 
CGB lectin affinity column, serum O-glycoproteins including the LDP1 were bound to the 
lectin ligands.  In the presence of 0.1 M melibiose which acted as a counter ligand, bound 
fractions consisting of CGB lectin reactive serum proteins were eluted out.  Separation of 
the LDP1 protein from the mixture of CGB lectin-reactive proteins was subsequently 
performed by subjecting the bound fraction to 2-DE.  Following electrophoresis, 
visualization of the separated proteins was performed using Coomassie stain.  Based on 
reports by Abdul-Rahman et al. (2007) the LDP1 spots were located and excised prior to 
MS/MS analysis.  
 
4.2.1 Identification of the LDP1 protein 
When the LDP1 was subjected to MS/MS analysis and subsequent database search, 
the protein was initially identified as inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4).   
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The ITIH4, also previously denominated as sgp120, PK-120 and IHRP, is a member of the 
inter-alpha-trypsin inhibitor (ITI) family (Pineiro et al., 1999; Salier et al., 1996).  This 
protein has been reported to be a 120 kDa (Gonzalez-Ramon et al., 1995) acute phase 
glycoprotein of hepatic origin (Nishimura et al., 1995).  Interestingly, ITIH4 is the only 
member of the ITI family which harbors a kallikrein-released bradykinin-like domain on its 
C-terminal sequence (Nishimura et al., 1995) making it plasma kallikrein sensitive (Cai et 
al. 1998; Hashimoto et al.,1996; Saguchi et al.,1995).  It has been reported that trace 
amount of plasma kallikrein will first cleave the ITIH4 to yield two fragments, i.e., the C-
terminal 35 kDa and the N-terminal 85 kDa fragments (Saguchi et al., 1995).  The 35 kDa 
ITIH4 fragment, which is O-glycosylated (Nishimura et al., 1995; Pu et al., 1994), is 
assumed to remain intact.  However, the 85 kDa ITIH4 fragment is further cleaved to 
produce an N-terminal 57 kDa fragment and a putative 28 kDa fragment.  The latter is 
believed to be further processed by protease(s) to generate smaller fragments (Song et al., 
2006; Pu et al., 1994). 
However, in the present study, the LDP1 spot cluster that was detected on the 2-DE 
gel appeared to be resolved at a much lower molecular weight region than 120 kDa.  In the 
Coomassie stained 2-DE gel, the LDP1 appeared to demonstrate a relative molecular mass 
of approximately 35,000.  Therefore, the serum LDP1 protein that was detected using the 
CGB lectin was not the intact ITIH4 but most likely a fragment derived from the kallikrein 
proteolytic activity onto the ITIH4 molecule.  In addition, based on the MS/MS derived 
sequences, 14 out of the 15 peptide sequences appeared to be from the 35 kDa fragment 
region of ITIH4.  As such, this strongly suggested that the LDP1 spot cluster detected by 
the CGB lectin was actually the 35 kDa cleavage fragment of ITIH4.  This notion is further 
supported by the presence of three O-linked oligosaccharides at positions 696, 701 and 702 
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within the 35 kDa fragment (Nishimura et al, 1995; Pu et al., 1994) which explains its 
interaction to the CGB lectin.  
 
 
4.3 Prevalence of the 35 kDa ITIH4f 
In this study, the expression of the 35 kDa ITIH4 fragment (ITIH4f) was analyzed 
using the well established enzyme-conjugated CGB lectin-probed 2-DE electrophoretic 
approach.  Five groups of patients with different cancers were subjected to analysis; OsSa, 
NPCa, BrCa, GOCa, and EOCa.  Out of the five groups studied, only three of them 
demonstrated significant enhanced expression of the 35 kDa cleavage fragment.  Using 
similar approach, Abdul-Rahman et al. (2007) have previously shown that the ITIH4f was 
only up-regulated in the sera of patients with EACa, whilst its expression in the groups of 
patients with SCCa and ACCa were comparable to the controls.  Hence, the results from the 
present study when taken together with the previous findings of Abdul-Rahman et al. 
(2007) demonstrated that the 35 kDa ITIH4f appeared to be enhanced selectively in cancers 
like BrCa, EOCa, GOCa and EACa but not in NPCa, OsSa, ACCa and SCCa.  
One of the differences between the groups of cancers showing up-regulated 
expression of their 35 kDa ITIH4f with those that did not is that the former is associated 
with estrogen dysregulation (Key et al., 2001; Henderson and Feigelson, 2000).  The idea 
that endogenous sex steroid hormones can, under wrong circumstances, contribute to 
neoplastic transformation has been dwelled upon for a long time (Henderson et al., 1982).  
Besides clinical research, there have been a lot of cross-sectional as well as epidemiological 
studies (Greenwald and Dunn, 2009; Ganmaa and Sato, 2005) conducted to investigate the 
relationship of sex-steroids on the outcome, risk and control of cancer.  To date, the best 
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studied sex-hormone is estrogen and it has been implicated in carcinogenesis of several 
different cancers (Greenwald and Dunn, 2009), being most evident in cancers of the breast 
(Key et al., 2002; Schairer et al., 2000), endometrium (Allen et al., 2008; Weiderpass et al., 
1999) and ovary (Lukanova and Kaaks, 2005; Persson and Riman, 2000).  Therefore, it was 
speculated that the 35 kDa ITIH4f was over-expressed in cancers under the influence of 
estrogen dysregulation.  In such a case, however, there is a possibility that the abundance of 
the particular ITIH4f may not be restrictive to patients with cancer but may also be present 
in other diseases associated with the increased levels of estrogen. 
To investigate the possibility that the 35 kDa ITIH4f may also be over-expressed in 
non-cancer conditions that are associated with enhanced levels of estrogen, the expression 
analyses was extended to include groups of non-cancer patients with  similar hormonal 
dysregulation.  In this study, two groups of pregnant women undergoing estrogen 
dysregulation were chosen.  Both groups of subjects were with increased levels of estrogen, 
with the former representing a normal condition, while the latter a benign condition 
(Ahmed et al., 2000).   Throughout a normal pregnancy, the maternal levels of circulating 
estrogens increases continuously as it is required to support fetal development (Takeyama 
et al., 2001; Loriaux et al., 1972).  On the other hand, women with hydatidiform mole 
(HM) were reported to have plasma estrogen levels as high as those of normal pregnant 
controls (Hegab and Schindler, 2004).  
 In the present study, sera of women with NP and HM were subjected to similar 
CGB lectin-based electrophoretic approach.  The expression of the ITIH4f was indeed 
prominently up-regulated in both groups of pregnant women as previously expected.  
Hence, these results generally indicate that the over-expression of the 35 kDa ITIH4f was 
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not exclusive towards estrogen-related cancers but also in other diseased conditions 
associated with estrogen dysregulation. 
The marked difference in the expression of the 35 kDa ITIH4 cleavage fragment 
detected in the selective groups of subjects with estrogen-related conditions may be 
attributed by three possible reasons.  One possibility is that the elevated levels of 
circulating kallikreins in the serum leads to increased cleavage of the ITIH4 protein.  The 
second reason lies in the possibility that the ITIH4 protein is truly over-expressed in 
patients with increased levels of estrogen.  Alternatively, a combination of the two said 
reasons may also contribute to the high abundance of the ITIH4f that was observed in the 
present study. 
The idea that the abundance of the ITIH4 fragment is linked to the high amount of 
serum kallikreins is derived from previous reports demonstrating the over-expression of 
members of the kallikrein family in cancers of the breast, ovary and endometrium (Borgono 
and Diamandis, 2004; Myers and Clements, 2001; Diamandis et al, 2000).  This is not 
surprising as kallikreins are known to be expressed in hormone-dependant tissues such as 
the breast and ovary (Diamandis and Yousef, 2002).  In addition, the expression of these 
kallikrein genes have been shown,  using cancer cell lines, to be regulated by steroid 
hormones including estrogen (Myers and Clements, 2001; Yousef et al., 2001).  As the 
ITIH4 protein is kallikrein-sensitive, there is likelihood that the over-expression of 
kallikrein may lead to increased cleavage of serum ITIH4 which in turn led to the enhanced 
liberation of its 35 kDa fragment (Mohamed et al., 2008; this thesis).  In support of this 
correlation between the circulating serum kallikrein concentration and the abundance of the 
35 kDa ITIH4f is a study conducted by Gangadharan et al. (2007).  Based on their study, it 
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was demonstrated that the down-regulation of kallikrein in patients with hepatic cirrhosis 
resulted in low abundance of the ITIH4 fragments including the 35 kDa fragment.  
Another possibility is that the expression of the ITIH4 may have been induced as 
part of an acute-phase response towards the studied conditions.  ITIH4 has been shown to 
be an acute-phase protein (Gonzalez-Ramon et al., 1995).  This notion is in line with 
several reports indicating the elevation of the ITIH4 protein in pregnancy conditions 
(Heitner et al., 2006; Geisert et al., 1998), as well as in conditions of acute stress both in 
human (Piniero et al., 1999) and cattle (Piniero et al., 2004).  However, at present, no such 
finding has been reported with regard to cancers even though elevation in the level of the 
various ITIH4 fragments has been documented (Opstal-van Winden et al. 2012; van den 
Broek et al, 2010; Gast et al., 2009).  At present, the mechanism underlying the increase in 
the intact ITIH4 protein as well as its function is not clear but it has been reported that 
members of the ITIH family, including the ITIH4, play important roles in stabilization of 
the extracellular matrix (Heitner et al., 2006; Bost et al., 1998; Salier et al., 1996).   This 
role is attained via the interaction of the ITIH heavy chains with hyaluronic acid.  The 
hyaluronic acid, which is a major component of the extracellular matrix, has been 
demonstrated to play modulatory roles in tissue scaffolding and remodeling activities 
(Bhanumathy et al., 2002), which are among the critical events of normal or pathological 
cellular morphogenesis in benign as well as cancerous conditions (West and Kumar, 1989).  
It has also been postulated that there may be a strong involvement of the ITIH4 protein with 
attachment of the placenta to the uterus during pregnancy (Geisert et al., 2003).  In 
addition, numerous studies have also pointed out the role of the ITIH proteins with 
inhibition of apoptosis (Fujita et al., 2004; Mangnall et al., 2003).  To further corroborate 
this suggestion is the fact that aside from the ITIH protein, estrogen also has a role in 
   
 188 
regulating the extracellular matrix integrity in responsive organs such as the uterus and 
vagina (Cox and Helvering, 2006).  Hence, when taken together, there is a likelihood of 
deregulation of the expression of the ITIH4 protein in patients with conditions associated 
with increased levels of estrogen. 
 Alternatively, the detection of the highly abundant 35 kDa ITIH4f may have 
resulted from the synergistic effect of both conditions of up-regulated expression of the 
ITIH4 protein and its proteolytic enzyme, kallikrein.  As discussed earlier, the erratic 
secretion of estrogen is known to affect the expression of kallikrein genes (Borgono et al., 
2004; Yousef and Diamandis, 2001) which resulted in the elevated levels of kallikreins in 
the serum.  Mean while, the ITIH4 protein may also be highly expressed in serum of 
patients with estrogen dysregulation.  Taken together, these two possibilities may lead to a 
high amount of the 35 kDa ITIH4f, product of the kallikrein fragmentation activity on the 
ITIH4 protein.   However, all three possibilities warrant further studies to uncover the 
underlying mechanism connecting to the differential expression of the 35 kDa ITIH4 
fragment to the estrogen-related cancers and diseased conditions.  
In the present study, detection of the 35 kDa ITIH4f in serum samples using the 
HRP-conjugated CGB lectin is a simple bioanalytical approach that may be further 
exploited.  ITIH4f is not possibly detected by silver staining of the 2-DE gels.  The inability 
to detect the 35 kDa ITIH4f with the rest of the ITIH4-related fragments in serum samples 
that were subjected to the silver staining approach could be due to the considerably low 
concentration of the ITIH4 protein in the human serum ie. 55.1-176.6 µg/ml (Choi-Miura, 
2001).   
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Based on the ability of the CGB lectin detection method, there is a potential in using 
it to assess the activity of kallikreins in clinical samples.  This is in view of the fact that the 
35 kDa ITIH4f is liberated through the enzymatic activity of kallikrein.  Hence, the 
expression of the ITIH4 cleavage fragment may indicate the in vivo activity of circulating 
kallikreins.  In addition, the approach may be incorporated in the assessment of the 
physiological relevance of the ITIH4 fragmentation.  To the best of our knowledge, little is 
known on the expression of the 35 kDa cleavage fragment of the ITIH4.  The peptide has 
only been detected in sera of patients with severe acute respiratory syndrome (Chen et al., 
2004).  Most reports concerning the ITIH4, in relation to cancer and diseased conditions, 
were focused on the 85 kDa proline-rich region and its proteolytic processing (van den 
Broek et al., 2010; Song et al., 2006; Fung et al., 2005).  The question of why the 35 kDa 
ITIH4f did not get the same attention as its counterpart is rather intriguing.  One factor that 
may have contributed to the lack of information on the 35 kDa cleavage fragment of the 
ITIH4 could be in the difficulty to detect the fragment.  Unlike the 35 kDa fragment, the 85 
kDa N-terminal region undergoes further proteolytic activities resulting in smaller 
fragments which made them easily identified by SELDI-TOF-MS, MALDI-TOF-MS or 
LC-MS.  In contrast, the 35 kDa ITIH4 fragment remained intact making its identification 
and evaluation as potential disease markers using similar tools unfeasible.  Therefore, at 
present, the enzyme-conjugated CGB lectin electrophoretic approach may appear to be the 
solution to the bottleneck detection issue.  Currently, several studies have been conducted 
using this approach and the researchers have managed to detect the aberrant expression of 
the 35 kDa ITIH4f in urinary protein profiles of patients with cancers of the ovary (Mu et 
al., 2012; Abdullah-Soheimi et al., 2010) and prostate (Jayapalan et al., 2012; Jayapalan, 
personal communication, 2013).  
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4.4 Profiling of serum proteins of women with NP and HM by 2-DE 
Human serum contains a wide variety of different proteins and peptides.  Due to 
different diseases and physiological states, modifications in the production of specific 
proteins and enzymes can occur.  This leads to alterations in the serum composition which 
could therefore serve as indicator of an individual‟s physical condition (van den Broek et 
al., 2008).  Hence, the aberrantly expressed proteins and peptides could be utilized as 
valuable biomarkers, enabling diagnosis as well as prognosis of different diseased 
conditions. 
In this study, attempts to profile the maternal serum proteins of women with NP and 
HM were performed using the gel- and lectin-based proteomic approach.  Maternal serum 
samples at 11 weeks of gestation, on average, were initially subjected to 2-DE separation, 
followed by isolation of their O-glycoproteins using enzyme-conjugated CGB lectin as 
probes.  Since O-glycosylated serum proteins have been strongly associated with several 
different types of cancers (Mohamed et al., 2008 (this thesis); Chen et al., 2008; Abdul-
Rahman et al., 2007; Brockhausen, 2006) it would be interesting to determine if these O-
glycoproteins were also aberrantly expressed in the groups of women with conditions that 
are considered to be benign and normal such as HM and NP.    
When comparative analysis was performed on the serum O-glycoproteins resolved 
on the lectin-interacted membranes, different altered levels of several high-abundance 
proteins were detected in the groups of women with NP and HM, relative to their healthy 
non-pregnant controls.  Three O-glycoproteins, including the 35 kDa ITIH4f, ACT and 
LRG, were differently expressed.  In the two groups of pregnant women studied, the up-
regulated expression of the 35 kDa ITIH4f was consistently observed.  The 35 kDa ITIH4f 
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was also the sole O-glycoprotein that was found to be differentially expressed when 
comparison was made between the O-glycoprotein profiles of the women with HM and the 
controls.  However, since its enhanced expression has been specifically discussed in the 
preceding section, the following discussion will only focus on the other two aberrantly 
expressed O-glycoproteins.  In the case of the group of women with NP, the expression of 
ACT and LRG was found to be significantly higher compared to those of the control 
subjects.  When the expression levels of the O-glycoproteins of the women with HM were 
compared to those generated from the sera of NP women, the only conspicuous difference 
was in the doubling of the levels of ACT in the sera of women with NP.   
To corroborate our earlier findings from the enzyme-conjugated CGB lectin 
approach, analysis of the serum proteins of the three groups of women was further extended 
using a different detection method.  In the second approach, whole serum samples were 
separated using the 2-DE technique and the resulting protein spots were then detected using 
silver staining.  Earlier, several researchers have managed to develop high-resolution 2-DE 
serum protein expression profiles of patients diagnosed with early stages of cancers of the 
breast (Doustjalali et al., 2004), ovary (Chen et al., 2008), cervix (Abdul-Rahman et al., 
2007), endometrium (Abdul-Rahman et al., 2007), nasopharynx (Doustjalali et al., 2006) 
and prostate (Jayapalan et al., 2012), as well as other diseased conditions such as congenital 
hypothyroidism (Yong et al., 2006) and IgA nephropathy (Shuib et al., 1998) by using a 
similar approach.  In the present study, analysis of the silver-stained 2-DE gels of women 
with NP, HM and their normal subjects also managed to reveal the differential expression 
of several high abundance serum proteins.  Some of the aberrantly expressed proteins were 
not detected earlier in the CGB lectin probed serum protein profiles as they were naturally 
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without any O-linked glycans, such as CLU (Stewart et al., 2007; Zhang et al., 2003) and 
ZAG (Hassan et al., 2008; Delker et al., 2004).   
By subjecting the 2-DE serum protein profiles of women with NP and control 
subjects to densitometry analysis, the enhanced expression of ACT and LRG in the sera of 
NP women that was earlier detected using the CGB lectin was further confirmed.  Added to 
the existing list of differentially regulated serum proteins of the women with NP was the 
over-expression of ZAG and CLU that was found in this part of the study.  Similarly, the 
serum samples from the group of women with HM were also found to contain higher 
amounts of LRG and CLU, compared to those of the controls.  When comparative analysis 
was performed on the profiles of women with NP and HM, the higher expression of ACT in 
the women with NP that was detected earlier in the lectin work, was also confirmed. 
In the present study, confirmation on the identities of the four aberrantly expressed 
serum proteins was performed using mass spectrometry.  The gel plugs containing the 
desired protein were subjected to MS/MS analysis followed by NCBInr database search, 
which positively identified the proteins as ACT, CLU, LRG and ZAG.  Meanwhile, to 
validate the aberrant expression of the four serum proteins in the respective groups of 
women studied, an immunoblotting approach was employed.  Using commercial antibodies 
to detect the expression of the electroblotted proteins, the altered levels of ACT, CLU, LRG 
and ZAG in the respective groups of pregnant women were confirmed, although the 
magnitude of deviation was generally much lower compared to the 2-DE experiments.  This 
is indicative of the higher sensitivity of 2-DE compared to immunoblotting when used to 
evaluate the levels of serum proteins.  Similar findings have been reported by previous 
researchers in their attempts to confirm the altered expression of serum proteins using 
competitive ELISA (Chen et al., 2008; Abdul-Rahman et al., 2007; Doustjalali et al., 2004 
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and 2006).  By using the immunoblotting approach, the enhanced expression of ACT, CLU, 
LRG and ZAG, in the sera of women with NP, managed to be confirmed.  Similarly, the 
high amounts of circulating CLU and LRG in the serum of women with HM were also 
shown. 
In this study, the different altered expression of high abundance serum proteins in 
the maternal serum samples are thought to be the consequence of the various response of 
the body towards pregnancy.  During pregnancy, the endometrium of the uterine responds 
to hormonal cues and growth factors to accommodate a developing fetus (Brown and 
Bundle, 1996).  Thus, serum proteins which are sensitive to hormonal fluctuations, such as 
CLU (Brown et al., 1996) and fragmentation of the ITIH4 protein (Mohamed et al., 2008; 
this thesis), are at high risk of being differentially regulated.    
The increased level of maternal serum CLU in association with pregnancy is well 
described.  CLU, also known as apoJ, is an 80 kDa glycoprotein composed of two non-
identical, 35 kDa disulfide-linked subunits generated in vivo by proteolytic cleavage of 
proapoJ (Scaltriti et al., 2004; Burkey et al., 1991).  It was first characterized in the rat 
testis fluid as a sulphated secreted glycoprotein with a capacity to elicit clustering of cells 
(Blaschuk et al., 1983).  The glycoprotein is found in most, if not all, biological fluids 
(Jordan-Starck et al., 1992) and based on its wide distribution, many physiological roles 
have been proposed for this protein.  Several studies have reported on the involvement of 
CLU in apoptosis (Trougakos et al., 2005; Koch-Brandt and Morgans, 1996), sperm 
maturation (Rosenberg and Silkensen, 1995), lipid transport (Calero et al., 1999; de Silva et 
al., 1990), cell adhesion (Blaschuk et al., 1983; Fritz et al., 1983) and injury repair (Grima 
et al., 1990).  There is also evidence on the association of CLU with tissue remodeling and 
cellular differentiation processes (French et al., 1996; Brown et al., 1995) which are 
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essential for embryonic development.  At present, the exact role of CLU in remodelling of 
the uterus tissues is still unclear, even though there have been reports on the expression of 
the CLU gene in the uterus (Aronow et al., 1993).  However, in 1993, French et al. had 
reported on the association between the expression of CLU gene with epithelial 
differentiation during murine embryogenesis.  In addition, CLU has also been shown to 
play an active role in the implantation process of blastocyst onto the uterine tissue (Brown 
et al., 1996).  Hence, the reported involvement of CLU in pregnancy may provide some 
explanation to its enhanced expression in the groups of women with NP and HM, as both 
conditions require similar implantation and cellular differentiation of the embryo regardless 
of whether the women were with normal and abnormal pregnancies. 
Aside from being over-expressed during pregnancy, the increased expression of 
CLU has also been seen in other pathological conditions including aging, diabetes, 
neurodegenerative diseases, atherosclerosis, myocardial infarction and cancers (Trougakos 
and Gonos, 2009; Trougakos et al., 2005; Jones and Jomary, 2002; Rosenberg and 
Silkensen, 1995).  Recently there have been numerous reports on the over-expression of 
CLU in patients with several human cancers, such as cancers of the prostate (Ouyang et al., 
2001; Steinberg et al., 1997), breast (Doustjalali et al., 2004; Redondo et al., 2000), ovary 
(Chen et al., 2008; Hough et al., 2000), renal (Kang et al., 2004; Miyake et al., 2002), 
colon (Pucci et al., 2004; Chen et al., 2003) and endometrial (Abdul-Rahman et al., 2007; 
Vollmer, 2003).  
Aside from CLU, high levels of maternal serum LRG were also detected in the two 
groups of pregnant women studied.  LRG, which is a trace protein of the human plasma, 
was initially isolated by Haupt and Baudner in 1977.  However, its amino acid sequence 
was determined in 1985 by Takahashi et al. in 1985.  LRG was reported to contain 312 
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amino acid residues, out of which 66 were leucines.  It also possesses eight repeating 
consensus sequence, termed leucine-rich repeat, which is commonly exhibited by members 
of the Leucine Rich Repeats family.  The LRG polypeptide chain has been shown to 
contain an O-link oligosaccharide (Rodriquez-Pineiro et al., 2004), which explains its 
interaction to the CGB lectin.  
The presence of leucine rich repeats in a polypeptide chain has been suggested to 
provide a versatile structural framework for the formation of protein-protein interactions 
(Kobe and Kajava, 2001).  The respective peptide has also been shown to be involved in 
signal transduction as well as cell adhesion and development (Buchanan and Gay, 1996).  
However, relatively little is known on the function of LRG itself as not many studies have 
been carried out on this protein, especially in relation to pregnancy.   At present, LRG has 
been proposed to be a membrane-associated glycoprotein (Eisenberg et al., 1984; Kaiser 
and Kezdy, 1983) and may be involved in the binding of extracellular matrix proteins 
(Saito et al., 2002) as well as the granulocytic differentiation of neutrophils (O‟Donnell et 
al., 2002).   
In 1996, Bini et al. had suggested LRG to be an acute phase protein as its level in 
plasma was found to be increased during the early stage of inflammation.  This finding was 
further corroborated by the work of Shirai et al. (2009).  Based on their observations, this 
glycoprotein was demonstrated to be a secretory type-1 acute-phase protein whose 
expression was up-regulated by the mediator of acute-phase response.  Being an acute-
phase protein, conditions such as inflammation, infection, trauma and cancer would trigger 
the over-expression of LRG (Gabay and Kushner, 1999; Heegaard et al., 1998).  On the 
other hand, pregnancy is also accepted as a form of a tumor by some researchers.  This 
notion of „pseudo-malignant‟ condition is supported by the many similarities shared 
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between the conditions of pregnancy and cancer.  Among the similarities are in the unique 
characteristics of their cellular components (Soundararajan and Rao, 2004; Quenby et al., 
1998) as well as the dysregulated expression of several of their proteins (Fest et al., 2008; 
Toth et al., 2008; Jeschke et al., 2003).  Hence, it is not surprising that elevated levels of 
LRG were detected in the sera of the two groups of pregnant women studied if that was the 
case.  
To date, there have been very few studies in which the expression of LRG was 
evaluated.  LRG was shown to be over-expressed in various diseases only recently, with the 
development of proteomic analysis.  The aberrant expression of this glycoprotein has been 
reported in sera of patients with cancers of the ovary (Boylan et al., 2010; Chen et al., 
2008), lung (Li et al., 2011; Okano et al., 2006) and pancreas (Kakisaka et al., 2007; Deng 
et al., 2007).  In addition, the abundance of LRG has also been found in the cerebrospinal 
fluid of patients with idiopathic normal pressure hydrocephalus (Li et al., 2007).   
Contrary to the expression of CLU and LRG, which were over-expressed in both 
types of normal and abnormal pregnancy conditions, the aberrant expression of ACT and 
ZAG appeared to be exclusive for women with normal pregnancy.  In the present study, the 
finding of the up-regulated expression of serum ACT is compatible with the result of a 
previous study conducted by Chelbi et al. (2007) which showed elevated levels of ACT in 
the placenta of normal pregnant women.  It is possible that higher maternal serum level of 
ACT is a consequence of a balancing mechanism to control trophoblast invasion of the 
uterus tissues.  The development of pregnancy is highly dependent on the ability of the 
placenta‟s trophoblastic cells to invade the basement membrane of the uterus, especially in 
the first trimester of pregnancy.  The trophoblast invasion on the other hand, is mediated by 
metalloproteases and serine proteases and its invasiveness is, in turn, controlled by protease 
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inhibitors such as ACT (Picken et al., 1990) and the tissue inhibitor of metalloproteases 
(TIM) and transforming growth factor-ß (TGF-ß) (Lala and Grahamm, 1990).  However, 
the mechanism underlying the absence of such over-expression in the serum samples of 
women with HM is not known with certainty.  A probable reason that may be considered is 
that the inhibitory activity of ACT is only for the strictly regulated normal pregnancies 
whereas the molar pregnancy is characterized by an uncontrolled excessive placental 
invasion by the molar tumor.  This presumption is based on similar observation on PAI-1, 
also known as serpine E1, in placentas of normal and molar pregnancies (Floridon et al., 
2000). 
ACT, also known as serpina 3, is a member of the serine protease inhibitor family 
(Travis and Salvesen, 1983).  As a protease inhibitor, ACT binds cognate proteases to form 
a serpine-protease complex, which is cleared from the circulation via the liver.  Among the 
targeted serine proteases are pancreatic chymotrypsin, leukocyte cathepsin G, mast cell 
chymases, human glandular kallikrein 2, kallikrein 3 (PR3), pancreatic cationic elastase and 
an uncharacterised lung serum protease (Baker et al., 2007).  Although the exact function 
of ACT in vivo remains to be determined, it has been implicated in a number of diseases 
including chronic obstructive pulmonary disease, Parkinson disease, Alzheimer‟s disease, 
stroke, cystic fibrosis, cerebral haemorrhage and multiple system atrophy (Baker et al., 
2007).  In addition, the aberrant expression of this protein has also been documented in 
several cancers.  The increase in the expression of ACT has been reported in cancers of the 
breast (Mbeunkui et al., 2007; Doustjalali et al., 2004), lung (Zelvyte et al., 2004; 
Higashiyama et al., 1995), gastrointestine (Wittekind et al., 1997; Bernacka et al., 1988) 
and ovary (Chen et al., 2008).  The significant increase of ACT in several cancers is not 
surprising.  It is believed that tumorogenesis, similar to fetal development, is generally 
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associated with extensive tissue remodelling, which has been shown to be under the 
influence of proteinases.  Hence, proteinase inhibitors, such as ACT, would be produced in 
abundance to protect tissues against the proteolytic activities of the proteinases (Zelvyte et 
al., 2004).   
In the case of ZAG, its over-expression was also solely exhibited in the maternal 
sera of women with NP.   However, there has been no report yet on the abundance of ZAG 
as well as its association with pregnancy.  ZAG is a 41 kDa glycoprotein secreted by a 
variety of normal epithelia including those in the breast, prostate, liver as well as in the 
salivary, bronchial, gastrointestinal and sweat glands (Tada et al., 1991).  Thus, it is 
secreted into different types of body fluids such as serum, semen, sweat, saliva, 
cerebrospinal fluid, milk, urine and amniotic fluid (Jain et al., 2005; Ding et al., 1990; 
Bundred et al., 1987; Burgi et al., 1989; Burgi and Schmid, 1961).  ZAG was first 
identified in human serum and named for its tendency to precipitate zinc salts and for its 
electrophoretic mobility that was similar to plasma α2 globulins (Burgi and Schmid, 1961).  
The ZAG protein has been shown to consist of three isoforms based on the work of Jirka 
and Blanicky (1980), and this is consistent with the ZAG spot cluster that was detected by 
2-DE in the present study.     
Currently, the presence of ZAG is known to stimulate lipolysis, which is involved in 
depletion of fatty acids from the adipose tissues (Hassan et al., 2008; Hirai et al., 1998).  
However, due to its presence and different degree of expression in various tissues and body 
fluids, several other possible functions may be attributed to this protein.  ZAG has been 
suggested to play a vital role in fertilization (Garcia-Ramirez et al., 2007; Ohkubo et al., 
1990), immunoregulation (Willcox et al., 2002; West and Bjorkman, 2000) and cell 
   
 199 
adhesion (Lei et al., 1999; Sanchez et al., 1999).  Several studies have also suggested ZAG 
to be indirectly involved in deterring tumor progression (He et al., 2001). 
Although the exact mechanism by which ZAG actively participates in tumor 
proliferation is not known, a lot of data exists on the over-expression of ZAG in different 
cancers.  The concentration of ZAG has been reported to increase dramatically in cancers 
of the prostate (Bondar et al., 2007; Hale et al., 2001), breast (Diez-Itza et al., 1993; 
Bundred et al., 1987), oral cavity (Brysk et al., 1997), skin (Lei et al., 1997), endometrium 
and cervix (Abdul-Rahman et al., 2007).  In addition, ZAG has also been considered as a 
marker for tumor differentiation (Lopez-Otin and Diamandis, 1998; Diez-Itza et al., 1993).  
Previous reports have demonstrated that higher ZAG level was detected in well-
differentiated tumors relative to that in the moderately or poorly differentiated tumors of 
cancers of the prostate (Hale et al., 2001) and breast (Diez-Itza et al., 1993).    
Changes in the patterns of glycosylation, which may occur during pregnancy 
(Mackiewicz and Mackiewicz, 1995; van Dijk et al., 1994), would most likely be reflected 
in the microheterogeneity of the isoforms of the glycoproteins (van Dijk et al., 1994; 
Mackiewicz et al., 1987).  Hence, in the present study, densitometry analysis was 
performed on the isoforms of the protein clusters resolved in the 2-DE gels as well as blots 
of the groups of women studied.  Comparative analysis between the profiles of women with 
NP and HM, relative to their normal subjects, revealed that all of the isoforms of the highly 
expressed 35 kDa ITIH4f, ACT, CLU and ZAG, although generally over-expressed, were 
similarly distributed in the silver stained gels as well as the CGB lectin detected blots.  
Hence, the abundance of the 35 kDa ITIH4f, ACT, CLU and ZAG in the women with NP 
and HM, appeared to be attributed by the overall increase in the expression levels of their 
isoforms and may not involve any alteration in their O-linked side chains.   
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Also detected in this study was the over-expression of LRG in the sera of women 
with HM, relative to the controls.  The marked difference in the expression levels of LRG 
which was detected when using whole serum was quite intriguing since the disparity was 
not detected in the earlier studies using the HRP-conjugated CGB lectin.  It is possible that 
the decreased binding of LRG to the Galß1-3GalNAc-reactive CGB lectin is due to the lack 
of O-glycans.  A similar finding has been reported by Hashim et al. (2001) in their attempt 
to establish the pathogenesis of IgA nephropathy using the CGB lectin.  In their work, the 
affinity of the CGB lectin to the serum IgA1 was significantly weaker in patients with IgA1 
as compared to normal controls.  The alteration in the glycosylation pattern of LRG, 
however, was independent of the rate of synthesis of LRG itself.  This was reflected in the 
abundance of LRG in the silver stained profiles.  In contrast, the expression of LRG in the 
group of women with NP appeared to be up-regulated in both profiles of the CGB lectin 
detected blots as well as the silver stained gels.   Hence, this generally implies that the O-
glycan moieties of LRG in women with NP were structurally different from those of 
women with HM.   
In addition, analysis of the isoforms of CLU in the 2-DE silver stained gels of the 
pregnant women and their controls demonstrated different distribution pattern for the 
women with NP and HM.  The enhanced expression of CLU in the women with NP was 
contributed by the over-expression of isoforms 2 and 3.  In contrast, isoforms 1 and 2 were 
significantly up-regulated in the CLU protein cluster of the women with HM.  The 
differential distribution of the volume of the isoforms generally implies that the CLU of 
HM women were more cationic as compared to those of NP women.  This observed 
difference may be attributed by the lack of sialic acid content (Hashim et al., 2001; Shuib et 
al., 1998) in the CLU polypeptide chain of the women with HM as compared to that of the 
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women with NP.  However, these findings, as well as those of LRG, warrant more in-depth 
analysis.  Further investigation could be performed by subjecting the respective serum 
proteins to exoglycosidase digestion followed by analysis using either the high-
performance liquid chromatography (Saldova et al., 2007) or the liquid chromatography 
(Heo et al., 2007).  Alternatively, methods such as the lectin glycoarray (Qiu et al., 2008), 
isotopic glycosidase elution and labelling on lectin-column chromatography (IGEL) (Ueda 
et al., 2010) and Lectin-directed Tandem Labelling (LTL) (Shetty et al., 2012) could also 
be used to confirm the aberrant glycosylation of LRG as well as the sialylation changes of 
CLU detected in the present study. 
Taken together, the present study demonstrated that the 35 kDa ITIH4f, ACT, CLU, 
LRG and ZAG were selectively over-expressed in the women with NP and HM, relative to 
their controls.  In addition, there are possibilities that the oligosaccharide side-chains of 
CLU and LRG were structurally altered in the HM women.  However, to use any of the 
aberrantly expressed proteins as individual candidate biomarker may not be practical as 
they are also elevated in different types of cancers.  Nevertheless, the expression of the all 
potential candidate biomarkers when analyzed together appeared to demonstrate differently 
altered patterns and seemed to differ from those previously reported for cancers of the 
breast, nasopharynx, cervix, endometrium and prostate.  This is illustrated in Figure 4.1, 
which summarizes the expression of selective high abundance serum proteins in the women 
with NP and HM that were investigated in the present study, relative to the earlier findings 
of previous researchers.  The checkered diagram appears to highlight the distinctive 
patterns of the selective benign conditions of the pregnant women from those exhibited by 
the different cancers.  For example, EOCa is associated with the over-expression of ACT,  
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Diseased 
conditions 
Serum proteins  
References AAT ABG ACT AHS ATR APO 
A2 
C3f  CFB CLU CLP HAP KNG LRG ZAG 
NP*   +      +    + + This thesis 
HM*         +    +  This thesis 
FDB*   +      +   _ +  Doustjalali et al., 2004 
BrCa -  +     + +   _   Doustjalali et al., 2004 
NPCa          +     Doustjalali et al., 2006 
EACa - +   +    +   _ +  Abdul-Rahman et al., 2007 
SCCa - +   +       _  + Abdul-Rahman et al., 2007 
ACCa - +   +       _  + Abdul-Rahman et al., 2007 
GOCa +   -     + + +  +  Chen et al., 2008 
EOCa +  +      +  +  +  Chen et al., 2008 
PCA      + +        Jayapalan et al., 2012 
 
Figure 4.1: Aberrantly expressed serum proteins in several benign and cancer conditions.  Checkered diagram of aberrantly expressed serum proteins in 
benign conditions (marked with asterisks) and cancers generated from analyses of whole sera subjected to 2-DE and silver staining. (+) indicates up-
regulated expression and (-) indicates down-regulated expression of serum proteins in patients compared to healthy controls. FDB, fibrocystic disease 
of the breast; SCCa, squamous cell cervical carcinoma; GOCa, germ cell ovarian carcinoma; PCa, prostate cancer; APOA2, apolipoprotein AII, C3f, 
complement C3 ß chain fragment; CFB, complement factor B. 
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CLU, LRG, AAT and HAP, while NP is also associated with the enhanced levels of ACT, 
CLU and LRG but with increased level of ZAG.   
Hence, the findings of the current study appear to provide additional evidence on 
the strength of assessing multiple biomarkers simultaneously as compared to the current 
usage of single biomarkers such as CA125 for ovarian cancer and PSA for prostate cancer.  
And since the profiles of the aberrantly expressed serum proteins demonstrated in Figure 
4.1 were unique for each of the diseased conditions, the altered expression patterns may act 
as typical signatures or fingerprints to distinguish the different types of cancers, as 
suggested by Pang et al. (2010).  However, although there is compelling evidence for the 
diagnostic and/or prognostic potential of the respective patterns, further validation using 
clinically acceptable sample sizes and involving other types as well as subtypes of cancers 
are required.  These investigations may not be possible using the current gel-based 
proteomics technique, which is laborious and time-consuming but can perhaps be done 
using other state-of–the-art approaches such as the multiplex immunoassay, protein array or 
the targeted chip-based proteomic assays. 
 
 
4.5 Development of a multiplex immunoassay  
In the present study, an in-house multiplex assay was developed in an attempt to 
simultaneously detect altered expression of circulating serum proteins.  Ideally, the 
developed multiplex assay would have the capacity to detect the levels of the four 
circulating serum proteins (ACT, CLU, LRG and ZAG) that had previously been shown to 
be differently altered in the groups of women with NP and HM.  Also included in the 
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development of the multiplex assay were four other serum proteins (AAT, AHS, ATR and 
CLP) that had been shown to be differentially expressed in different types of cancers, 
relative to the controls (Chen et al., 2008; Abdul-Rahman et al., 2007; Doustjalali et al., 
2004 and 2006).  However, the development of multiplex assay in the present study was 
only successful for quantifying three serum proteins, i.e., CLU, CLP and ATR.   
In order to develop the multiplex assay, serum proteins of interest were covalently 
coupled to carboxylated beads using carbodiimide reaction.  In this study, the Bio-plex 
carboxylated beads were chosen due to the ease of their binding to any protein with 
molecular weights ranging from 6-150 kDa.  However, the challenge in performing the 
coupling procedure was in establishing the best amount of protein that would promote 
optimal binding between a protein and the carboxylated beads.  Thus, in the present study, 
six sets of coupling reactions were performed using various amounts of proteins, ranging 
from 2 to 12 µg for each of the protein used.  Subsequent to the coupling reaction, the 
various sets of the protein-conjugated beads were subjected to a validation test to identify 
the set with successful coupling, which was reflected by a fluorescent intensity of greater 
than 2,000 MFI.  Production of such signal intensity was demonstrated by the ATR-, CLU- 
and CLP-conjugated beads with values of 10,783.0, 3,132.5 and 6,314.5 MFI, respectively.  
Also noted was that the optimal amounts of proteins used in the conjugation reaction were 
apparently different for the different types of proteins used.  This was demonstrated by the 
different amounts of proteins required in preparing the sets of ATR-, CLU- and CLP-
coupled beads.  The successful coupling of these proteins to the carboxylated beads were 
obtained when 7, 10 and 5 µg of the respective proteins were used.   
In this study, attempts to develop the AAT-, ACT-, AHS-, KNG- and ZAG-coupled 
beads proved to be unsuccessful.  This was demonstrated by their low fluorescent signal 
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intensities.  However, the actual underlying cause, which leads to the unsuccessful 
development of the respective sets of protein-coupled beads was not able to be identified.  
Nevertheless, this could be due to two probable reasons.  One possibility is that the proteins 
were not successfully conjugated onto the surfaces of the carboxylated beads due to the 
incorrect range in the amount of protein used in the coupling reactions.  The search for an 
optimal amount of protein that would successfully couple a protein to the beads proved to 
be a difficult task and take quite a considerable amount of time.  Similar difficulties have 
been earlier reported by van Gageldonk et al. (2008) in their attempt to develop an in-house 
multiplex assay for simultaneous determination of serum antibodies to Bordetella pertussis, 
Corynebacreruim diptheriae and Clostridium tetani.  In the present study, it was observed 
that although the amount of proteins used in the conjugation process was in accordance to 
the range suggested by the manufacturer, optimal binding for each of the five proteins to 
their respective beads could not be established.  In addition, there was no consistent 
correlation between the amount of protein used and the results of the coupling reaction.  It 
was demonstrated that for some of the proteins, increasing the amount of protein or using 
the highest level of protein would not necessarily yield optimal binding reaction.   
Alternatively, the unsuccessful development of the five sets of beads could also be 
attributed by the inability of the biotin-labeled antibodies to recognize their respective 
protein-coupled beads.  There is a possibility that the protein may lose its three-dimensional 
structure when it was coupled or immobilized to the surface of the beads (Angenendt, 
2005).  These structural changes may result in the protein losing its antigenic recognition 
epitopes, thus making it no longer recognizable by the antibody that usually binds to it in its 
native form.  In the same context, the failure in establishing a specific interaction between 
the antibody and the antigenic protein could also be due to stearic hindrance or masking of 
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the antigenic epitopes of the protein in its newly formed configuration, which is one of the 
common side-effects of the chemical reactions involved during the protein coupling 
procedure (MacBeath, 2002).   
In an attempt to test the efficiency of the three sets of beads, which were 
successfully conjugated, to quantify the respective proteins simultaneously, the beads were 
then assembled into a single assay platform.  Performance of the developed multiplex assay 
for the three proteins i.e., ATR, CLP and CLU, was evaluated in terms of its specificity, 
sensitivity and reproducibility.  The specificity of each individual assay within the 
multiplex is of great importance in any multiplex immunoassay.  This is due to the fact that 
multiple antibodies and various types of protein-conjugated beads are present in a single 
assay suspension, which may lead to non-specific binding of the protein-conjugated beads 
to the various antibodies.  In addition, suspension arrays are also vulnerable to cross-
reactivity between proteins as cross-linking may occur between the beads due to their 
ability to circulate freely in the assay fluid (Ling et al., 2007).  Presence of cross-reactivity 
within the multiplex immunoassay would in turn, result in a decrease of the assay‟s 
sensitivity.  In this study, the binding of the protein-conjugated beads to their respective 
antibodies were rather specific since the results from the specificity test demonstrated that 
the individual antibodies exhibited strong reactivity only to the beads carrying their specific 
antigenic proteins.  In contrast, reactivity of the various antibodies was minimal on beads 
with other proteins.  For example, when the ATR-conjugated beads were tested with anti-
ATR, significant fluorescence signal was only demonstrated by the ATR beads (8,165.3 
MFI), whilst the values from the CLP- and CLU-conjugated beads were merely 5 and 3.5 
MFI, respectively.  Hence, results obtained from the sensitivity test generally indicated that 
there was no significant cross-reactivity between the different antibodies and protein-
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coupled beads used in the multiplex assay, and that the developed assay appeared to 
possess a sensitivity level within the desired working range. 
In the present study, the sensitivity of the developed multiplex immunoassay for the 
detection of the three serum proteins was also determined using a method described by de 
Jager et al. (2009).  In this sensitivity assay, serum samples were spiked with different 
concentrations of ATR, CLU and CLP, ranging from 0.0002 to 0.2 µg/ml.  When analysis 
was performed, the assay was demonstrated to be sensitive enough to detect the small 
changes in the concentrations of the various proteins.   
In addition, the reproducibility of the developed multiplex assay was determined by 
analyzing its coefficients of variations (%CV) between intra-assays as well as between 
inter-assays.  The value of %CV reflects the degree of agreement between different 
measurements conducted on replicate specimens using the multiplex assay.  In the present 
study, both the intra- and inter-assay variability was measured using the sera from control 
subjects.  Based on the range of %CV obtained, variations observed from different wells 
within the same plate (intra-assay) or between different plates (inter-assay), were 
considered to be acceptable for all the three proteins.  In this study, the %CV obtained for 
the intra-assays was <13% whilst that of the inter-assays was <29%.   Findlay et al. (2000) 
have suggested that the acceptable %CV for the intra- and inter-assays of a multiplex 
immunoassay should be <30%.  Hence, the assays performed using the developed 
multiplex immunoassay was shown to be reproducible based on a proposed standard 
operating procedure.   
Besides subjecting the developed multiplex assay to a set of tests to evaluate its 
specificity, sensitivity and reproducibility, the optimal conditions required in running the 
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assay was also performed.  This is due to the fact that an immunoassay performance is 
frequently related to the dilution at which samples were assayed (Drummond et al., 2008; 
Pfleger et al., 2008).  When serum proteins are analyzed in cohorts of pathological and non-
pathological subjects, it is expected that large dynamic variations of the proteins are present 
in the assay.  As such, the dilution of a sample should preferably cover a concentration 
range, which includes highly down- and up-regulated expression levels of the proteins of 
interest.  Hence, in order to determine the optimal dilution factor of serum samples that was 
capable of accommodating all the three sets of protein-conjugated beads, five dilutions of 
serum samples across a range of 1/4 to 1/200 were tested.  Based on the results obtained, a 
dilution factor of 1/50 was chosen.  This was based on the maximal signal intensities that 
were achieved when the serum samples were tested for CLU and CLP, although the signal 
intensity obtained for ATR was not quite optimal.  Nevertheless, the concentration of serum 
ATR was still within quantifiable limit of the developed multiplex assay as fluorescence 
level detected was high (1,717.5 MFI) compared to the intensity emitted by the CLP- and 
CLU-conjugated beads (359.5 and 427.4 MFI, respectively).   
Once validation on the performance of the developed assay was completed, the 
multiplex competitive immunoassay was used to profile the levels of ATR, CLP and CLU 
in the serum samples of patients with NP and HM as well as their control subjects.  By 
using this technique, the up-regulated expression of CLU in the sera of women with NP and 
HM, relative to the controls, was confirmed.  In addition, the levels of ATR and CLP in the 
serum samples of patients with NP and HM were also found to be comparable to those of 
the controls.  This was based on the overall signal intensities from the sets of ATR- and 
CLP-conjugated beads, which were quite similar to those emitted from the serum samples 
of the controls.   
   
 209 
The results of the multiplex assay that was developed in the present study were 
comparable to those that were earlier obtained using 2-DE.  Hence, it is reasonable to 
conclude that the multiplex immunoassay developed in the present study had the ability to 
specifically measure the three different proteins simultaneously in small amounts of serum 
samples.  Nevertheless, it needs to be further developed to include the other five proteins 
which were not successfully conjugated in the earlier part of this study.  
The multiplex immunoassay that was partially developed in the present study offers 
several advantages that will probably make it an attractive assay platform in the future.  The 
fact that it allows elimination of multiple samples processing, which greatly reduces the 
amount of time and labor, makes this technique operationally practical and feasible for 
routine diagnostic application.  And most interestingly, the flexibility and robustness of this 
approach, makes it possible for continuous addition of target proteins or biomarkers to 
existing panels.  This in turn will provide the opportunity to increase the diagnostic power 
of the immunoassay.  In addition, the multiplex approach is also in line with the current 
trend of looking at multiple biomarkers in the diagnosis of different malignancies (Pang et 
al., 2010). 
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CHAPTER 5: 
CONLUSIONS 
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A 35 kDa glycoprotein, whose abundance was previously demonstrated to be 
enhanced in the sera of patients with EACa, was isolated from the pooled sera of three 
EACa patients with the use of an immobilised CGB lectin affinity chromatography.  
Subjecting the isolated protein spot cluster to mass spectrometry analysis, the targeted 
glycoprotein was identified as the 35 kDa O-glycosylated fragment of the ITIH4 chain 
(ITIH4f).  Subsequent to its identification, the expression of the 35 kDa ITIH4f in other 
cancers was investigated using the 2-DE and HRP-conjugated CGB lectin approach.  When 
compared to the controls, the expression of the ITIH4 cleavage fragment was demonstrated 
to be significantly enhanced in sera of patients with BrCa, EOCa and GOCa, but not in 
patients with NPCa and OsSa.   The data of the present study, when taken together with the 
reports of others (Abdul-Rahman et al., 2007; Chen et al., 2008) appeared to correlate the 
abundance of the 35 kDa ITIH4f specifically with cancers associated with estrogen 
dysregulation.    
To determine if the fragment is also over-expressed in other non-cancer conditions 
with irregularities in the levels of estrogen, its expression in women with normal pregnancy 
(NP) and hydatidiform mole (HM) as well as menopausal women under the hormone 
replacement therapy (HRT) were studied.  The 35 kDa ITIH4f was similarly over-
expressed in the groups of NP and HM women, but was not differentially expressed in the 
group of women with HRT.  Hence, it appeared that the expression of the 35 kDa ITIH4f 
was not exclusive to cancers but is also enhanced in normal and benign conditions that are 
associated with estrogen dysregulation. 
Using the conventional 2-DE approach in combination with either the HRP-CGB 
lectin or silver staining to detect the resolved spots, an attempt to establish the serum 
protein profiles of women with NP and HM were performed.   The aberrant expression of 
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the differentially expressed proteins was further validated using immunoblotting technique.  
Comparative analyses of the serum proteins in the profiles of the silver stained gels and 
lectin detected blots demonstrated simultaneous enhanced expression of the 35 kDa ITIH4f, 
ACT, CLU, LRG and ZAG in the women with NP, relative to the controls.  In contrast, the 
women with HM were characterized only by the up-regulated expression of the 35 kDa 
ITIH4f, CLU and LRG.  However, LRG of the HM women appeared to be differentially 
glycosylated from that of NP women.  In addition, CLU of the women with HM seemed to 
be more cationic, relative to the CLU of the women with NP.  The aberrant individual 
expression of ACT, CLU, LRG and ZAG which was detected in the present study, has also 
been previously reported in different types of malignancies.  However, when taken 
together, the aberrantly expressed serum proteins formed profiles or “protein signatures” 
that were generally different from those of the different types of cancers.  Hence, these 
findings provide an insight on the potential importance of using panels of biomarkers to 
further refine the diagnosis as well as prognosis of a particular diseased condition.  
An attempt to simultaneously detect the differential expression of the panels of 
serum proteins was subsequently performed using a multiplex immunoassay that was 
developed in-house in the final part of the present study.  However, this was only 
successful for the detection of ATR, CLU and CLP, whilst the other five targeted proteins 
were not quite successfully developed.  Nonetheless, the assay was capable of detecting the 
enhanced expression of CLU and confirming the unaltered expression of ATR and CLP in 
sera of women with NP and HM.  At this juncture, it is therefore reasonable to conclude 
that, when further refined to include other altered potential biomarkers that have been 
previously uncovered, the comprehensive multiplex assay may be possibly developed.  
Such an assay can be of value to confirm the hypothesis that, the serum proteins of interest 
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when analysed simultaneously, may ultimately be used as a “protein signature” in the 
diagnoses as well as prognoses of different types of cancers.   
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